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Recently, two separate high-throughput screens (HTS) identified itraconazole
(ITZ), a well-known antifungal agent, as both an inhibitor of the hedgehog (Hh) pathway
and angiogenesis (IC50 = 690 nM and 160 nM, respectively). Dysregulation of both the
Hh pathway and angiogenesis are implemented in the growth and metastasis of various
types of cancer. Aberrant Hh signaling may lead to cell proliferation and tumor growth
most notably associated with basal cell carcinoma (BCC) and medulloblastoma (MB).
Currently, there are a few Hh pathway inhibitors that are FDA approved for the
treatment of BCC. However, there has been an emergence of resistance towards these
compounds highlighting the need for novel Hh pathway inhibitors. The ITZ scaffold has
not been thoroughly explored in terms of Hh pathway inhibition.

As a result, four

generations of ITZ analogues were designed, synthesized, and evaluated for Hh
pathway inhibitory activity. Structure-activity relationship (SAR) studies indicated that
the triazole moiety is not necessary for potent Hh pathway inhibition and removal of this
functionality also abolishes coordination with CYP3A4. While the stereochemistry of the
sec-butyl side chain region was not important, stereochemistry at the 4-position of the
dioxolane ring proved to be crucial. In terms of the triazolone/side-chain region of the
scaffold, truncation of the side-chain region to the free triazolone and truncation of the
triazolone to smaller moieties (–NO2 and –NH2) maintain potency. Amide functionality
in replacement of the triazolone/side-chain region is tolerated with preference to polar

Jennifer R. Pace – University of Connecticut, 2018
substituents at the meta- position of the phenyl ring. Early evidence suggests that cyclic
functionality is not necessary within the triazolone region indicating that acyclic
functionalities could be explored for Hh pathway inhibitory activity. A subset of ITZ
analogues was evaluated in two additional assays to explore angiogenesis inhibitory
activity. Results indicated that the triazole region of ITZ seems to be important for
angiogenesis inhibition. Overall, a total of 60 analogues were designed, synthesized,
and evaluated to thoroughly explore the ITZ scaffold in terms of these novel biological
activities. In addition to these medicinal chemistry efforts, a preliminary ITZ liposome
formulation was designed and evaluated in vitro for Hh pathway inhibition.
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CHAPTER I: Repurposing Itraconazole as an Anticancer Chemotherapeutic

1

1. Introduction
1.1 Drug Repurposing
Drug development is a long and expensive process; on average it takes about
13-15 years and $2-3 billion for a drug to become clinically approved.1 To bypass this
route, it is becoming increasingly popular to explore FDA-approved or clinical stage
compounds for novel biological activities. Applying an existing therapeutic towards a
novel biological indication can be described as drug repurposing or drug repositioning.1
FDA-approved compounds have already been deemed safe in phase I clinical trials and
as a result, many of these drugs can immediately enter phase II clinical trials for new
disease indications. It has been estimated to cost $300 million and take 6.5 years to
repurpose a clinically approved drug for a novel ailment (Figure 1).2 Drug repurposing
may also help improve Eroom’s Law which can be described as the efficiency of
research and development of new drugs in the United States; on average, this number
is said to be cut in half every nine years. 1,2

Figure 1. Drug Discovery Pipeline2

2

Although there are clear benefits from drug repurposing, most successes to date
have been serendipitous (Figure 2).1 Some of these successes include repurposing
sildenafil, a phosphodiesterase inhibitor designed for angina, which is now marketed as
Viagra to treat erectile dysfunction.1,3 The antibiotic erythromycin has been repurposed
for impaired gastric motility. Finally, even drugs with detrimental side effects have been
successfully repurposed for novel indications. Thalidomide, originally an antiemetic, is
now approved for the treatment of multiple myeloma.3 Side effects such as
teratogenicity may be acceptable for treatment of a life-threatening disease but are not
ideal for treatment of a chronic disease such as nausea.3 It is important to consider the
risk versus reward aspect when repurposing a drug.1,2 Drug repurposing is especially
advantageous during disease epidemics when there is not enough time for a novel
therapeutic to go through the drug development pipeline.4 For example, the global
outbreaks of both the Ebola and Zika viruses affected a large population of our world
and there is still an immediate need for better treatment and/or prevention.

High

throughput screening efforts of FDA-approved and clinical stage drugs have been
performed for both of these disease indications.5,6
O
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Figure 2. Structures of Representative Repurposed Drugs
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In addition to the plethora of benefits, there are also a few downfalls to this drug
repurposing strategy. First, if the dose or mode of administration is significantly different
from the original indication, the compound will have to be entered into phase I safety
clinical trials.1–3 As drug repurposing is based upon improving time and cost efficiency,
this raises a huge argument. In addition, it is difficult to obtain the rights to explore
novel compounds for new indications.1–3 Generally, pharmaceutical companies are
going to explore potential secondary indications before other pharmaceutical
competitors or academia can obtain them.1 Overall, drug repurposing is a promising
form of drug development but there are still challenges associated with bypassing
clinical stages and maintaining time/cost efficacy.1,3
Modern drug discovery focuses on the development of a drug candidate that has
high selectivity and potency for one target. “Promiscuous drugs” or “dirty drugs”, which
have multiple biological activities and target sites, tend to have a negative reputation
due to their presumed increase in side effects.7 However, this idea of one drug having
multiple activities, known as polypharmacology, is gaining a renewed appreciation.7
When a single-target drug is being used, cells may acquire resistance or decrease their
dependence on that specific target. For instance, in diseases such as cancer, there is
generally a high rate of genetic mutations, which may lead to certain populations of
cancer cells that are drug resistant; this ultimately results in treatment failure.7 Drugs
that are able to treat a variety of different diseases may be beneficial in drug
development as well as drug repurposing. It is also advantageous to develop one drug
that has multiple different biological activities as opposed to using combination therapy.7
The use of drug cocktails complicates and inconveniences patients, increases the

4

prevalence of acute and delayed toxicities, and results in unpredictable pharmacokinetic
properties. It is more appealing and cost efficient to develop single-molecule drugs with
multiple activities rather than administering multiple drug combinations within a single
cocktail.7
1.2 Itraconazole

Figure 3. Structures and Regions of Itraconazole
Itraconazole (ITZ) is a clinically efficacious antifungal agent that was FDA
approved in 1992 (Figure 3).8 Recently, two separate high-throughput screens have
determined that ITZ inhibits both the hedgehog (Hh) pathway and angiogenesis.9,10
Both of these screens were performed at Johns Hopkins University School of Medicine
and consisted of ~2,400 FDA-approved and post-phase I drugs.9,10 Preclinical in vitro
assays have concluded that ITZ has anticancer activity and may serve as a potential
chemotherapeutic.

There have been a variety of pilot studies to determine the

anticancer effects of ITZ in humans.11 Clinical trials range from phase 0 to phase 2 and
include patients suffering from leukemia, prostate cancer, non-small cell lung cancer
(NSCLC), basal cell carcinoma (BCC), ovarian clear cell carcinoma, breast cancer,
pancreatic cancer, and T-cell lymphoma (Table 1).11,12

5

Table 1. Itraconazole Clinical Trials
Clinical Trial

Clinical
Status

Cancer Type

Reference

NCT01787331
NCT02357836
NCT02120677
NCT02354261
NCT02366884

Phase II
Phase 0
Phase 0
Phase II
Phase II

Prostate
NSCLC
BCC
BCCNS
All cancer
types

[11, 12]
[11, 12]
[11, 12]
[11, 12]
[11,12]

ITZ is a member of the well-known azole antifungal class. It is considered to be
a small molecule despite its large size (MW = 705.64 g/mol). ITZ is a lipophilic drug
with a LogP of 5.66 and as a result, has poor solubility in H2O (1 ng/mL).13 ITZ has three
stereocenters and has the potential to exist as eight distinct stereoisomers. However,
ITZ is clinically administered as a mixture of 1:1:1:1 cis-racemates as this orientation
predominantly forms during synthesis.14 ITZ has a complex scaffold highlighted by its
triazole moiety and phenyl-piperazine-phenyl linker region. As an antifungal agent, ITZ
is generally well tolerated and causes minimal side effects.15 ITZ has been well studied
in terms of its antifungal activity as well as its novel anticancer and antiviral activities.16
Table 2. Properties of Itraconazole 13
Property
Molecular Weight
H-bond Donor
H-bond Acceptor
Rotatable Bond Count
pKa
LogP
Melting Point
Solubility in H2O pH = 7

Value
705.64 g/mol
0
9
11
3.7
5.66
166.2°C
1 ng/mL

6

1.2.1 Antifungal Activity of ITZ
The first report of an azole exhibiting antifungal activity was in 1944 with
benzimidazole.8

In 1958, the first topical azole antifungal, chlormidazole, sparked an

interest which lead to more topical azole antifungal agents: clotrimazole, miconazole,
and econazole. In 1981, ketaconazole was FDA-approved for systemic fungal
infections.8 Ketaconazole remained the standard for treatment and the only orally
bioavailable agent for the next decade. However, due to poor toxicity and recurring
fungal infections, a second generation of azole derivatives were discovered which
included terconazole, fluconazole, and eventually itraconazole.8 Throughout the 1990s,
resistance to azole antifungals was uncommon.

8,17

However, this acquired resistance

has become more prevalent as fluconazole is used in immunosuppressed and critically
ill patients. Janssen Pharmaceuticals developed itraconazole and it became FDA
approved in the United States in 1992.8,17 ITZ was developed to combat fluconazoleacquired resistance. It is less toxic and can be used to treat a broad range of fungal
infections including Candida, Aspergillus, Cryptococcus neoformans, Coccidioides
immitis,

Histoplasma

capsulatum,

Blastomyces

dermatitidis,

Paracoccidioides

brasiliensis, Sporothrix schenekii, and some phaeohyphomycetes.8,17 ITZ began to be
utilized as the standard form of treatment for non-meningeal, non-life threatening cases
of histoplasmosis, blastomycosis, and paracoccidioidomycosis.

Despite ITZ’s

advantageous activity in aspergillosis and sporotrichosis, fluconazole has a more
favorable pharmacological and toxicity profile.8,17
ITZ is more lipid-soluble than fluconazole and this poses issues with drug
formulation and absorption.8 Originally formulated into a capsule, ITZ was not very

7

effective due to low blood concentrations (< 500 ng/mL). In 1997, an oral solution was
FDA-approved and utilized the excipient hydroxypropyl-β-cyclodextrin to aide in
solubility.8 Eventually, an intravenous formulation was approved and this allowed for a
more flexible use of ITZ; steady-state plasma concentrations could be obtained in 2-3
days as opposed to 1-2 weeks with ITZ capsules. This was crucial for patients that had
advanced HIV or were in intensive care.8
ITZ exhibits its antifungal activity by inhibiting the enzyme cytochrome P450 14α-demethylase (14LDM).

This enzyme represents an intermediate step in the

conversion of lanosterol to ergosterol (Scheme 1).8 Ergosterol is required for cell wall
synthesis and disruption of this biosynthesis results in cell death. It is essential for
aerobic growth of most fungi. It is important to point out that ergosterol is the major
product of sterol biosynthesis in fungi, whereas mammalian systems synthesize
cholesterol as the major membrane lipid.13,18,19

8
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Scheme 1. Biosynthetic Pathway to Ergosterol 19,20
Cytochrome P450 contains an iron protoporphyrin moiety, which is located at the
active site.14,18 Azole antifungals bind to the iron atom via a nitrogen atom in the
imidazole/triazole ring. The remainder of the azole molecule binds to the apoprotein in
a manner dependent on the individual azole’s structure.14,18 The exact confirmation of
the active site differs between fungal species and amongst the many mammalian P450
mono-oxygenases.14,18 For ITZ specifically, the N4 of the triazole ring moiety interacts

9

with the heme group of 14LDM, preventing coordination of the molecular oxygen
required to initiate oxidation (Figure 4).14
O

O

OH

N

N
Fe
N

OH

N
N
N
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O
N

O

N

Cl

N

N
N

Figure 4. Mechanism of Action: Antifungal Activity
While ITZ is FDA-approved and has been studied for many years, it still contains
a few properties that are not considered to be “drug-like”.

While important for its

antifungal activity, the triazole moiety of ITZ is able to coordinate with CYP3A4, which
leads to drug-drug reactions and adverse side effects.21 If ITZ is going to be repurposed
for a disease such as cancer, there should be minimal side effects/drug-drug
interactions as cancer patients are often on a multi-drug treatment regimen to both treat
the cancer and maintain comfort.

Second, ITZ is a rather large compound with a

molecular weight over the typical threshold of small molecule therapeutic agents (< 500
g/mol). Lastly, ITZ is poorly soluble with a solubility of 1 ng/mL in H2O at pH 7.22,23,24 If
ITZ is going to be utilized as an anticancer chemotherapeutic agent, it must be
evaluated and deemed safe in cancer patients.
1.2.2 Repurposing Screen Results
A library of ~2,400 FDA-approved and post-phase I drugs was screened for Hh
pathway inhibition.9 This screen utilized a reporter cell line Shh-light which contains a
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stably integrated Gli-luciferase reporter that responds to stimulation by ShhN, the active
form of sonic hedgehog (SHH) signaling protein.

This screen yielded a few hits

including microtubule inhibitors (vinca alkaloids), which are cytotoxic and were not
further explored.9 In addition, ITZ inhibited the Hh pathway (IC50 = ~690 nM) and as a
result, a few more azole antifungals were evaluated for this novel biological activity.
Results concluded that the azole antifungals as a class did not inhibit the Hh pathway
(Table 3).9
A library of 2,604 FDA-approved and phase II compounds were screened in an
endothelial cell proliferation assay to explore potential angiogenesis inhibitors.10 This
assay was performed in a 96 well plate with human umbilical vein endothelial cells
(HUVECs) with a final drug concentration of 10 µM. Cells were incubated for 36h and
proliferation was measured with [3H]-thymidine for the final 8h of incubation.10
Preliminary screen results identified 210 drugs with at least 50% inhibition at 10 µM.
Some hits were excluded due to cytotoxicity and some were excluded due to being
topical agents.10 ITZ inhibited VEGF-induced proliferation (IC50 = 0.16 µM) and as a
result, a few more azole antifungals were explored for this novel biological activity.
Results concluded that the azole antifungals as a class did not inhibit angiogenesis
(Table 3).10
Table 3. Results from High Throughput Screens9,10
Azole
Itraconazole
Ketoconazole
Miconazole
Fluconazole

IC50 Hh Pathway
0.69 µM
9.2 µM
12.0 µM
> 100 µM
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IC50 Angiogenesis
0.16 µM
10.4 µM
2.47 µM
> 100 µM

2. Hedgehog (Hh) Pathway
The Hh pathway is an embryonic developmental cell-signaling cascade that plays
a role in cell differentiation, tissue growth, and tissue patterning (Figure 5).25 While the
pathway is generally quiescent in healthy adults, it is required for the homeostasis of
stem cell populations in the skin and the central nervous system (CNS).

Aberrant

regulation of the Hh pathway leads to constitutive activation which results in abnormal
cell proliferation and tumor growth most notably associated with basal cell carcinoma
(BCC) and medulloblastoma (MB).25

Figure 5. (A) Inactive and (B) active form of the Hh pathway25
Reused with permission from John Wiley and Sons
The Hh pathway is regulated by the 12-transmembrane (TM) cell surface
receptor, Patched (Ptch) and the 7-TM G-protein coupled receptor (GPCR)-like protein,
Smoothened (Smo). In the absence of Hh ligand, Ptch suppresses Smo through a
complicated mechanism that is not well understood (Figure 5A).

In this state, a

heteroprotein complex is formed between Suppressor of Fused (Sufu) and the glioma
12

(Gli)-associated oncogene family of zinc-finger transcription factors.26–28 This complex
remains in the cytosol where Sufu serves as a negative regulator of Gli by promoting a
series of phosphorylation events (PKA, GSK-, and CK1) leading to the proteosomal
cleavage of Gli to the N-terminal truncated form (GliR).

Sufu confiscates the

unprocessed cytosolic Gli and only the inactive transcriptional repressors Hh target
genes are able to travel to the nucleus.26–28
In the presence of Hh ligand (Sonic Hh [SHh], Indian Hh [IHh], and Desert Hh
[DHh], Ptch removes its suppression on Smo (Figure 5B). Smo is then able to migrate
to the primary cilium where it inhibits the phosphorylation of the Gli-Sufu complex.26–28
This allows for the formation of full length GliA proteins that travel to the nucleus and
induce the transcription of Hh target genes. Typical Hh target genes include: PTCH,
GLI1, Cyclin D, Cyclin E, Wnt, N-Myc, VEGF, BCL2, SNAIL, ELK1, MSX2, osteopontin,
BMI1, and NANOG.26–28
2.1 The Hedgehog Pathway and Cancer
Aberrant Hh pathway activity may lead to unwanted cell proliferation and tumor
growth most commonly seen in basal cell carcinoma (BCC) and medulloblastoma (MB).
Hh pathway dysregulation arises from mutations in Ptch, Smo, or Sufu. For instance, in
sporadic BCC cases, mutations include Ptch1 (~75%), Smo (10%), and Sufu
(~5%).26,29,30 Cancers resulting from Hh pathway dysregulation have been categorized
by either being Hh ligand independent or Hh ligand dependent (Type I and Type II
cancer, respectively). Ligand independent aberrant Hh activity can be attributed to lossof-function mutations in Ptch or Sufu and/or gain-of-function mutations in Smo.26,27 Ptch
mutations include deletions, insertions, or nonsense mutations, which result in loss of
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function. Ptch loss of function results in aberrant up-regulation of the Hh pathway, as
Smo is no longer repressed even in the “off-state”. Loss of function Ptch mutations are
commonly seen in Gorlin Syndrome, which predisposes a patient to cancers such as
BCC, MB, and rhabdomyosarcoma.26,27 Smo mutations result in gain of function; Active
Smo would result in up-regulation of the Hh pathway as it can continuously generate
active forms of Gli leading to increased transcription of Hh target genes. Smo gain of
function mutations are typically associated with sporadic BCC and other skin
abnormalities.26,27
Cancers can also result from aberrant Hh pathway activity that arises from
abnormalities regarding Hh ligand.

Constitutive pathway activation results from a

continuous receiving of Hh ligand.26,27 This phenomenon can be divided into three
different models: autocrine-juxtacrine model, paracrine model, and reverse paracrine
model. The autocrine-juxtacrine model involves Hh ligand being secreted and absorbed
by the same or adjacent tumor cells; this leads to tumor growth.26,27 The paracrine
model involves Hh ligand being secreted from tumor cells and interacting with normal
cells; this leads to angiogenesis and metastasis. Lastly, the reverse-paracrine model
involves Hh ligand being excreted from normal cells and interacting with cancer
cells.26,27
2.1.1 Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common form of skin cancer affecting 4
million US residents annually.31 This cancer arises from the basal layer of the epidermis
and usually develops on skin that is exposed to the sun. This skin cancer grows slowly
and rarely spreads to other parts of the body. If left untreated, BCC can grow wide and
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deep resulting in destroyed skin, tissue and bone.31 Treatment options for BCC depend
on the tumor’s size and location as well as the patient’s age and general health. All
treatment options are effective and include surgery (curettage + electrodessication,
excision, and Mohs surgery), radiation therapy, cryotherapy, and chemotherapy
(vismodegib and sonidegib). With early diagnosis and treatment, recurrence-free cure
rates are between 85-95%.31,32
2.1.2 Medulloblastoma
Medulloblastoma (MB) is a cancerous tumor also known as cerebellar primitive
neuroectodermal tumor (PNET) that originates in the posterior fossa, the lower rear
region of the brain (Figure 6). These tumors rapidly grow in the cerebellum, a part of
the brain that is important for balance, posture, and complex motor functions.33,34 MB
tumors have the potential to spread to other regions of the brain or to the spinal cord. It
accounts for less than 2% of all primary brain tumors and 20% of childhood brain
tumors.33,34 About 400 children are diagnosed with MB in the United States each year.
It is the most common malignant brain tumor in children 4 and under and is the second
most common malignant brain tumor in children between the ages of 5-14 years of
age.33,34 It is slightly more common in males over females. About 70% of all MBs are
diagnosed in children under 10 and the median age of diagnosis is 7 years old. MB is
not common in adults and very few children under 1 receive a diagnosis.33,34
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Figure 6. Location of MB Tumors in Brain 33

Types of MB
MB is considered to be an “embryonal” cancer arising from immature cells.
Embryonal tumors are typically pink/purple-gray masses. MB tumors are not all the
same and vary histologically. While this is not necessarily important for prognosis, it is
important to note that MB should not be considered a single disease but rather a group
of different diseases.33,34 Classic MB tumors contain tissue that is densely packed and
have small round cells with large dark nuclei. Desmoplastic nodular medulloblastoma
contains scattered densely packed tumor cells mixed with looser-packed cells. MB with
extensive nodularity is similar to desmoplastic nodular MB but has more pronounced
nodularity. Large-cell MB consists of tumor cells with large round nuclei.33,34 Anaplastic
MB contains tumor cells with increased proliferation and abnormally shaped nuclei. It is
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important to make note that sometimes these histological variants co-exist (Figure
7).33,34

Figure 7. Histological MB Types35
Reused with permission from Nature Publishing Group
Genetic subtypes of MB will eventually be important as oncologists predict this
will declare route of treatment. MB treatment may become more targeted based on
what genetic abnormality is resulting in tumor growth.33,34 There are currently four
different subtypes of MB: WNT, SHH, Group 3, and Group 4. Each subgroup targets a
different age of children/adults and may have a different prognosis and survival rate
(Figure 8).33,34 WNT and SHH subtypes are named specifically for the cellular pathway
that affects the tumor; Group 3 and Group 4 are more broadly labeled as a distinct
pathway has not been found to cause tumor growth to date.33,34
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The first group of MB is termed WNT. About 10-15% of patients suffer from this
subgroup of MB. The average age of diagnosis is 10 years of age and it is the only
subgroup that is more common in girls than boys.33,34 Tumors typically are located in
the fourth ventricle of the posterior fossa. Tumors have been found to accumulate a
protein, β-catenin, in the nucleus; this results in the activation of the WNT pathway.33,34
The WNT pathway is a cell-signaling cascade that has been found to play a role in
tumor growth. Patients with this subtype of MB have an excellent outcome.34,33
The second type of MB is named SHH and affects about 25% of MB patients. It
is more prominent in children under 5 years of age and over 16 years of age. This
subtype is typically caused by aberrant Hh pathway activity.33,34 Tumors are generally
located in the body of the cerebellum and the tumor can grow on the sides of the organ.
Survival rate for this subtype depends on the metastatic rate at time of diagnosis,
histology type of tumor, and age of patient at diagnosis.33,34
An increased copy of the growth gene MYC generally categorizes group 3 MB.
Like SHH, it affects 25% of MB cases. It primarily affects children between the ages of
1-10 years of age and is almost never seen in adults.33,34 There is often metastasis at
the time of diagnosis and the tumor is generally located in the fourth ventricle like WNT
subtype MB. The histology type is most commonly large cell/anaplastic.33,34 Group 3
subtypes have the worst survival rate among all of the MBs; this survival rate depends
on the metastatic state at time of diagnosis and the age of patient at diagnosis.33,34
Group 4 is the most common subtype of MB accounting for 35-40% of cases. It
occurs in all ages but is most prevalent during mid-childhood. Tumors are located in the
fourth ventricle similarly to Group 3 and WNT subtypes.33,34
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The hallmark of this

subtype is abnormalities in chromosome 17. If the cancer does not spread, 5-year
survival rates with standard therapy are 80% however, with metastasis this drops to
60%.33,34

Figure 8. MB Subgroup Prevalence35
Reused with permission from Nature Publishing Group
Current Treatment of MB
Current treatment for MB consists of surgery followed by high-dose
chemotherapy and radiation. Treatment plans are individualized based on the risk of
tumor occurrence.33,34 This risk is based on the amount of metastasis and the amount
of tumor remaining post-surgery. For instance, in pediatric MB, “high” risk patients are
less than 3 years of age, have a tumor volume of 1.5 cm2 post-surgery, and have
metastasis.34,33
Surgically removing the tumor is an important part of treating MB. The obvious
goal is to remove the entirety of the tumor, but sometimes this is not possible as a result
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of where the tumor has grown.33,34 In a third of MB patients, the tumor grows into the
brain stem; attempted removal of this tumor type would result in neurological damage.
The goals of this initial surgery are to remove as much of the tumor as possible without
causing neurological damage, to obtain a tissue sample for diagnosis, and to relieve
cerebrospinal

fluid

buildup

caused

by

tumor

growth

and

swelling.33,34

Glucocorticosteroids (decadron, dexamethasone) are used before and during surgery to
reduce swelling in the tumor. Technological advances have aided in this step of treating
MB. MRI scanning and computer-aided navigation tools help with mapping the tumor
removal before surgery.33,34

High powered microscopes, ultrasounds, and gentle

suction devices are necessary for tumor removal. MRI scanning is either performed
right after surgery or days after surgery to determine how much tumor was resected.33,34
After surgery, MB is treated with radiation therapy. Even after removal of the
tumor, cancer cells remain in the surrounding brain tissue. If not killed with radiation,
these cells can spread and lead to cancer regrowth.33,34 Radiation to the brain/spinal
cord can damage a developing brain and this is important to consider, as MB patients
are typically children. Therefore, this form of therapy is not used in children under the
age of 3 and caution is used in patients between the ages of 3-7 as they are at the
highest risk of neurocognitive defects as a result of radiation.33,34 On average, radiation
therapy is given 5 days a week for 6 weeks. Extra radiation is given to the site where
the tumor was removed due to increased risk of tumor growth.33,34
Chemotherapy is described as the use of powerful chemicals to kill cancer cells
after surgery and radiation therapy. These drugs halt tumor regrowth and the spread of
cancer metastatically.33,34 MB patients fare better with radiation but some children that
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are too young to get radiation rely on chemotherapy alone. Chemotherapy generally
consists of a cocktail of drugs that target cell death at different cycles of cell growth.
The drugs that are mainly used for MB are vincristine, cisplatin, carboplatin,
cyclophosphamide, and lomustine (Figure 9).33,34

These drugs are administered in

cycles with each cycle differing between 3-4 weeks; this allowed the body to recover
after being administered these harsh chemicals. The cycle length and amount of cycles
depends on the severity of the cancer and the age of the patient.33,34
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Figure 9. Structures of Common Chemotherapeutic Agents
Side Effects
Unfortunately, side effects are evident due to this harsh treatment regimen
combining major surgery, radiation, and chemotherapy. In terms of surgery, about 25%
of children experience loss/delay of speech 6-24 hours after waking up; this is referred
to as “posterior fossa mutism syndrome.”33,34

A small percentage of children have

abnormal speech and unsteadiness years after surgery.

Radiation short-term side

effects include: fatigue, loss of appetite, nausea, sore throat, difficulty swallowing, and
hair loss.33,34 Long-term side effects include: lower intellectual ability, attention deficit,
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and memory loss. Younger children are more prone to these long-term side effects as
their brains are still developing.

Radiation can also affect the hypothalamus and

pituitary gland, which regulate hormones for bodily function and growth.33,34 This can
lead to issues with obesity and hypothyroidism. Generally, children can be treated with
growth hormone replacement therapy.

Radiation can also cause short stature and

scoliosis as the spinal cord is very close to the site of tumor growth.

In terms of

chemotherapy, short-term side effects are very similar to those of radiation: hair loss,
nausea, vomiting, fatigue, and weakness.33,34

Long-term side effects include early

onset lung, heart, and kidney disease as well as the development of secondary cancers
such as leukemia. Hearing loss is a direct side effect of the chemotherapeutic agent
cisplatin; as this drug is crucial towards MB treatment, additional drugs are currently in
development for administration with cisplatin to limit hearing loss.33,34
2.2 Established Smo Antagonists
Smo became a popular drug target after the discovery of the first Smo inhibitor,
cyclopamine, a naturally occurring alkaloid.

While cyclopamine exhibited poor

pharmacokinetic properties, it was utilized in the exploration of Hh pathway function and
subsequent tumor growth.36 To date, Smo has been identified as the most druggable
target for the development of small molecule Hh pathway inhibitors; each of the Hh
pathway inhibitors that have advanced into clinical trials is a direct Smo antagonist
(Figure 10).28 Curis and Genentech co-developed the first small molecule Smo
antagonist to enter clinical trials and ultimately gain FDA approval for the treatment of
advanced

basal

cell

carcinoma,

vismodegib

(GDC-0449/Erivedge™).

Erismodegib/Sonidegib (NVP-LDE225) was originally identified and developed at the
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Novartis Institute for Biomedical Research and has recently been FDA-approved for
locally advanced basal cell carcinoma.11,37 A medicinal chemistry program at Pfizer
resulted in the identification and development of PF-04449913 as a potent Smo
antagonist that exhibits favorable pharmacological and pharmacokinetic (PK) properties
in vitro and in vivo.38 PF-04449913 is currently being evaluated in multiple Phase I and
Phase II studies for the treatment of both acute myeloid leukemia and myelodysplastic
syndrome.11 Exelixis and Bristol-Myers Squibb collaborated to develop XL-139/BMS833923, which has been studied in Phase I and II trials as both a single agent and in
combination regimens (Dasatinib, carboplatin, cisplatin, etoposide, and more) for the
treatment of a variety of human cancers including chromic myeloid leukemia and
extensive small cell lung cancer.11,39 Eli Lilly has also advanced a small molecule Smo
antagonist, LY2940680 (Taladegib) into Phase I and II trials for pediatric
medulloblastoma, rhabdomyosarcoma, and small cell lung cancer; it is also in phase II
clinical trials in combination with paclitaxel, carboplatin, and radiation.11,40 Due to the
well-established nature of these compounds as Hh pathway inhibitors, each of them has
been extensively reviewed elsewhere and their path to clinical candidacy will not be
detailed further.41,26,27,42,43
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Figure 10. Structures of Established Smo Antagonists
Table 4. Clinically Relevant Synthetic Smo Inhibitors.26
Compound
GDC-0449
NVP-LDE225
PF-04449913
BMS-833923
LY294068

IC50
Wild-Type
Smo
3-22 nM**
2.5 nM
5 nM
21 nM
2.4 nM

IC50
D473H Smo

Development
Status

References

Loss of activity
Loss of activity
ND
ND
Active*

Clinically approved
Clinically approved
Clinical (Phase II)
Clinical (Phase II)
Clinical (Phase II)

[11, 44]
[11,37,45]
[11, 38]
[11, 46 ]
[11, 47]

ND: Not determined/reported
*Specific IC50 values were not provided
**Dependent on cellular assay

A major challenge for the continued advancement of small molecule Hh pathway
inhibitors towards clinical efficacy is the development of multiple mechanisms of
resistance to these Smo antagonists.48 An unsuccessful clinical trial for vismodegib in
an MB patient resulted in the discovery of a clinically relevant Smo mutant (D473H)
24

(Table 4).

This point mutation in Smo rendered the patient insensitive to further

treatment with vismodegib.49,50,51

Additional point mutations in Smo have been

identified (H231R, W281C,Q477E, V386A, V321M, I408V, C469Y, T241M) to confer
resistance in patients receiving vismodegib for the treatment of advanced BCC.52,53,54
Half of the vismodegib-treated patients that experienced a relapse in BCC were found to
have a Smo mutation.

Similar Smo mutations that result in constitutive pathway

activation were identified in a preclinical Hh-dependent MB murine model upon
treatment with sonidegib.55 Other mechanisms of Smo antagonist resistance include
direct activation of Gli downstream, induced expression of p-glycoprotein, and
chromosomal amplification of GLI2 and SUFU.53,54,55,56,57,48 These results highlight a
therapeutic need to determine small molecule Hh pathway inhibitors that maintain
potent inhibitory activity in the presence of wild-type Smo and mutant forms of Smo.
While many universities and industrial laboratories are searching for Smo-wild
type and Smo-mutant antagonists, there are many other drug targets within the Hh
pathway that are less popular in the drug discovery community. The focus on targeting
Smo has offered some information regarding limitations.58 First, Smo inhibitors are
characterized by their structural moieties. If one compound succumbs to resistance, the
whole class of compounds may result in resistance.

Second, there is evidence

emerging that the downstream components in the Hh pathway may be compensating
for upstream inhibition. There are many oncogenic-cell signaling pathways that interact
with the Hh pathway: TGF- β, RAS/RAF/MEK/EK, and PI3K/AKT/Mtor.58 Gli
transcription factors are regulated by other pathways such as TGF-β.58 Therefore, if
vismodegib is inhibiting Smo, Gli transcription activity can still take place if another
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pathway is simultaneously producing Gli transcription factors. This crosstalk between
Hh pathway and other oncogenic signaling pathways exemplifies an additional need for
the exploration of downstream Hh inhibitors.58
2.3 Recently Disclosed Smo Antagonists
The emergence of resistance towards vismodegib influenced Novartis to identify
a series of pyridazines as second-generation Hh inhibitors that remain potent in the
presence of Smo mutant D473H. The most active compound identified through this
process, NVP-LEQ506, inhibits Hh signaling in vitro against both wild-type and mutant
Smo (IC50 values = 1 and 96 nM, respectively) (Figure 9).59 NVP-LEQ506 reduced Gli
mRNA expression and promoted tumor regression in a murine Hh-dependent MB
allograft following oral administration (10-40 mg/kg, q.d. dosing).59 Preclinical in vivo PK
studies for NVP-LEQ506 resulted in a good bioavailability profile, low clearance, and the
ability to cross the blood-brain barrier.59
The Scripps Research Institute, Novartis, and Harvard University collaborated on
efforts to identify Hh inhibitors that maintain activity in the presence of wild-type and
mutant forms of Smo.60 Both ALLO-1 and ALLO-2 were discovered via a highthroughput screen of ~50,000 compounds from Maybridge and ChemDiv libraries
(Figure 11). Both ALLO-1 and ALLO-2 inhibit Hh signaling in Smo agonist (Hh-Ag1.5)
stimulated TM3-Gli-Luc cells, a stable clone of mouse TM3 cells expressing the Gli-luc
reporter construct (IC50= 50 nM and 6 nM, respectively).60 This Hh inhibition was further
confirmed in a secondary Gli-luciferase reporter assay utilizing TM3-Gli-Luc cells
stimulated with recombinant ligand ShhN (ALLO-1 IC50= 320 nM and ALLO-2 IC50= 39
nM) as well as in a mouse Gli1 expression assay that utilized both human HEPM and
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NIH3T3 cells (ALLO-1 IC50= 805 nM and ALLO-2 IC50= 40 nM.)60 Both compounds
inhibited cell proliferation in ShhN stimulated mouse cerebella granule neuron
progenitors (CGNPs) (ALLO-1 IC50= 410 nM and ALLO-2 IC50= 22 nM) and Ptch1+/-p53/-

mouse medulloblastoma cells (IC50= 0.47 µM and 0.12 µM, respectively).60 Due to

structural similarity to several kinase inhibitors, ALLO-2 was screened for inhibitory
activity against a panel of kinases.

ALLO-2 did not show inhibitory activity in the

presence of these kinases indicating its specificity for the Hh pathway. A multitude of in
vitro assays were utilized to try and determine a mechanism of action for both ALLO-1
and ALLO-2.60 Neither compound inhibited the Hh pathway following treatment with
Sufu-specific siRNA confirming that ALLO-1 and ALLO-2 act upstream within the Hh
signaling cascade. Both compounds successfully competed with BODIPY-cyclopamine
for binding to murine Smo over-expressed in CHO-K1 cells, indicating that they form
direct binding interactions with Smo (ALLO-1, IC50 = 140 nM and ALLO-2, IC50 = 2.8
nM).60 Interestingly, while ALLO-2 demonstrated competitive characteristics with
[3H]cyclopamine at concentrations comparable to its displacement of BODIPY-Cyc in
reporter assays, ALLO-1 did not compete with [3H]cyclopamine. These results suggest
that the binding site of ALLO-1 might reside in a pocket adjacent to the Cyc binding site
where the BODIPY interacts with Smo.60 Finally, both ALLO-1 (IC50 = 1 µM) and ALLO2 (IC50 = 83 nM) were capable of inhibiting the murine homolog of Smo D473H (D477G)
overexpressed in the TM3-Gli-Luc cell line with only a slight reduction in potency
compared to wild-type Smo.60
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Figure 11. Smo Antagonists
Utilizing a cell based screen, researchers at the University of Texas
Southwestern Medical Center identified a series of small molecule Hh pathway
inhibitors.61 Several compounds were identified as potent inhibitors of the Hh signaling
pathway (IHR-1 – IHR-7) with IC50 values ranging from 7.6 – 200 nM 62 (Figure 11). In a
competition assay with BODIPY-Cyc utilizing Smo over-expressed Cos-7 cells, all IHR
compounds demonstrated binding to Smo. The most potent of these compounds, IHR1 (IC50 = 8.9 nM) further demonstrated the ability to prevent translocation of Smo to the
primary cilia and also exhibited down-regulation of endogenous expression of Gli mRNA
in PTCH1-/- cells.61 Interestingly, IHR-1 was significantly less active in the presence of
SAG, a small molecule Smo agonist (IC50 > 10 µM). Follow-up studies demonstrated
that IHR-1 is cell impermeable and is unable to compete with SAG for Smo binding
when the receptor is within the cell. An acetylated version of IHR-1, IHR-NAc,
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demonstrated enhanced cell permeability and was significantly more active against Hh
signaling when the pathway is upregulated with SAG (IC50 = 19 nM).61 These results
strongly suggest that Smo antagonists may not be exhibiting maximum results due to
potential cell impermeability and subsequent inability to reach all cellular Smo
populations.61
Researchers at the Centre National de la Recherche Scientifique utilized a
combined molecular modeling and virtual screening approach to design, synthesize,
and evaluate multiple generations of Smo antagonists consisting of acylureas,
acylthioureas, and acylguanidines.63,64 After comprehensive medicinal chemistry of
these molecular scaffolds, acylguanidine MRT-83 was identified as a potent Hh pathway
inhibitor (IC50 value = 15 nM), with the ability to displace BODIPY-Cyc from Smo (IC50 =
5 nM).64 Molecular docking studies of MRT-83 with several conformations of murine
Smo suggested that MRT-83 bound to a cleft-opened conformation of Smo and that
further extension of the biaryl moiety would provide enhanced interactions between the
scaffold and binding pocket.65 Based on these computational results, a series of
elongated MRT-83 derivatives were synthesized and evaluated for Hh pathway activity.
The most potent of these analogues, MRT-92, is a potent inhibiter of Hh signaling (IC50
= 6 nM) (Figure 11), prevents Smo accumulation in the primary cilia, and displaces
BODIPY-Cyc from human Smo in vitro. Binding studies with a tritiated analogue of
MRT-92 demonstrated that the compound binds comparably to both wild type and
mutant (D473H) Smo (Ki values for both forms of Smo = 0.7 nM).65 There have been
extensive binding studies between several Smo antagonists (including MRT-92) and
various Smo mutants, which account for its ability to retain binding affinity to Smo
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D473H and potentially provide a new binding mechanism to be considered for the
development of Smo antagonists.65
2.4 Novel Smo Antagonist Scaffolds
Combining structural features of ALLO-2, LDE-225, and BMS-833923 lead to a
novel series of Smo antagonists consisting of the N-(2-pyrimidinylamino)benzamide
scaffolds. Researchers at Jiangsu Simcere Pharmaceutical designed this series by
incorporating a 4-(trifluoromethoxy)phenyl moiety of LDE-225 and ALLO-2 (A), a
pyrimidinylamino moiety of ALLO-2 (B) and a biaryl amide functionality of BMS-833923
(C and D) into a single scaffold (Figure 12). An initial screen of these novel hybrid
compounds identified compound 1 as a potent Hh pathway inhibitor (IC50 values = 1.3
nM) (Figure 12).66

Figure 12. Synthetic Smo Antagonists
This novel scaffold was further explored in order to determine the optimal
functionality for potent Hh pathway inhibition. Each region of the scaffold (A-D) was
modified to generate a series of N-(2-pyrimidinylamino)benzamide analogues that were
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evaluated for their ability to inhibit Hh signaling in a luciferase assay utilizing NIH3T3
cells stably transfected with Gli-reporter construct.66 Structure-activity relationship (SAR)
results for region A suggested that a single electron-withdrawing substituent (-OCF3, CN, -F) in either the ortho- or para- position of a phenyl ring was important for optimal
Hh inhibition. The incorporation of various heteroaryl functionalities was also well
tolerated in this region. SAR results for region B determined that small hydrophobic
groups at either position 5 or 6 of the pyrimidinyl moiety retain potent activity.67 It is
important to note that removal of the N-1 of the pyrimidinyl ring was detrimental to Hh
inhibition. SAR studies for the benzamide phenyl ring, region D, demonstrated that a
wide range of functionalities was tolerated in this portion of the scaffold; however, a
basic amine was required to improve the PK properties of the overall scaffold.67 From
this series, analogues 2a and 2b demonstrated potent inhibition of Hh signaling (IC50
values = 0.53 and 0.73 nM, respectively) (Figure 12); however, both compounds
demonstrated unfavorable PK parameters, presumably due to elevated lipophilicity
values (2a, AlogP = 7.07 and 2b, AlogP = 7.37).67 Further structural modifications were
made in an attempt to decrease lipophilicity and to improve the overall drug-like
properties of the scaffold ultimately resulted in compound 3, which demonstrated potent
inhibition of Hh signaling (IC50 = 1.3 nM) and more favorable PK parameters (AlogP =
3.6) (Figure 12).67 Preliminary in vivo PK studies for compounds 2a, 2b, and 3 identified
analogue 3 as having enhanced oral bioavailability.
Researchers at Jiangsu also performed parallel optimization of the N-(2pyrimidinylamino)benzamide scaffold by replacing the pyrimidine ring (B) with a
pyrrolo[2,1-f][1,2,4]triazine moiety.68 This substitution proved promising as the initial
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compound in this series (compound 4) demonstrated potent Hh inhibitory activity with
an IC50 value of 1.6 nM. A typical SAR approach was undertaken and a series of
pyrrolo[2,1-f][1,2,4]triazine benzamide analogues was designed, synthesized, and
evaluated.68 These compounds proved promising in terms of in vitro analysis (IC50
values = 0.62-12.3 nM) and several of the most potent compounds were further
analyzed in vivo to determine preliminary PK properties. Compound 5 contained the
initial para-trifluoromethoxy aryl ring and a meta-morpholine moiety on ring D, had an
IC50 value = 0.83 nM, demonstrated good serum concentration (Cmax = 4185 ng/mL),
oral exposure (AUC = 1935 h ng/mL), and half-life (T1/2 = 8.34 h) (Figure 12).68
Jiangsu further developed a third series of Hh inhibitors developed at Jiangsu
that replace the pyridine ring functionality of vismodegib with an amide- or urea-linked
phenyl ring.69 The addition of this spacer was hypothesized to enhance hydrogenbonding interactions with Smo. The initial compound in this series demonstrated modest
inhibition of Hh signaling (IC50 = 300 nM) and thus further analogues were designed,
synthesized, and evaluated.69 The most active compounds identified, 6a (IC50 = 100
nM) and 6b (IC50 = 40 nM) were also capable of displacing BODIPY-Cyc from human
Smo over-expressed in HEK-293T cells (Figure 13). Compound 6b exhibited enhanced
water solubility and was further evaluated in a variety of in vitro and in vivo model
systems. Most importantly, compound 6b significantly decreased fluorescence
associated with Gli-dependent RFP in a transgenic zebra fish model of Hh signaling.69
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Figure 13. Additional Synthetic Smo Antagonists
A group of researchers at the Chinese Academy of Sciences designed and
synthesized a chimeric compound, NL-103, which contains the structural components of
both vismodegib and the FDA-approved histone deacetylase enzyme (HDAC) inhibitor,
vorinostat (Figure 13).70,71

This followed strong evidence that HDAC inhibitors

exhibited anti-Hh pathway activity.

NL-103 potently inhibited Hh signaling in a Gli-

reporter cell line (IC50 = 19.7 nM) and was capable of displacing BODIPY-Cyc from
human Smo overexpressed in HEK293T cells (KD = 79.6 nM).71 NL-103 also inhibited
HADC1-3 at levels comparable to the FDA-approved vorinostat. Further in vitro
evaluation was performed to distinguish vismodegib and vorinostat mediated Hh
pathway inhibition. Utilizing Hh-dependent cells, NL-103 was tested for its ability to
regulate Gli1, Gli2, and Gli3 mRNA levels.71 At higher concentrations (1-10 µM) both
NL-103 and vorinostat stimulated Gli1 but reduced Gli2 mRNA expression. By contrast,
vismodegib demonstrated significant down-regulation of Gli1 at all concentrations
evaluated but had minimal effects on Gli2 mRNA expression.71 These results suggest
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that while NL-103 does bind Smo, this binding is non-selective; this scaffold retains
significant cellular effects traditionally associated with vorinostat.71

Figure 14. Vismodegib-based Smo Antagonists
Researchers at Soochow University utilized a scaffold hopping approach to
design and optimize a series of Smo antagonists based on the combination of known
Smo antagonist scaffolds.72,73,74 Previous reports suggested that the amide bonds of
both vismodegib and NVL-LDE225 were not crucial for binding to Smo but where
important for linking the aryl regions of these two molecules.73,74,75,76 It was
hypothesized that replacing the amide bond of vismodegib with an alkyl or heteroalkyl
ring would reduce planarity and rotatable bonds, resulting in increased solubility,
absorption, and metabolic stability.72 This approach led to the development of two
related series of compounds based on either a tetrahydroimidazo[1,2-a]pyrazine or
tetrohydrothiazolo[5,4-c]pyridine scaffold.72,73

An extensive medicinal chemistry effort

yielded a variety of substituents on the imidazopyridine moiety: alkyl esters, aryl esters,
and amides. Phenyl amides that incorporated an electron withdrawing moiety at the
meta- or para- position demonstrated the most potency.72 Short alkyl substituents, both
straight chain and ring structures, were less active. The most active analogues in this
series, 7 and 8, inhibited pathway signaling (IC50 = 87 and 200 nM, respectively) (Figure
14). For the closely related thiazolopyridine scaffold, the most potent compounds
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evaluated either contained an ethyl side chain 9 (IC50 = 80 nM) or substituted piperidine
10 (IC50 = 58 nM) as the substituent (Figure 14).73 Both of these compounds displaced
BODIPY-Cyc from full length human Smo over-expressed in U2OS cells. Preliminary in
vivo studies for both 9 and 10 demonstrated promising PK properties similar to those
exhibited by vismodegib.72,73 A comprehensive table of clinically relevant and novel
Smo inhibitors is described below (Table 5).

35

Table 5. Key Synthetic Hh Pathway Inhibitors that Function via Smo.
Compound
NVP-LEQ506
ALLO-1
ALLO-2
IHR-1
IHR-NAc
MRT-92
1
2a
2b
3
4
5
6a
6b
NL-103
7
8
9
10

IC50
Wild-Type
Smo
1.0 nM
410 nM
41 nM
0.01 µM
0.0031 µM
0.7 ± 0.1 nM
1.3 nM
0.53 nM
0.73 nM
1.3 nM
1.6 nM
0.83 nM
100 nM
40 nM
19.7 nM
87 nM
200 nM
80 nM
58 nM

IC50
D473H Smo

Reference

96.0 nM
1 µM
83 nM
ND
ND
0.7 ± 0.2 nM
ND
ND
ND
ND
ND
ND
ND
ND
Active*
ND
ND
ND
ND

[59]
[60]
[60]
[77]
[77]
[65]
[66]
[67]
[67]
[67]
[68]
[68]
[69]
[69]
[71]
[73]
[73]
[73]
[73]

ND: Not determined/reported
*Specific IC50 values were not provided
**Dependent on cellular assay
2.5 ITZ and Hedgehog Signaling
The hedgehog (Hh) pathway is an embryonic cell-signaling pathway that is
responsible for cell differentiation and tissue growth. There are two main regulating
proteins of this pathway: Patched (Ptch) and Smoothened (Smo). As ITZ has been
determined to inhibit the Hh pathway, there have been various explorations into how ITZ
mediates this anticancer activity.

ITZ exhibited similar in vitro results as cyclopamine

and cyclopamine mimics including inhibition of Hh signaling in Ptch-/- cells, in cells
treated with oxysterols, and in cells over expressing Smo. Because of this, ITZ was
originally hypothesized to bind to Smo.9 However, ITZ failed to compete with BODIPY36

cyclopamine indicating that ITZ does not bind to Smo at the same position as
cyclopamine.9 Additional experiments have been performed in the presence of Smo
agonists (SAG) and antagonists (MRT-92); ITZ acts as a non-competitive inhibitor of
SAG and is able to inhibit MRT-92 binding to Smo.65 This evidence suggests that ITZ
may be binding to Smo in a distinct manner than other Smo inhibitors. However, the
binding mode and way in which ITZ is exhibiting Hh pathway inhibition has not been
determined.
In addition to inhibiting the Hh pathway via Smo, ITZ was also found to inhibit the
Hh pathway in the presence of vismodegib-resistant mutant SmoD477G.9,78 Since ITZ
acts in a distinct manner from cyclopamine and cyclopamine mimics, it was predicted
that ITZ may retain activity in the presence of mutant forms of Smo. In ShhN stimulated
Smo-/- mouse embryonic fibroblasts (MEFs) transfected with SmoWT or SmoD477G, ITZ
exhibited inhibitory activity (IC50= 270-690 nM and 500 nM, respectively).9,78 In the
presence of SmoWT or SmoD477G expressing MB tumors, ITZ retained similar inhibitory
activity (SmoWT IC50= 55 nM and SmoD477G IC50= 62 nM).

ITZ was also determined to

remain active in the presence of a variety of other Smo mutants (E522K, G457S,
S391N, D388N, N223D, L225R).78 This ability to inhibit the Hh pathway in the presence
of wild type Smo and mutant Smo makes ITZ a unique Hh pathway antagonist. As a
clinically approved drug, ITZ has a well-known safety profile and has been studied for
many years. Taken together, ITZ serves as a promising anticancer chemotherapeutic
agent.
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3. Angiogenesis
Angiogenesis is described as the formation of new blood vessels. Blood vessels,
which are constructed of endothelial cells (ECs), are essential for the distribution of
oxygen and nutrients throughout the body. These blood vessels play a major role in
embryonic organ growth and development.79,80 Adult blood vessels are necessary for
wound healing, the menstrual cycle, and in the placenta during pregnancy.81,80 The
dysregulation of angiogenesis is a hallmark in a variety of different diseases including
cancer, psoriasis, arthritis, and blindness.79 Angiogenesis is one of the few biological
functions that impact the well-being of many people across the world as its presence
results in a multitude of ailments; about 500 million people would benefit from
therapeutics that modulate angiogenesis.80 The process of angiogenesis remains
complex and involves a large number of cytokines and associated receptors. The stepwise process of forming new blood vessels is thought to consist of multiple signaling
pathways including the vascular endothelial growth factor (VEGF) pathway, the mTOR
pathway, and the Notch pathway. In healthy adults, a balance between pro-angiogenic
and anti-angiogenic molecules tightly regulates angiogenesis.82,83 Any extreme shift in
this equilibrium will lead to uncontrolled angiogenesis, which includes both vascular
insufficiency and vascular overgrowth. Various stimuli affect this “angiogenic switch”
and include metabolic stress, mechanical stress, immune/inflammatory response, and
genetic mutations. In response to these stimuli, the cell releases pro-angiogenic factors
and initiates the angiogenic switch.82,83
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3.1 Pathways Involved in Angiogenesis
The vascular endothelial growth factor (VEGF) receptor family is the most
studied in terms of angiogenesis and is responsible for regulating new blood vessel
growth.

VEGF aids in proliferation and survival of ECs and enhancing vascular

permeability.

This family includes VEGF A, B, C, D, E, and placental growth factor 1

and 2 (PIGF-1 and PIGF-2). VEGF molecules signal through tyrosine kinase receptors,
vascular endothelial growth factor receptors (VEGFR1-3).84–86

Out of the three

isoforms, VEGFR2 is responsible for effects that are directly related to angiogenesis.
VEGF is produced by cancer cells and results in tumor metastasis seen in a number of
different types of cancers. In cancer, VEGF is induced by a number of
pathophysiological factors such as hypoxia, low oxygen tension. After release of VEGF,
it can trigger more cellular pathways such as JAK-STAT, Erk/MAPK, and PI3K/Akt,
which are involved in DNA synthesis/cell growth and cell survival.62,84,85,86
Platelet derived growth factor (PDGF) is an essential protein for blood vessel
maturation. It plays a role in the development and differentiation of blood vessel walls.
PDGF interacts with VEGF and it is believed that these pathways converge and exhibit
activity such as the stabilization and formation of new blood vessels.84–86 It is also
hypothesized that PDGF is activated to overcome resistance acquired from VEGF
inhibition. There are four isoforms of PDGF (A-D) and two isoforms of receptor PDGFR
(a-b). Ultimately, activation of the PDGF pathway leads to downstream signaling of the
PI3K/Atk pathway and subsequent interactions with MAPK molecules, Src proteins,
phospholipase C-gamma, Ras protein, STAT proteins, and guanine-5’-triphosphate
(GTPase)-activating protein.62,84,86,85
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The fibroblast growth factor (FGF) pathway has been extensively studied as an
embryogenesis pathway.

There are 23 isoforms of FGF protein and 5 receptor

isoforms. FGF receptors contain an extracellular immunoglobulin (Ig)-like domain and
an intracellular tyrosine kinase domain.

Ligand binding to receptor causes a

dimerization of receptors and an intracellular signaling cascade.85–87 This signaling
cascade involves downstream proteins involved in the MAPK and PI3K/Akt cascades.
FGF may also exhibit its angiogenesis activity alongside VEGF; there may also be
some crosstalk with the Notch Pathway, which plays a role in cell patterning and
differentiation. The Notch Pathway has also been found to play a significant role in
angiogenesis regarding endothelial cell differentiation.62,87,86,85
Angiopoietin (Ang) exists as two isoforms (Ang-1 and Ang-2) and both may
interact with Tie2 receptor to enhance new vessel production.85,86 Ang-1 acts via the
Akt/survivin pathway to help stabilize new blood vessels.

Ang-2 acts alone or in

combination with other pro-angiogenic factors such as VEGF to establish and enhance
vasculature.85,86 Downstream signaling of the Ang/Tie2 receptor includes the PI3K/Akt
pathway, Protein Kinase B, MAPK/Erk molecules, and Ras pathway molecules.
Blocking the interaction between Ang/Tie2 leads to decreased sprouting and reduction
in number of tumor vessels highlighting this pathways role in angiogenesis.62,85,86
3.2 Angiogenesis and Cancer
Angiogenesis was first observed in malignant cancerous tumors over 100 years
ago. It was later proposed that tumor growth and metastasis are dependent on the
formation of new blood vessels.88 Additional evidence demonstrated that cells in
precancerous tissue develop angiogenic properties on their way to becoming
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cancerous.89

The hypothesis was thus made that inhibition of angiogenesis would

arrest tumor growth; the search began for the development of anti-angiogenic agents to
be utilized as chemotherapeutic agents.82 There are a wide variety of pro-angiogenic
molecules including the well-known vascular endothelial growth factor (VEGF) and
basic fibroblast factor (bFGF). The primary drivers of tumor angiogenesis are hypoxic
cells.82,84,87 Hypoxia results from the distance between the tumor cells and the oxygen
source.

This stimulus causes the cells to secrete pro-angiogenic factors, such as

VEGF, which bind to endothelial cells (ECs). Activation of ECs leads to blood vessel
formation. These newly formed blood vessels attach to the tumor mass and invade the
local tumor environment leading to tumor growth, metastatic spread, and the
pathogenesis of cancer (Figure 15). 84,82,87,62

Figure 15. Tumor Angiogenesis
3.3 Established Angiogenesis Inhibitors
This link between angiogenesis and tumor growth provided another therapeutic
route towards treating cancer.

A number of synthesized and naturally occurring

compounds have been explored for angiogenesis inhibition. These angiogenesis
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inhibitors would be used to indirectly arrest tumor growth by inhibiting the growth of
blood vessels and depriving tumor cells of oxygen and nutrients. Due to the complexity
of angiogenesis, there are a variety of drug targets for inhibiting this biological function.
As a result, there are a few different classes of angiogenesis antagonists such as
compounds that target angiogenic growth factors and compounds that target endothelial
cell (EC) migration/proliferation. A few angiogenesis inhibitors have been approved by
the FDA including bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent),
pazopanib (Votrient), and everolimus (Afinitor) (Figure 16). Most of these approved
agents are dual-action inhibitors targeting VEGFR/PDGFR and/or various pathways
such as RAF/MEK/ERK and mTOR.90–94 Bevacizumab is a monoclonal antibody (antiVEGF) and serves as the only angiogenesis inhibitor that is not a small molecule.93
While there has been a modestly positive outcome from angiogenesis antagonists in
clinical trials, there has been no long-term survival benefits documented.83 In most
cases, it has been determined that the combination of antiangiogenic agents and
chemotherapeutic agents is more effective than either therapy alone. In addition, while
most chemotherapeutic agents are toxic and confer resistance, antiangiogenic agents
have only shown mild side effects and there are not reported incidents of resistance.
This combination of conventional methods and angiogenesis inhibitors provides a novel
and safe approach for future cancer treatment.83,95
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Figure 16. Small Molecule Angiogenesis Inhibitors

3.4 Combination Therapies
As previously mentioned, angiogenesis inhibitors are not productive enough on
their own to be administered as monotherapy; in addition, resistance is rapidly acquired,
as there are many cellular pathways involved with angiogenesis.83,84 It is anticipated
that the most productive way to utilize angiogenesis inhibitors is in combination with
other chemotherapeutic agents.

Preclinical and clinical evidence suggest dual

treatment with an angiogenesis inhibitor and cytotoxic agents/radiation therapy result in
an additive antitumor effect.83,84 There are several preclinical and clinical trials exploring
angiogenesis inhibitors with EGFr/Her2 inhibitors (cetuximab, erlotinib, trastuzumab);
PDGFR/bcr-abl inhibitors (imatinib); proteosome inhibitors (bortezomib); and inhibitors
of integrins (alphavbeta3 and alpha5beta1).83,84 While combination therapy seems
possible, there are still debates on if this is a practical approach. Paradoxically, an
angiogenesis inhibitor may deteriorate blood vessels and blood flow, which would
decrease the efficacy of chemotherapy and drug delivery to the tumor site.83,84
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3.5 ITZ and Angiogenesis
Because angiogenesis is implicated in a variety of ailments, a therapeutic agent
that targeted angiogenesis would be beneficial to many people.10 Johns Hopkins
University screened 2,604 FDA approved drugs for antiangiogenic activity utilizing
human umbilical vein endothelial cell (HUVEC) proliferation assays.

From these

screens, ITZ was found to be a potent and selective inhibitor of VEFG-induced
proliferation in HUVEC cells (IC50= 0.16 µM).10 Other azole antifungals were also
screened for antiangiogenic activity. All other azole antifungals were less potent than
ITZ

including

ketoconazole

and

terconazole

(IC50=

10.4

µM

and

7.1

µM,

respectively).10,96
Clinically, ITZ is used as a 1:1:1:1 mixture of four diastereomers.14 Johns
Hopkins further explored the antiangiogenic activity of all eight stereoisomers of ITZ.
Stereochemistry minimally effected antiangiogenic activity.97 The most prominent effect
was seen within the dioxolane region, where the cis-diastereomers were more potent
than the trans-diastereomers. The stereochemistry of the sec-butyl group was found to
have little influence on the endothelial cell inhibitory activity.97 While the ITZ
antiangiogenic mechanism is still being unraveled, Johns Hopkins University
determined that ITZ inhibits cholesterol trafficking, the mTOR pathway, and VEGFR
signaling in HUVECs.98,96

It has also been determined that ITZ inhibits the mTOR

pathway and the ERK1/2 pathway in HMEC-1 cells, a primary cell line with a limited life
span and variable characteristics due to multi-donor origins.99
The antiangiogenic activity of ITZ can be attributed to its inhibition of the
mechanistic Target of Rapamycin (mTOR) signaling pathway via the disruption of
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cholesterol trafficking between the plasma membrane and late endosomes/lysosomes.98
This activity is due to ITZ’s ability to inhibit both Niemann-Pick Type C (NPC1) and
voltage-dependent anion channel 1 (VDAC1) which inhibit the mTOR pathway through
distinct mechanisms.100,101 NPC1 inhibition prevents the release of cholesterol from the
lysosome to the rest of the cell.

VDAC1 is a critical regulator of mitochondrial

metabolism and its inhibition leads to a drop in cellular energy levels; VDAC1 is shown
to be a novel target for modulation of the mTOR pathway (Figure 17).100,101 This
anticancer activity can also be attributed to its ability to inhibit vascular endothelial
growth factor receptor 2 (VEGFR2).96 Because of this, ITZ is currently in several clinical
trials that represent a broad range of cancers: breast, prostate, and non-small cell
lung.11
ITZ

VDAC1

↓ ATP
↑ AMPK
↑ HIF

↓ mTOR Activation

ITZ

NPC1

↓ Cholesterol
Trafficking
↑ VEGF

↑ Angiogenesis

Figure 17. ITZ Proposed Mechanism of Action: Antiangiogenesis Activity101
4. Conclusions
Exploring FDA-approved or clinical stage compounds for novel biological
activities is becoming a popular way to expedite the long and expensive drug
development process.2 There are many benefits to this approach such as decreased
time and expense, however, there are also disadvantages associated with this form of
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drug discovery.

Recently, two separate screening efforts found ITZ, a clinically

efficacious antifungal agent, to inhibit both the Hh pathway and angiogenesis.9,10 While
the Hh pathway has been studied for many years, the emergence of resistance
highlights the therapeutic need for novel Hh pathway inhibitors.50 ITZ is of therapeutic
promise due to its unique ability to inhibit the Hh pathway in the presence of both wild
type Smo and mutant Smo.78 In addition, ITZ has been found to contain other biological
activities, such as angiogenesis inhibition, that may aid in its anticancer properties.
These biological activities all seem to act in distinct manners from one another. It is
possible that these activities may yield synergistic effects in anticancer treatment
supporting the many clinical trials that ITZ is currently being studied.
The overall goal of this research project is to utilize the scaffold of the FDAapproved antifungal agent, ITZ, for the treatment of SHH subtype MB. To date, ITZ has
not been thoroughly explored in terms of its novel anticancer properties.

More

specifically, ITZ has not been studied as a potential anti-MB chemotherapeutic agent.
In terms of its anti-Hh activity, only one SAR study has been reported which focuses on
extending the side-chain region of the scaffold.

As there is currently not an FDA-

approved targeted treatment for MB, it is necessary to explore Hh inhibitors as an
alternative option for therapy. The ITZ analogues presented herein will be focused on
improving the general “drug-like” properties of this approved compound while also
maintaining potent Hh pathway activity. These analogues may be modified to have the
optimal properties necessary to penetrate the blood brain barrier (BBB) and treat
pediatric MB.

If optimal drug-like properties cannot be attained after considerable
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structure-activity relationship (SAR) studies, drug formulation will be utilized to assist the
most potent in vitro ITZ analogues to cross the BBB and reach the brain.

47

CHAPTER II: Structure-Activity Relationship Studies of Itraconazole Analogue
Generations I and II
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1. Introduction
Recently, two separate high-throughput screens of FDA-approved compounds
identified itraconazole (ITZ), a well-known antifungal agent, to be an inhibitor of both the
Hh pathway and angiogenesis (IC50 = 690 nM and 160 nM, respectively).9,10

The

potential to repurpose FDA-approved and clinical stage compounds with novel
biological activities is an increasingly popular drug development strategy.2 While ITZ is
now in various clinical trials for its anti-cancer potential, it contains some drug properties
that would not make it an ideal chemotherapeutic agent.12,11 ITZ contains a triazole
group, which is capable of coordinating with CYP3A4; this interaction leads to drug-drug
interactions and adverse side effects.102 As cancer patients are often on a multi-drug
regimen to both treat the cancer and manage the symptoms, these drug-drug
interactions would be probable in the presence of ITZ.
To date, the ITZ scaffold has been minimally explored in terms of its novel anticancer properties. The ability for ITZ to inhibit angiogenesis, specifically through
vascular-endothelial growth factor receptor 2 (VEGFR2), NPC1, and VDAC1 have been
previously reported.96,101

However, thorough structure-activity relationship (SAR)

studies have not been performed in regards to ITZ and its novel biological activities. In
terms of anti-Hh activity, the only structural component explored has been the sidechain region.103 Thus, a series of ITZ analogues have been designed, synthesized, and
evaluated to probe the ITZ scaffold for its anti-Hh and anti-angiogenic activities.
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2. Design, Synthesis, and Evaluation of Generation I Analogues
2.1 Analogue Design
As previously mentioned, ITZ is a rather large compound that has a complex
chemical structure, which is amendable to various modifications. This first generation
series of ITZ analogues designed, synthesized, and evaluated consists of conservative
modifications to either the dioxolane region or the triazolone/side-chain region (Figure
1). The overall goal of this initial series of analogues is to determine if all the structural
functionality of ITZ is necessary for its anticancer properties. This first generation of
analogues will provide preliminary data that suggests the favorable and unfavorable
structural components of ITZ-mediated Hh inhibition and angiogenesis inhibition.

Is the triazole group
necessary?

N
N

N

O
O

Cl

O

2 4

O

N

N

Cl

N

N
N

2'

Probe triazolone/
side-chain region

Probe dioxolane
region

Figure 1. Design of Generation I Analogues
2.2 Synthetic Routes
2.2.1 Synthesis towards Linker Region
All of the first-generation ITZ analogues contain a central phenyl-piperazinephenyl linker region.

This moiety is initially constructed by coupling commercially

available N-(4-methoxyphenyl)-piperazine (11) and 1-chloro-4-nitrobenzene (12). The
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nitro functionality (13) can then be reduced to the aniline (14) in the presence of
hydrazine monohydrate and 10% palladium on charcoal. The aniline then undergoes a
series of two well-characterized transformations to the carbamate (15) and hydrazine
carboxamide (16) intermediates before ultimately forming the triazolone ring (17)
(Scheme 1).97 The methoxy- substituent in the commercially available starting material
serves as a protecting group throughout this synthetic route; while other protecting
groups have been used during this synthesis, such as methoxymethyl- (MOM-), we
found that the methoxy- group proved more efficient in generating the triazolone
intermediate.103
Scheme 1. Synthesis towards Linker Region
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Reagents and conditions: (a) K2CO3, reflux, 12 h, 82%; (b) Pd/C, NH2NH2•H2O (10 eq), reflux,
3.5 h, 71%; (c) Pyr (17 eq), ClCOOPh (1.1 eq), 3 h, 90%; (d) NH2NH2•H2O (5.5 eq), reflux, 3 h,
quant; (e) formamidine acetate (4.5 eq), acetic acid, reflux, 3 h, 91%.

The triazolone intermediate was alkylated (24-27) with either commercially
available brominated alkyl chains (22,23) or alkyl brosylates (20,21) that were prepared
from corresponding commercially available and stereochemically defined alcohols
(18,19) (Scheme 2).97 The methoxy- group in the triazolone/side-chain intermediate was
removed with 48% hydrobromic acid in toluene to afford various phenols (28-31).104 It is
important to note that alkylation of the triazolone inverts the stereochemistry of the side

51

chain

region,

for

example,

(R)-brosylates

generate

(S)-intermediates.

The

stereochemistry of the triazolone/side-chain regions was monitored throughout these
reactions.

As enantiomers have similar physical properties such as melting points,

densities, boiling points, and refractive indexes, a polarimeter was used to aid in
determining the optical activity and corresponding orientation of the stereochemicallydefined intermediates. If a substance is not optically active, the polarimeter output will
read [α] = 0°. However, if a compound is optically active, the plane of light will either be
rotated clockwise or counter clockwise and the observer will read a (+) or (–) value. It is
important to note that a (+) or (–) value is not indicative of a particular isomer.105 These
polarized values were used in combination with crystal structures to determine the (R)
or (S) configurations of these stereochemically-defined intermediates.
Scheme 2. Synthesis towards Phenol
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alkyl chain, RT, 12 h, 45-88% (c) 48% HBr, toluene, reflux, 12 h, 55-80%.
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2.2.2 Synthesis towards Dioxolane Regions
Dioxolane regions containing the triazole moiety could not be formed under
standard ketalization conditions due to the basicity of the triazole ring.

For these

intermediates, the triazole moiety was added to various halogenated ketones.

In

parallel, tosylated glycerol was formed through standard tosylation of commercially
available dioxolane and subsequent acid mediated hydrolysis (Scheme 3).106 Finally
triazole-containing dioxolanes were prepared through a ketalization reaction utilizing
tosylated glycerol, ketone intermediates, and triflic acid.107 Other attempts were made to
add the triazole group directly to the dioxolane after the ring closing reaction, as this
would be helpful in developing subsequent triazole-mimic analogues; however, this
proved unsuccessful. The des-triazole dioxolanes were synthesized utilizing standard
ketalization conditions that make use of the Dean-Stark apparatus.108 Tosylated glycerol
was used to ketalize 2,4-dichloroacetophenone and yield des-triazole dioxolane.97
Scheme 3. Synthesis towards Dioxolane Region
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Reagents and conditions: (a) NaHCO3, toluene, reflux, 3h, 25-65%; (b) Pyr, TsCl, 0°C- RT, 12
h, 71%; (c) MeOH, 0.5N HCl, reflux, 5 h, 89%; (d) Triflic acid (3-4 eq), toluene, RT, 60 h 1070%.
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2.2.3 Synthesis towards Generation I Final Analogues
Tosylated dioxolane regions were coupled with the linker/triazolone/side-chain
region phenols in anhydrous dimethyl sulfoxide (DMSO) with cesium carbonate
(Cs2CO3) to yield final analogues (Scheme 4A).97 Truncated ITZ analogues were
synthesized via a reversed synthetic route.

Unprotected linker region (44) was

prepared in the same manner as methoxy-protected linker region.103 This intermediate
was then coupled with the tosylated dioxolane region under standard coupling
conditions to yield nitro intermediate (54). This intermediate was then reduced to the
aniline with palladium on charcoal in the presence of hydrazine monohydrate to yield
aniline intermediate (55) (Scheme 4B).103
Scheme 4. Synthesis towards Final Generation I Analogues
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Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 90ºC, 12 h, 45-88%; (b) Pd/C,
NH2NH2•H2O (10 eq), reflux, 3.5 h, 60-70%. The functional groups represented by X, Y, and Z
above can be found in Schemes 2 and 3.
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2.3. Biological Evaluation
Table 1. First Generation Series of ITZ Analogues

Compound

R1

R2

R3

45, ITZ

46

-CH3

47

48

49

-CH3
-CH3

-CH3

50

51

52

53

54

-NO2

55

-NH2

The first generation of ITZ analogues (Table 1) was evaluated for Hh pathway
inhibitory activity by monitoring endogenous Gli1 mRNA levels in C3H10T1/2 (C3H)
55

cells, an Hh-dependent mouse embryonic fibroblast (MEF), at a single concentration
(1µM).

This is a well-studied in vitro model system for evaluating small molecule

inhibition of Hh signaling. Addition of exogenous Hh agonist (recombinant Hh ligand or
small molecule) results in a characteristic increase in Gli1 mRNA expression.109
Combined treatment with Hh agonist and a pathway inhibitor reduces Gli1 expression.
ITZ analogues that reduced Gli1 mRNA expression below 20% at 1µM were
subsequently evaluated for their ability to reduce Gli1 mRNA expression levels in a
concentration dependent fashion in both the C3H cell line and an Hh-dependent murine
basal cell carcinoma cell line (ASZ-001).110,111 Finally, with the help of our collaborators
at Sanford Burnham Prebys Medical Discovery Institute, several generation I analogues
were also tested for their antiproliferative activity in primary Hh-dependent
medulloblastoma cells isolated from conditional Patched knockout Math1-Cre-ER; Ptcfl/fl
(MERP) mice.112,113,114 Only a small subset of analogues was evaluated due to the
difficult nature of culturing primary MERP cells.
As ITZ was found to also inhibit angiogenesis, generation I analogues were
screened for their ability to inhibit VEGF-induced proliferation of human umbilical vein
endothelial cells (HUVECs). Angiogenesis is dependent on endothelial cell proliferation
and the inhibition of HUVEC proliferation is commonly utilized as an early stage in vitro
model of antiangiogenic activity.97,103
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Table 2. In Vitro Activity of First Generation ITZ Analogues
Compound
ITZ
45
46
47
48
49
50
51
52
53
54
55
30
a

% Gli
Expression
(1 µM) b
1.7 ± 0.3
17.8 ± 0.5
13.1 ± 1.2
61.4 ± 3.5
71.4 ± 5.5
6.9 ± 3.1
3.0 ± 0.9
58.5 ± 6.4
1.1 ± 0.2
1.5 ± 0.05
6.1 ± 1.6
45.7 ± 3.0

IC50 (µM) a
C3H10T1/2 b
ASZ c

GI50 (µM) a, d
HUVEC

0.07 ± 0.02
0.06 ± 0.003
0.14 ± 0.04
0.42 ± 0.2
ND
ND
0.16 ± 0.04
0.14 ± 0.04
ND
0.043 ± 0.02
0.13 ± 0.03
0.16 ± 0.06
ND

0.40 ± 0.03
0.49 ± 0.09
23.8 ± 6.7
8.3 ± 0.7
18.4 ± 4.5
>100
2.5 ± 0.3
1.7 ± 0.4
4.7 ± 0.3
5.8 ± 0.8
8.4 ± 0.7
42.7 ± 4.4
>100

0.14 ± 0.02
0.17 ± 0.01
0.17 ± 0.04
0.45 ± 0.06
ND
ND
0.14 ± 0.01
0.16 ± 0.02
ND
0.12 ± 0.03
0.09 ± 0.03
0.12 ± 0.05
ND

GI50 (µM) a
MERP
MB c
0.44 ± 0.08
0.6 ± 0.1
ND
ND
ND
ND
ND
ND
ND
ND
ND
0.9 ± 0.7
ND

IC50 and GI50 values represent the Mean ± SEM of at least two separate experiments performed in
b
c
triplicate. All analogues evaluated following 24 hr incubation. All analogues evaluated following 48 hr
d
incubation. All analogues were evaluated following 72 hr incubation.

Evaluation of the first generation of ITZ analogues (Table 2) yielded structural
features that appear necessary for Hh pathway inhibition. First, the stereochemistry at
the 2’ position of the sec-butyl side-chain region does not appear to be important (50
and 51 are equipotent in the MEF and ASZ cell lines). Truncation to a propyl side-chain
(52) significantly reduces the overall activity of the scaffold. Interestingly, removal of the
side-chain region to the free triazolone (53) and further truncation of the triazolone
region to nitro or aniline substituents (54 and 55) maintained Hh pathway inhibition; all
three of these analogues maintained potent IC50 values in the MEF and ASZ cell lines in
relation to ITZ. In terms of the modifications made to the dioxolane region, removal of
the chlorine atoms of the phenyl ring (47) had minimal effects while truncation of the
phenyl ring all together (48) resulted in significant loss of Hh pathway inhibition.
Removal of the triazole moiety (46) maintained potent Hh pathway inhibition.
57

Not

surprisingly, removal of both the triazole and the phenyl functionality (49) or complete
truncation to the phenol (30) significantly reduced Hh pathway inhibitory activity. Our
synthesized ITZ (45) demonstrated comparable activity to commercially available ITZ in
both the MEF and ASZ cell lines. Overall, these analogues were equipotent in their
ability to down regulate Gli1 mRNA expression in both cell lines evaluated. ITZ, 45, and
55 were tested for their ability to inhibit proliferation of Hh-dependent murine MB cells
and all three of these compounds had slightly reduced activity (Table 2).115
First generation analogues were also evaluated for their ability to inhibit VEGFinduced anti-proliferation in HUVECs, a preliminary assay used to measure
angiogenesis inhibitory potential (Table 2). Commercially available ITZ and synthesized
ITZ (45) demonstrated comparable antiproliferative activity (GI50 values = 0.40 and 0.49
µM, respectively). Other ITZ analogues were significantly less active compared to ITZ.
Several analogues were moderately active (GI50 = 1.7 – 8.4 µM); however, there was no
clear SAR pattern in terms of angiogenesis. Finally, ITZ and des-triazole ITZ (46) were
evaluated for their ability to inhibit CYP3A4 (IC50 values = 50.4 nM and >10 µM,
respectively).

Removal of the triazole moiety results in potent Hh inhibition and

abolishes CYP3A4 inhibition making compound (46) the lead analogue from this first
generation of ITZ analogues (Figure 2).115
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Figure 2. CYP3A4 Inhibition
Calculated IC50 values (µM) for inhibition of CYP3A4 activity by the two compounds are as
follows: ITZ (0.051 ± 0.01 µM) and des-triazole ITZ (>10 µM).

3. Design, Synthesis, and Evaluation of Generation II Analogues
3.1 Analogue Design
Formation of the cis-conformation around the dioxolane ring predominates during
its synthesis and pharmaceutical preparations of ITZ are typically administered as a
1:1:1:1 mixture of cis-diastereomers.115 For efficiency, the first generation of ITZ
analogues was evaluated as mixtures of stereochemical isomers. To probe more fully
the absolute structural requirements of this scaffold for its novel biological activities, a
second generation of analogues was designed, synthesized, and evaluated (Figure 3).
This second generation contains the stereochemically-defined isomers of lead
compound, des-triazole ITZ (46). This generation of compounds will highlight if there is
an optimal stereochemical orientation for either Hh pathway inhibition or angiogenesis
inhibition.115
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Figure 3. Design of Generation II Analogues
It is important to note the difference in nomenclature of the stereochemistry
surrounding the dioxolane region differs between ITZ and des-triazole ITZ. In terms of
ITZ, the triazole moiety receives the priority within the dioxolane region; therefore, the
cis- orientation is in reference to the triazole and ether linkage. By contrast, removal of
the triazole group shifts the priority to the phenyl ring and a cis-des-triazole analogue
has the opposite absolute configuration between the phenyl ring and the ether linkage
as ITZ (Figure 4).115

Figure 4. (A) Representative cis-ITZ isomer, (B) cis- and (C) trans-des-triazole
analogues
3.2 Synthetic Routes
3.2.1 Synthesis towards Stereochemically-Defined Dioxolane Regions
The stereochemically-defined des-triazole dioxolane regions were synthesized
under standard ketalization reaction conditions utilizing a Dean-Stark apparatus.108
Stereochemically-defined tosylated glycerols were prepared via the method described
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previously only beginning with stereochemically-defined commercially available
dioxolane (Scheme 5).106 Formation of the dioxolane ring predominately forms the
trans- isomer and these isomers were best separated via preparative thin layer
chromatography (TLC).
Scheme 5. Synthesis towards Stereochemically Defined Dioxolanes
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Reagents and conditions: (a) p-TsOH (cat.), toluene, reflux (Dean Stark), 48h, 70-90%.

3.2.2 Synthesis towards Final Stereochemically Defined Analogues
As previously described, tosylated dioxolane regions were coupled with the
linker/triazolone/side-chain region phenols in anhydrous dimethyl sulfoxide with cesium
carbonate to yield final analogues (Scheme 6).97
Scheme 6. Synthesis towards Final Generation II Analogues
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3.3 Biological Evaluation
Table 3. Second Generation ITZ Analogues

Compound

R1

Final
Stereochemistry

R2

63

Trans-2,4

64

Cis-2,4

65

Trans-2S,4S,2’S

66

Cis-2R,4S,2’S

67

Trans-2R,4R,2’S

68

Cis-2S,4R,2’S

69

Trans-2S,4S,2’R

70

Cis-2R,4S,2’R

71

Trans-2R,4R,2’R

72

Cis-2S,4R,2’R

73

Trans-2R,4R

62

74

Cis-2S,4R

75

Trans-2S,4S

76

Cis-2R,4S

Evaluation of our stereochemically defined analogues (Table 3) for their ability to
inhibit Hh signaling in the C3H10T1/2 and ASZ cell lines provided both interesting and
confounding results. The majority of compounds evaluated were more active in the
ASZ cells, with numerous analogues exhibiting 100- to 1000-fold improvement in activity
when compared to C3H cells.

Several compounds that were “inactive” in the C3H

cells (IC50 >10 µM) exhibited potent down-regulation of Gli (IC50 – 0.2-0.5 µM) in the
ASZ cell line. In addition, several other compounds with modest inhibitory effects in the
MEF cell line (64, 68, 72) exhibited low nanomolar IC50 values in the ASZ cells (Table
4).115
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Table 4. In Vitro Activity of Second Generation ITZ Analogues

Compound

IC50 (µM) a
C3H10T1/2 b

ASZ c

GI50 (µM) a, d
HUVEC

GI50 (µM) a
MERP
MB c

63
64
65
66

0.091 ± 0.02
0.85 ± 0.1
1.1 ± 0.17
>10

0.077 ± 0.01
0.071 ± 0.02
2.5 ± 0.7
0.55 ± 0.07

3.32 ± 0.55
3.69 ± 1.1
7.7 ± 4.4
78.3 ± 17.3

2.0 ± 1.3
2.9 ± 1.9
ND
ND

67

0.47 ± 0.001

0.38 ± 0.07

18.3 ± 11.8

ND

68

1.85 ± 0.09

0.15 ± 0.038

2.5 ± 0.7

0.39 ± 0.2

69
70
71
72

0.54 ± 0.24
6.6 ± 0.3
0.19 ± 0.04
2.4 ± 0.6

0.13 ± 0.04
2.8 ± 0.9
0.022 ± 0.01
0.024 ± 0.02

12.1 ± 4.7
65.0 ± 11.5
53.2 ± 25.2
12.8 ± 2.9

ND
ND
0.6 ± 0.2
1.0 ± 0.5

73

4.1 ± 1.5

1.3 ± 0.65

26.5 ± 3.5

ND

74
75

>10
>10

1.4 ± 0.5
0.2 ± 0.08

49.9 ± 15.9
84.1 ± 33.5

ND
22.4 ± 12

76
PSZ

>10
0.14 ± 0.02

0.54 ± 0.06
0.54 ± 0.05

24.9 ± 2.2
1.6 ± 0.02

ND
1.5 ± 0.3

a

IC50 and GI50 values represent the Mean ± SEM of at least two separate experiments performed in
b
c
triplicate. All analogues evaluated following 24 hr incubation. All analogues evaluated following 48 hr
d
incubation. All analogues were evaluated following 72 hr incubation.

Despite the conflicting results between cell lines, several interesting SAR
developments with respect to optimal configuration were identified for the second
generation of ITZ analogues (Table 4). These results reiterated that the orientation of
the sec-butyl side-chain substitution is not significant but the methyl group must be
present.

Truncation to the propyl side-chain region abolishes Hh pathway activity.

Compounds containing the propyl side-chain region were significantly less active than
sec-butyl analogues containing the same dioxolane ring orientation.

Generation II

analogues with the trans-orientation around the dioxolane ring were generally more
potent than the cis-orientation throughout all cell lines evaluated. Finally, compounds

64

containing the 4R configuration were generally more active than the 4S configuration;
des-triazole analogues with the 2R,4R configuration demonstrated the most comparable
activity between the two cell lines.115
After evaluation of Hh pathway inhibitory activity in both the C3H10T1/2 and ASZ
cells, select compounds were further evaluated in primary MB (MERP) cells (Table
5).112,113,114

Analogues selected for the antiproliferative assay were chosen either

because they exhibited potency in both cell lines (ASZ and MEF) or because they were
significantly less active in the MEFs in comparison to the ASZs.

Testing the

antiproliferative effects of these analogues in the Hh-dependent primary culture
provided additional in vitro data for the most active trans-oriented compounds and also
aided in determining discrepancies in the Hh pathway inhibitory activity across the two
preliminary cell lines.

The mixtures containing trans- and cis- (63 and 64)

stereoisomers were less active than the single stereochemically defined analogues.
The most active analogue in this assay was analogue 68 (GI50 = 0.39 µM) which has the
cis-2R,4R configuration around the dioxolane moiety.

Further, the reduced

antiproliferative activity exhibited for analogue 75 further highlights the importance of the
methyl group on the side chain region of Hh pathway inhibition.

Based on these

antiproliferative results, several generation II analogues (68, 71, and 72) were evaluated
for their ability to down regulate endogenous Gli1 mRNA expression in the MERP
primary cell line.112–114 Each of these analogues, along with parent compound ITZ,
demonstrated potent down-regulation of Gli1 mRNA expression in this assay.

In

addition, the anti-Hh activity of these analogues in the MERP MB cells more closely
correlated with the data obtained in the ASZ cells. This suggests that the immortalized
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BCC cell line may be a more appropriate early stage in vitro cellular model for Hh
inhibition. Specifically, this model should be utilized in testing compounds that contain
the ITZ scaffold.115
Table 5. Down-Regulation of Gli1 mRNA in MERP MB cells
Compound

IC50 (µM) a, b

ITZ

0.39 ± 0.06

68

0.26 ± 0.12

71

0.19 ± 0.07

72

0.29 ± 0.08

a

b

IC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. All
analogues evaluated following 48 hr incubation.

Following the discovery of ITZ and its novel biological activities, the entire class
of azole antifungals was screened for Hh-inhibitory activity.9 The only other compound
to exhibit comparable activity to ITZ was posaconazole (PSZ), which interestingly has a
very similar chemical structure; ITZ and PSZ share the same phenyl-piperazine-phenyl
linker and differ in their dioxolane and furan rings, halogenated substituents, and sidechain regions (Figure 5). PSZ and the most active generation II analogue (71) share a
similar orientation in terms of their dioxolane/furan rings. Therefore, PSZ was evaluated
for its ability to inhibit Gli1 expression in the C3H, ASZ, and MERP cell lines (Table 4).
Due to its moderate activity in MERP cells, it was concluded that the dioxolane and
hydrophobic side-chain region of ITZ may be more advantageous than the furan and
hydroxylated side-chain region of PSZ.115
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In terms of angiogenesis inhibition, results obtained from the HUVEC
antiproliferation assay did not yield a clear SAR pattern that distinguished one
stereoisomer to be more potent (Table 4). The stereo-defined analogue that had the
most potent activity against HUVEC proliferation was 68 (IC50 = 2.5 ± 0.7 µM), which
contains the (R)-cis-dioxolane region and the (S)-sec-butyl side chain region. When
only the stereochemistry of the sec-butyl moiety is inverted (72), activity is weakened
(IC50 = 12.8 ± 2.9 µM). Overall, compounds containing the (S)-sec-butyl side chain
region were more potent than compounds containing the (R)-sec-butyl side chain
region; compounds containing the (R)-dioxolane region were more potent than the (S)dioxolane, specifically, the (R)-trans dioxolane region carried the most potent activity.
These results differ from the SAR results for Hh pathway inhibition in that the
stereochemistry of the sec-butyl side chain did not play a crucial role in achieving potent
activity. In terms of HUVEC antiproliferation, there is not one dioxolane region that can
be determined as the most potent across the second generation of ITZ analogues.115
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Figure 6. Representative fields from tube formation assay
Treated cells were grown on Matrigel ® for 16h. Phase contrast images were taken from
multiple locations in each well (~8 images/well) on an inverted microscope: (A) DMSO treatment
served as a negative control; (B) Suramin treatment served as a positive control; (C) ITZ
treatment at 10 µM; (D) des-triazole ITZ treatment at 10 µM; (E) 69 treatment at 10 µM; (F) 72
treatment at 10 µM.

Due to this lack of clear SAR, a several of the generation II analogues were
evaluated in a Matrigel® tube formation assay to further explore antiangiogenic
properties of the ITZ scaffold (Figure 6).

Normally, HUVECs plated and grown on

matrigel migrate toward each other, align, and form tubes that resemble in vivo capillary
beds. This type of assay is a more accurate model of angiogenesis as it takes into
account several aspects of proper vessel formation: adhesion, migration, and tube
formation.116 Compounds evaluated in this assay were chosen based on their overall
structure and activity in antiproliferation assays in an attempt to provide the most
relevant preliminary data in terms of generation II analogues and angiogenesis
inhibition. Inhibition of tube formation can be measured via two different parameters:
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tube length and tube junctions. Based on these parameters, inhibition of tube formation
for both ITZ and des-triazole ITZ were comparable at 10 µM. At lower concentrations,
there was a decrease in activity seen in des-triazole ITZ (Figure 7). This highlights the
importance of the triazole moiety in terms of ITZ-mediated angiogenesis inhibition.
Interestingly, the stereochemically defined analogues presented a decrease in activity
even at high concentrations such as 10 µM (Figure 7). Overall, there was minimal
correlation between the HUVEC antiproliferation assay and the HUVEC tube formation
assay. For example the stereochemically-defined analogues were more potent than the
des-triazole ITZ mixture in terms of inhibiting HUVEC proliferation, however showed
opposite activity against HUVEC tube formation. Taken together, these data suggest
that the triazole group of ITZ is important for the antiangiogenic activity of the scaffold
and future SAR studies into this region should be undertaken.115
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Figure 7. Comparison of (A) total tube length and (B) total tube junctions
Phase contrast images were taken from multiple locations in each well (~ 8 images/well) on an
inverted microscope and tube formation parameters (total tube length and total tube junctions)
were quantified using ImageJ (NIH) software. DMSO (negative control) was set to 100% tube
formation for analysis purposes. Suramin (10 µM) was used as the positive control for each
experiment and its ability to inhibit total tube length (51.9 ± 7.8%) and tube junctions (57.6 ±
6.1%) was consistent.

69

In addition to exploring ITZ and its analogues for these novel biological activities,
a few of these compounds were evaluated in pharmacokinetic (PK) assays. These PK
data helped determine if the structural changes made were advantageous to improving
the overall drug-like properties of the ITZ scaffold (Table 6). None of these compounds
are substrates for BBB efflux proteins p-glycoprotein (P-gp) or breast cancer resistant
protein (BCRP).

The trans-dioxolane improves solubility in comparison to the cis-

dioxolane analogue (Solubility = 1.56 and 0.8 µM, respectively). Interestingly, the cisdioxolane analogue has a more optimal IC50 value against CYP3A4. Compounds ITZ,
71, and 72 were also screened for their ability to passively permeate membranes in a
parallel artificial membrane permeability assay (PAMPA).

The des-triazole ITZ

analogues have poor permeability in comparison to parent compound ITZ.
Table 6. Pharmacokinetic Data for Generation II Analogues
Compound

Solubility (µM)

BCRP

P-gp

PAMPA

ITZ
71
72

0.8
1.56
0.8

No
No
No

No
No
No

Moderate
Poor
Poor

CYP3A4
IC50 (µM)
0.4
1.02
>20

4. Conclusion
Analogue generations I and II provided interesting information regarding the ITZ
scaffold and its novel anticancer activities. First, the triazole moiety can be removed
and still maintain Hh pathway inhibition. This is important as removal of this triazole
region decreases the overall size of the scaffold and abolishes coordination with
CYP3A4. Second, while the stereochemistry of the side-chain region does not play a
significant role in Hh pathway inhibition, the stereochemistry of the dioxolane region
proved to be important.115 SAR studies indicated that the most potent stereochemical
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orientation was the 2R,4R-trans-dioxolane region. In terms of angiogenesis inhibitory
activity, no clear SAR pattern was determined even after a tube formation assay on
Matrigel®.

While the triazole region is less important for Hh inhibitory activity, this

moiety seems to be necessary for angiogenesis inhibition, as ITZ remained the most
potent compound in both the HUVEC proliferation assay and the tube formation
assay.115 As future analogues will not contain the triazole region, angiogenesis will no
longer be explored. ITZ is a large compound and there are still regions and structural
functionality to explore in terms of these novel biological activities. The SAR studies of
ITZ analogue generations I and II remain important for the design, synthesis, and
evaluation of future des-triazole ITZ analogues.

Thank you to Dr. Albert DeBerardinis for his assistance with the synthesis, purification,
and preliminary evaluation of the des-triazole ITZ analogues.

4.1 Experimental
Purity Analysis of Final Analogues: It is important to note that generation I final ITZ
analogues were synthesized and evaluated as stereoisomeric mixtures.

This initial

series was not separated into individual isomers and the ratio between cis/trans was not
determined after the dioxolane reaction. The mixtures of these final analogues are
reflected in the 1H and

13

C NMR characterization data described below and the spectra

provided in Appendix A. Purity analysis for all final analogues was determined via one
of the following methods.
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Method A: ITZ analogues were dissolved in HPLC-grade MeCN and injected (20µL of a
1mM solution) into an Agilent Manual FL-Injection Valve (600 bar) on an Agilent
1100/1200 Series HPLC equipped with an Agilent Eclipse Plus C18 (4.6 x 100mm)
column and Agilent 1100 Series Photodiode Array Detector.

The mobile phase

consisted of 60% MeCN/40% H2O for analogues containing the triazole moiety and 70%
MeCN/30% H2O for des-triazole ITZ analogues. All analogues were run at a flow rate of
1.0 mL/min for 20 min and purity was assessed at 254 nm.
Method B: ITZ analogues were dissolved in HPLC-grade MeCN and injected (20µL of a
1mM solution) into an Agilent HPLC system coupled to an Agilent ESI single quadrupole
mass spectrometer equipped with a Kinetix C18 (150 x 4.6 mm) column and an Agilent
G1315 diode array detector. The mobile phase consisted of 70% MeCN/30% H2O for
des-triazole ITZ analogues. All analogues were run at a flow rate of 0.7 mL/min for 30
min and purity was assessed at 254 nm.
Previously Characterized Intermediates: Common ITZ linker region, dioxolane region,
side chain, and coupled intermediates were prepared primarily as described previously
for the ITZ scaffold with the minor modifications described in Appendix A.
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4triazol-3-one (46) . To a solution of 30 (50 mg, 0.127 mol) in DMSO (2 mL) was added
dioxolane tosylate 43 (67 mg, 0.139 mmol) followed by Cs2CO3 (0.41 mg, 1.27 mmol).
The mixture was warmed to 80 °C and stirred for 16 h. The mixture was cooled to RT
and water was added slowly (6 mL) with vigorous stirring to form a precipitate. The
precipitate was filtered, washed with water, and determined to be the product with only
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DMOS as an impurity. The precipitate was dissolve in EtOAc (60 mL) and washed with
water (50 mL). The aqueous layer was washed with EtOAc (1 X 50 mL) and the
combined organic layers were dried (Na2SO4), filtered, and concentrated. The crude
residue was purified by column chromatography (SiO2, 0-80% acetone in hexanes) and
sonicated in pentanes to produce 46 as a white solid (62 mg, 69%). 1H NMR (500 MHz,
CDCl3) δ 8.20 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 10.6 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.50 –
7.39 (m, 3H), 7.06 – 6.99 (m, 2H), 6.94 (d, J = 9.1 Hz, 1H), 6.88 (d, J = 8.9 Hz, 1H),
6.84 – 6.77 (m, 1H), 6.69 – 6.61 (m, 1H), 4.88 – 4.70 (m, 2H), 4.40 – 4.19 (m, 2H), 3.96
– 3.87 (m, 1H), 3.85 – 3.76 (m, 2H), 3.54 – 3.44 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H),
1.87 (m, 1H), 1.72 (m, 1H), 1.39 (dd, J = 6.7, 1.4 Hz, 3H), 0.91 (m, 3H).

13

C NMR (126

MHz, CDCl3) δ 152.52, 152.43, 151.94, 151.49, 151.31, 150.45, 145.94, 145.89,
144.81, 144.60, 135.98, 135.70, 134.97, 133.97, 133.81, 133.04, 132.89, 131.35,
131.06, 129.52, 129.42, 127.15, 126.98, 125.87, 123.46, 118.37, 118.27, 116.58,
115.19, 115.08, 74.62, 67.57, 67.37, 54.30, 53.53, 52.58, 50.49, 49.15, 28.35, 19.17,
10.70. DART-HRMS: m/z calcd. for C35H38Cl2N8O4 [MH]+, 705.2471; Found: 705.2474.
IR (solid) vmax: 3125, 2966, 2832, 1698, 1585, 1551, 1510, 1450, 1379, 1228, 1184,
1139, 1042, 976, 944, 824, 736. Purity: 98.0% (Method A).
1-(sec-butyl)-4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one

(47).

To

a

solution of 30 (64 mg, 0.163 mmol) in DMSO (10 mL) was added sodium hydride (1.14
mmol). The mixture was warmed to 50° C and stirred for 2 h. To this solution was added
57a (62 mg, 0.148 mmol in DMSO, 5 mL). The solution was warmed to 90° C and
stirred for 12 h. The mixture was cooled to RT and H2O (30 mL) was added slowly with
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vigorous stirring. The mixture was washed with EtOAc (3 X 100 mL), and the organic
layers were combined, dried (Na2SO4), filtered, and concentrated. The crude residue
was purified by column chromatography (SiO2, 0-5% MeOH in DCM) to afford 47 as a
reddish-brown solid in modest yield (34%). A portion of 47 was dissolved in chloroform
and slow evaporation provided off-white crystals that were utilized for the biological
assays. 1H NMR (500 MHz, CDCl3) δ 7.66 – 7.59 (m, 2H), 7.46 – 7.36 (m, 3H), 7.21 (m,
1H), 7.06 – 7.00 (m, 2H), 7.01 – 6.71 (m, 4H), 4.37 – 4.25 (m, 2H), 4.12 (m, 1H), 4.01
(m, 1H), 3.96 (m, 1H), 3.79 (m, 1H), 3.36 (d, J = 6.2 Hz, 4H), 3.31 – 3.17 (m, 4H), 1.89 –
1.82 (m, 1H), 1.82 (s, 3H), 1.78 (s, 1H), 1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.90 (t, J
= 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.0, 150.5, 138.1, 134.5, 133.8, 132.8,

131.1, 128.8, 128.5, 126.7, 126.6, 125.9, 123.5, 118.4, 116.6, 115.5, 109.0, 73.9, 69.2,
66.9, 52.7, 50.6, 49.2, 28.4, 25.8, 25.7, 19.2, 10.7. DART-HRMS: m/z calcd. for
C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2298. IR (solid) vmax 2960, 2922, 2874,
2850, 1696, 1552, 1509, 1462, 1449, 1376, 1226, 1192, 1149, 1076, 1034, 870, 734.
Purity: 98.0% (Method A).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-phenyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-(sec-butyl)-1H-1,2,4-triazol-5(4H)-one
(48). ITZ analogue 48 was prepared using the general method described above for
analogue 46 utilizing the requisite linker/side chain and dioxolane intermediates (23 mg,
47%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.91 (s, 1H), 7.61 (s, 1H), 7.57 – 7.51
(m, 2H), 7.46 – 7.34 (m, 5H), 7.06 – 7.00 (m, 2H), 6.96 – 6.90 (m, 2H), 6.82 – 6.76 (m,
2H), 4.54 (d, J = 1.6 Hz, 2H), 4.39 – 4.25 (m, 2H), 3.90 (dd, J = 8.4, 6.7 Hz, 1H), 3.77
(m, 2H), 3.44 (m, 1H), 3.39 – 3.33 (m, 4H), 3.26 – 3.16 (m, 4H), 1.93 – 1.80 (m, 1H),
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1.78 – 1.65 (m, 1H), 1.39 (d, J = 6.8 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H).

13

C NMR (126

MHz, CDCl3) δ 152.45, 151.61, 145.20, 139.21, 134.33, 129.63, 129.08, 126.23,
123.97, 118.89, 117.09, 115.69, 74.96, 68.39, 67.73, 56.33, 53.09, 51.03, 49.65, 28.86,
19.67, 11.21. DART-HRMS: m/z calcd. for C35H40N8O4 [MH]+, 637.3251; Found:
637.3271. IR (solid) vmax 3122, 3058, 2961, 2825, 1693, 1602, 1551, 1508, 1448,
1388, 1327, 1296, 1226, 1180, 1135, 1939, 944, 823, 736, 701, 676. Purity: 97.1%
(Method A).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4triazol-3-one (49). ITZ analogue 49 was prepared using the general method described
above for analogue 46 utilizing the requisite linker/side chain and dioxolane
intermediates. (45%) 1H NMR (500 MHz, CDCl3) δ 8.30 – 8.10 (m, 1H), 7.94 (s, 1H),
7.62 (s, 1H), 7.43 (d, J = 8.5 Hz, 2H), 7.03 (d, J = 8.9 Hz, 2H), 6.97 – 6.87 (m, 2H), 6.84
(t, J = 9.9 Hz, 2H), 4.49 (t, J = 5.8 Hz, 1H), 4.39 (s, 1H), 4.36 – 4.24 (m, 2H), 4.15 (m,
1H), 4.03 – 3.84 (m, 1H), 3.79 (m, 1H), 3.69 – 3.59 (m, 1H), 3.42 – 3.33 (m, 4H), 3.24 (t,
J = 5.0 Hz, 4H), 1.92 – 1.81 (m, 1H), 1.72 (m, 1H), 1.44 (s, 1H), 1.43 – 1.36 (m, 5H),
0.90 (t, J = 7.4 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 152.7, 152.0, 151.4, 150.5, 145.9,
144.6, 133.9, 125.9, 123.5, 118.5, 118.4, 116.6, 115.3, 115.2, 108.0, 75.4, 74.8, 68.5,
67.7, 67.5, 67.1, 55.7, 55.6, 52.6, 50.6, 49.2, 28.4, 23.5, 22.5, 19.2, 10.7. IR (solid)
vmax 3121, 3053, 2930, 2850, 2809, 1702, 1683, 1548, 1510, 1471, 1452, 1336, 1251,
1134, 1106, 1068, 1050, 940, 883, 735.

DART-HRMS: m/z calcd. for C30H39N8O4

[MH]+, 575.3094; Found: 575.3090. IR (solid) vmax: 2967, 2934, 2878, 2837, 1701,
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1554, 1510, 1450, 1382, 1225, 1181, 1136, 1042, 1017, 942, 826, 784. Purity: 95.1%
(Method A).
1-(sec-butyl)-4-(4-(4-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (50). ITZ analogue 50 was prepared using the
general method described above for analogue 47 utilizing the requisite linker/side chain
and

dioxolane

intermediates.

The

crude

residue

was

purified

via

column

chromatography (SiO2, 0-5% MeOH in DCM) to afford 50 in modest yield (14 mg, 21%)
1

H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 2H), 7.03 (d,

J = 8.5 Hz, 2H), 6.94 (s, 1H), 6.89 (d, J = 8.4 Hz, 2H), 4.46 (m, 1H), 4.29 (m, 1H), 4.16
(t, J = 7.4 Hz, 1H), 4.04 (m, 1H), 3.90 (m, 2H), 3.37 (s, 2H), 3.24 (s, 2H), 1.86 (m, 1H),
1.71 (m, 1H), 1.46 (s, 3H), 1.39 (d, J = 7.8 Hz, 6H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR

(126 MHz, CDCl3) δ 152.44, 134.28, 124.08, 123.96, 118.93, 117.14, 115.81, 110.13,
74.49, 69.77, 67.32, 53.11, 51.11, 49.62, 33.08, 28.86, 27.22, 25.79, 19.66, 11.20.
DART-HRMS: m/z calcd. for C28H37N5O4 [MH]+, 508.2924; Found: 508.2909. IR (solid)
vmax: 3126, 3060, 2967, 2926, 2878, 2828, 2212, 1681, 1584, 1556, 1510, 1452, 1380,
1226, 1149, 1037, 941, 819, 736. Purity: 97.5% (Method B).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((S)-sec-butyl)-2,4-dihydro-3H-1,2,4triazol-3-one (51). ITZ analogue 51 was prepared using the general method described
above for analogue 46 utilizing the requisite linker/side chain and dioxolane
intermediates (55%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.89 (s, 1H), 7.61 (s,
1H), 7.57 (d, J = 8.3Hz, 1H), 7.47 (d, J = 2.1Hz, 1H), 7.43 (d, J = 8.9Hz, 2H), 7.03 (d, J
= 9.0Hz, 2H), 6.94 (m, 2H), 6.80 (m, 2H), 4.80 (m, 2H), 4.36 (m, 1H), 4.28 (m, 1H), 3.92
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(m, 1H), 3.81 (m, 2H), 3.48 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.72 (m,
1H), 1.39 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ

152.6, 151.4, 150.5, 146.0, 144.8, 136.0, 134.0, 133.8, 133.1, 131.4, 129.6, 127.2,
125.9, 123.5, 118.4, 116.6, 115.2, 109.9, 107.6, 74.7, 67.6, 67.4, 53.6, 52.6, 50.5, 49.2,
28.4, 19.2, 10.7. DART-HRMS: m/z calcd. for C35H39Cl2N8O4 [MH]+, 705.2471; Found:
705.2465. IR (solid) vmax: 2967, 2930, 2878, 1695, 1586, 1552, 1509, 1451, 1378,
1226, 1183, 1130, 1038, 947, 816, 736. Purity: 97.9% (Method A).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((R)-sec-butyl)-2,4-dihydro-3H-1,2,4triazol-3-one (52). ITZ analogue 52 was prepared using the general method described
above for analogue 46 utilizing the requisite linker/side chain and dioxolane
intermediates (77%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.89 (s, 1H), 7.64 –
7.54 (m, 2H), 7.50 – 7.40 (m, 3H), 7.03 (d, J = 8.6 Hz, 2H), 6.95 (s, 1H), 6.81 (d, J = 8.4
Hz, 2H), 4.84 (d, J = 14.7 Hz, 1H), 4.76 (d, J = 14.7 Hz, 1H), 4.39 – 4.25 (m, 2H), 3.92
(m, 1H), 3.86 – 3.77 (m, 2H), 3.50 (m, 1H), 3.38 (s, 2H), 3.25 (s, 3H), 1.87 (m, 1H), 1.72
(m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
152.5, 152.0, 151.3, 150.5, 146.0, 136.0, 134.0, 133.8, 133.1, 131.4, 129.5, 127.2,
125.9, 123.5, 118.4, 116.6, 115.2, 107.6, 77.2, 74.7, 67.6, 67.4, 53.6, 52.6, 50.5, 49.2,
28.4, 19.2, 10.7. DART-HRMS: m/z calcd. for C35H39Cl2N8O4 [MH]+, 705.2471; Found:
705.2468. IR (solid) vmax: 3067, 2966, 2934, 2878, 2832, 1695, 1585, 1551, 1509,
II

1450, 1379, 1225, 1180, 1136, 1039, 944, 820, 794. Purity: 95.0% (Method A).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-propyl-1H-1,2,4-triazol-5(4H)-one (53).
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ITZ analogue 53 was prepared using the general method described above for analogue
47 utilizing the requisite linker/side chain and dioxolane intermediates (50 mg, 68%). 1H
NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.89 (s, 1H), 7.59 (d, J = 21.6 Hz, 2H), 7.48 (s,
1H), 7.41 (s, 2H), 7.04 (s, 2H), 6.93 (s, 2H), 6.81 (s, 2H), 4.80 (d, J = 23.3 Hz, 2H), 4.36
(s, 1H), 3.92 (s, 1H), 3.82 (s, 4H), 3.52 (s, 1H), 3.37 (s, 4H), 3.24 (s, 5H), 1.84 (s, 2H),
0.98 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.60, 136.48, 134.30, 133.55, 131.85,

130.02, 127.65, 123.98, 117.08, 115.73, 108.05, 75.13, 68.11, 54.05, 51.01, 49.60,
47.62, 22.43, 11.50. DART-HRMS: m/z calcd. for C34H36Cl2N8O4 [MH]+, 691.2315;
Found: 691.2329. IR (solid) vmax: 3068, 2960, 2925, 2873, 2835, 1696, 1585, 1553,
1510, 1452, 1379, 1225, 1160, 1136, 1045, 944, 823, 794. Purity: 95.2% (Method A).
1-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)-4-(4-nitrophenyl)piperazine (54). To a solution of 44 (100 mg,
0.336 mmol) in DMSO (4 mL) was added Cs2CO3 (1.1 g, 3.36 mmol) and 43 (0.29 g,
0.604 mmol). The solution was warmed to 90° C and stirred for 12 h. The mixture was
cooled to room temperature and water was added slowly with vigorous stirring (~6 mL).
A yellow precipitate formed, which was filtered and recrystallized in EtOH to yield 54
(150 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 8.22 – 8.12 (m, 3H), 7.90 (s, 1H), 7.58 (d,
J = 8.5 Hz, 1H), 7.48 (d, J = 2.1 Hz, 1H), 6.95 – 6.86 (m, 4H), 6.86 – 6.78 (m, 2H), 4.84
(d, J = 14.8 Hz, 1H), 4.76 (d, J = 14.7 Hz, 1H), 4.36 (m, 1H), 3.92 (m, 1H), 3.85 – 3.75
(m, 3H), 3.61 – 3.55 (m, 4H), 3.48 (m, 1H), 3.26 – 3.20 (m, 4H). 13C NMR (126 MHz,
CDCl3) δ 154.79, 152.90, 151.42, 145.67, 144.94, 138.79, 136.14, 134.08, 133.17,
131.49, 129.63, 127.28, 125.99, 118.58, 115.39, 112.90, 107.69, 74.72, 67.71, 67.45,
53.63, 50.33, 47.29. DART-HRMS: m/z calcd. for C29H28Cl2N6O5 [MH]+, 611.1577;
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Found: 611.1601. IR (solid) vmax: 3116, 2923, 2852, 1589, 1557, 1506, 1456, 1377,
1318, 1226, 1136, 1029, 975, 942, 896, 823, 737, 691. Purity: 95.0% (Method A).
4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)aniline (55). 10% palladium on carbon (1.04 mg,
5% mole ratio) was added to a dry round bottom flask. Ethanol (25 mL) was added
followed by slow addition of 54 (120 mg, 0.196 mmol). Hydrazine monohydrate (0.06
mL, 1.96 mmol) was added dropwise and the mixture was stirred at reflux for 2 h. Upon
cooling to RT, the mixture was filtered through celite. The celite was washed with
ethanol (100 mL) and chloroform (250 mL) to ensure complete elution of the aniline.
The filtrate was concentrated to afford a yellow solid, which was recrystallized in EtOH
to afford 55 (70 mg, 61%). 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 8.15 (d, J = 9.4Hz,
2H), 7.89 (s, 1H), 7.57 (d, J = 8.4Hz, 1H), 7.47 (m, 1H), 7.25 (m, 1H), 6.92 (m, 2H), 6.88
(d, J = 9.5Hz, 2H), 6.80 (d, J = 9.0Hz, 2H), 4.80 (m, 2H), 4.36 (m, 1H), 3.91 (m, 1H),
3.80 (m, 2H), 3.58 (m, 4H), 3.47 (m, 1H), 3.22 (m, 4H).

13

C NMR (126 MHz) δ 154.7,

152.8, 151.3, 145.6, 144.9, 138.7, 136.1, 134.0, 133.1, 131.4, 129.6, 127.2, 125.9,
118.5, 115.3, 112.8, 107.6, 74.6, 67.6, 67.4, 53.6, 50.3, 47.2. DART-HRMS: m/z calcd.
for C29H31Cl2N6O3 [MH]+, 581.1835; Found: 581.1818. IR (solid) vmax: 3084, 2886,
2827, 1558, 1504, 1313, 1224, 113, 1030, 942, 821, 749. Purity: 96.1% (Method A).
General protocol for tosylate/phenol coupling and final analogue purification. To
a solution of alkyl-substituted phenol (28-31) (40 mg, 0.102 mmol) in DMSO (2.0 mL)
was added des-triazole-tosylate (57b-57c, 59-62) (46 mg, 0.110 mmol) followed by
Cs2CO3 (0.82 mmol). The mixture was warmed to 80° C and stirred for 16 h. The
mixture was then cooled to RT and water was added slowly (6 mL) with vigorous
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stirring, which resulted in formation of a precipitate. The mixture was transferred to a
separatory funnel, diluted with EtOAc (60 mL) and washed with water (50 mL). The
aqueous layer was washed with EtOAc (1 X 60 mL). The organic layers were combined,
dried (MgSO4), filtered, and concentrated. The crude residue was purified by column
chromatography (SiO2, 0 to 24% acetone in hexanes) to afford 47, 63-76 as white to
slightly off-white solids in good yields (45-88%). Final analogues were subsequently
sonicated in pentanes (10-30 min) to remove a “grease-like” impurity (observed in 1H
NMRs at 0.88, 1.31 ppm) and collected for purity analysis and biological evaluation
following filtration on a fine-fritted glass Buchner style filter funnel.
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4triazol-3-one (63). 1H NMR (500 MHz, CDCl3) δ 7.62 (m, 2H), 7.42 (m, 3H), 7.23 (m,
1H), 7.03 (m, 2H), 6.92 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.01 (m, 1H), 3.97 (m, 1H),
3.84 (m, 1H), 3.36 (m, 4H), 3.24 (m, 4H), 1.87 (m, 1H), 1.81 (s, 3H), 1.72 (m, 1H), 1.39
(d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.7, 152.0,

150.5, 145.8, 139.2, 134.2, 133.8, 132.7, 130.9, 128.5, 126.6, 125.9, 123.5, 118.3,
116.6, 115.2, 109.1, 73.9, 69.3, 66.9, 52.6, 50.6, 49.2, 28.4, 25.6, 19.2, 10.7. DARTHRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2328. IR (solid)
vmax 2961, 2918, 2849, 1694, 1584, 1556, 1509, 1449, 1374, 1329, 1294, 1224, 1186,
1149, 1094, 1035, 1017, 942, 873, 821, 802, 734. Purity: 97.0% (Method B).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4triazol-3-one (64).

1

H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H),
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7.42 (m, 2H), 7.38 (d, J = 2.1 Hz, 1H), 7.19 (m, 1H), 7.01 (m, 2H), 6.89 (m, 2H), 6.73
(m, 2H), 4.60 (m, 1H), 4.29 (m, 2H), 3.94 (m, 1H), 3.73 (m, 1H), 3.35 (m, 4H), 3.21 (m,
4H), 1.85 (m, 1H), 1.77 (s, 3H), 1.71 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4
Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.7, 152.0, 150.5, 145.8, 139.2, 134.2, 133.8,

132.7, 130.9, 128.5, 126.6, 125.9, 123.5, 118.3, 116.6, 115.2, 109.1, 75.0, 68.3, 67.3,
52.6, 50.5, 49.2, 28.4, 25.8, 19.2, 10.7. HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+,
638.2301; Found: 638.2325. IR (solid) vmax 3102, 3008, 2961, 2918, 2899, 2849,
1699, 1597, 1538, 1515, 1411, 1355, 1337, 1254, 1236, 1189 1159, 1106, 1064, 1036,
1024, 999, 936, 896, 831, 807, 741. Purity: 95.1% (Method B).
2-((S)-sec-butyl)-4-(4-(4-(4-(((2S,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (65).
1

H NMR (500 MHz, CDCl3) δ 7.61 (m, 3H), 7.42 (m, 2H), 7.40 (m, 1H), 7.23 (m, 1H),

7.02 (m, 2H), 6.94 (m, 2H), 6.88 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.00 (m, 1H), 3.96
(m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.85 (m, 1H), 1.81 (s, 3H), 1.72 (m, 1H), 1.39 (d, J
= 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.9, 152.0,

150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9, 123.5, 118.4,
116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2, 10.7. DARTHRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2282. IR (solid)
vmax 2962, 2875, 2826, 1694, 1555, 1509, 1448, 1374, 1224, 1186, 1149, 1035, 942,
824, 735. Purity: 97.4% (Method A).
2-((S)-sec-butyl)-4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (66).
1

H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.4 Hz, 2H), 7.61 (s, 1H), 7.42 (d, J = 8.5 Hz,
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2H), 7.38 (d, J = 2.2 Hz, 2H), 7.19 (m, 1H), 7.02 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz,
2H), 6.73 (d, J = 8.5 Hz, 2H), 4.60 (m, 1H), 4.30 (m, 2H), 3.94 (m, 1H), 3.73 (m, 2H),
3.35 (m, 4H), 3.21 (m, 4H), 1.86 (m, 1H), 1.78 (s, 3H), 1.72 (m, 1H), 1.39 (d, J = 6.7 Hz,
3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.8, 152.0, 150.5, 145.8,

139.3, 134.3, 133.8, 132.7, 130.9, 128.5, 126.6, 125.9, 123.5, 118.4, 116.6, 115.2,
109.1, 75.0, 68.4, 67.3, 52.6, 50.6, 49.2, 28.4, 25.8, 19.2, 10.7.

DART-HRMS: m/z

calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2288. IR (solid) vmax 2923,
2851, 1714, 1703, 1683, 1613, 1548, 1509, 1452, 1374, 1271, 1226, 1188, 1150, 1094,
1035, 965, 942, 817, 735. Purity: 95.5% (Method A).
2-((S)-sec-butyl)-4-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (67).
1

H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.41 (m, 3H), 7.23 (m, 1H), 7.02 (m, 2H),

6.94 (m, 2H), 6.89 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.00 (m, 1H), 3.96 (m, 1H), 3.84
(m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.81 (s, 3H), 1.72 (m, 1H), 1.39 (d, J
= 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.9, 152.0,

150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9, 123.5, 118.4,
116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2, 10.7. DARTHRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2284. IR (solid)
vmax 2966, 2935, 2874, 2824, 1693, 1584, 1555, 1508, 1464, 1447, 1373, 1293, 1223,
1186, 1149, 1095, 1035, 942, 875, 824, 734. Purity: 97.3% (Method A).
2-((S)-sec-butyl)-4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (68).
1

H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 7.42 (m, 2H), 7.38
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(d, J = 2.1 Hz, 1H), 7.19 (m, 1H), 7.02 (m, 2H), 6.89 (m, 2H), 6.73 (m, 2H), 4.60 (m, 1H),
4.30 (m, 2H), 3.94 (m, 1H), 3.73 (m, 2H), 3.35 (m, 4H), 3.21 (m, 4H), 1.85 (m, 1H), 1.78
(s, 3H), 1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126

MHz, CDCl3) δ 152.8, 152.0, 150.5, 145.8, 139.3, 134.3, 133.8, 132.7, 130.9, 128.5,
126.6, 125.9, 123.5, 118.4, 118.4, 116.6, 115.2, 109.1, 75.0, 68.4, 67.3, 52.6, 50.6,
49.2, 28.4, 25.8, 19.2, 10.7.

DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+,

638.2301; Found: 638.2281. IR (solid) vmax 2919, 2876, 2849, 1693, 1585, 1555, 1509,
1450, 1375, 1329, 1295, 1225, 1188, 1149, 1095, 1034, 934, 872, 819, 734. Purity:
98.4% (Method A).
2-((R)-sec-butyl)-4-(4-(4-(4-(((2S,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (69).
1

H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.42 (m, 2H), 7.41 (m, 1H), 7.23 (m, 1H),

7.03 (m, 2H), 6.94 (m, 2H), 6.89 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.01 (m, 1H), 3.96
(m, 1H), 3.84 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.87 (m, 1H), 1.81 (s, 3H), 1.72 (m,
1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ

152.9, 152.0, 150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9,
123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2,
10.7. DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2282.
IR (solid) vmax 2967, 2932, 2878, 2827, 1695, 1612, 1586, 1552, 1510, 1460, 1377,
1292, 1253, 1225, 1187, 1147, 1096, 1036, 940, 827, 735. Purity: 95.0% (Method B).
2-((R)-sec-butyl)-4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (70).
1

H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 7.42 (m, 2H), 7.38
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(m, 1H), 7.20 (m, 1H), 7.02 (m, 2H), 6.90 (m, 2H), 6.73 (m, 2H), 4.60 (m, 1H), 4.30 (m,
1H), 3.94 (m, 1H), 3.73 (m, 1H), 3.35 (m, 4H), 3.21 (m, 4H), 1.86 (m, 1H), 1.78 (s, 3H),
1.71 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz,

CDCl3) δ 152.9, 152.0, 150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.7, 126.7,
125.9, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 52.6, 50.6, 49.2, 28.4, 25.7,
19.2, 10.7.

DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found:

638.2287. IR (solid) vmax 3060, 2967, 2932, 2830, 1698, 1611, 1586, 1550, 1512,
1461, 1384, 1296, 1252, 1225, 1189, 1149, 1098, 1036, 940, 896, 824, 735. Purity:
95.0% (Method B).
2-((R)-sec-butyl)-4-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (71).
1

H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.43 (m, 2H), 7.41 (m, 1H), 7.23 (m, 1H),

7.03 (m, 2H), 6.94 (m, 2H), 6.89 (m, 2H), 4.31 (m, 2H), 4.11 (m, 1H), 4.01 (m, 1H), 3.96
(m, 1H), 3.84 (m, 1H), 3.36 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.81 (s, 3H), 1.72 (m,
1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ

153.0, 152.0, 150.5, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1, 128.8, 126.7, 125.9,
123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 67.0, 52.6, 50.6, 49.2, 28.4, 25.7, 19.2,
10.7. DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found: 638.2285.
IR (solid) vmax 2971, 2937, 2879, 2827, 1697, 1509, 1451, 1376, 1296, 1225, 1194,
1147, 1073, 1035, 942, 819, 734. Purity: 97.5% (Method B).
2-((R)-sec-butyl)-4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (72).
1

H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 2H), 7.61 (s, 1H), 7.42 (m, 2H), 7.37
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(m, 1H), 7.19 (m,1H), 7.02 (m, 2H), 6.90 (m, 2H), 6.73 (m, 2H), 4.60 (m, 1H), 4.30 (m,
2H), 3.95 (m, 1H), 3.73 (m, 2H), 3.35 (m, 4H), 3.22 (m, 4H), 1.86 (m, 1H), 1.78 (s, 3H),
1.72 (m, 1H), 1.39 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz,

CDCl3) δ 152.8, 152.0, 150.5, 145.9, 139.3, 134.3, 133.8, 132.7, 130.9, 128.5, 126.6,
125.9, 123.5, 118.4, 118.4, 116.6, 115.2, 109.1, 75.0, 68.4, 67.3, 52.6, 50.6, 49.2, 28.4,
25.8, 19.2, 10.7. DART-HRMS: m/z calcd. for C33H38Cl2N5O4 [MH]+, 638.2301; Found:
638.2284. IR (solid) vmax 2966, 2932, 2904, 2829, 1695, 1553, 1512, 1460, 1444,
1399, 1382, 1254, 1224, 1187, 1148, 1063, 1036, 939, 827, 735.

Purity: 96.4%

(Method A).
4-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3one (73). 1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.41 (m, 3H), 7.23 (m, 1H), 7.02
(m, 2H), 6.94 (m, 2H), 6.89(m, 2H), 4.32 (m, 1H), 4.11 (m, 1H), 4.01 (m, 1H), 3.96 (m,
1H), 3.82 (m, 3H), 3.36 (m, 4H), 3.23 (m, 4H), 1.84 (m, 2H), 1.81 (s, 3H), 0.98 (t, J = 7.4
Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 153.0, 152.1, 150.6, 145.9, 138.1, 134.5, 133.8,

132.8, 131.1, 128.8, 126.7, 125.8, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9,
50.6, 49.2, 47.2, 25.7, 22.0, 11.1. DART-HRMS: m/z calcd. for C32H36Cl2N5O4 [MH]+,
624.2144; Found: 624.2143. IR (solid) vmax 3125, 3059, 2935, 2876, 2829, 1703,
1686, 1614, 1585, 1551, 1510, 1454, 1405, 1375, 1336, 1297, 1225, 1194, 1143, 1094,
1035, 944, 869, 814, 733. Purity: 96.6% (Method B).
4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3one (74). 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.41 (m,
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2H), 7.38 (d, J = 2.1 Hz, 1H), 7.20 (m, 1H), 7.02 (d, J = 8.9 Hz, 2H), 6.90 (d, J = 8.9 Hz,
2H), 6.73 (d, J = 8.9 Hz, 2H), 4.64 (m, 1H), 4.30 (m, 1H), 3.94 (m, 1H), 3.82 (t, J = 7.2
Hz, 2H), 3.73 (m, 2H), 3.35 (m, 4H), 3.21 (m, 4H), 1.83 (m, 2H), 1.78 (s, 3H), 0.98 (t, J =
7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.8, 152.1, 150.5, 145.8, 139.3, 134.3,

133.8, 132.7, 130.9, 128.5, 126.6, 125.8, 123.5, 118.4, 116.6, 115.2, 109.1, 99.9, 75.0,
68.3, 67.3, 50.6, 49.2, 47.2, 25.8, 22.0, 11.1. HRMS: m/z calcd. for C32H36Cl2N5O4
[MH]+, 624.2144; Found: 624.2142. IR (solid) vmax 2966, 2932, 2904, 2830, 1698,
1609, 1585, 1550, 1511, 1461, 1402, 1385, 1336, 1296, 1224, 1189, 1148, 1097, 1036,
940, 875, 824, 735. Purity: 96.5% (Method B).
4-(4-(4-(4-(((2S,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3one (75). 1H NMR (500 MHz, CDCl3) δ 7.64(d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.41 (d, J =
8.8 Hz, 2H), 7.38 (d, J = 2.1 Hz, 1H), 7.02 (m, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.73(m,
2H), 4.60 (m, 1H), 4.30 (m, 1H), 3.94 (m, 1H), 3.81 (t, J = 7.2 Hz, 2H), 3.73 (m, 2H),
3.35 (m, 4H), 3.22 (m, 4H), 1.83 (m, 2H), 1.78 (s, 3H), 0.98 (t, J = 7.4 Hz, 3H).

13

C

NMR (126 MHz, CDCl3) δ 153.0, 152.1, 150.6, 145.9, 138.1, 134.5, 133.8, 132.8, 131.1,
128.8, 126.7, 125.8, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9, 50.6, 49.2,
47.2, 25.7, 22.0, 11.1. DART-HRMS: m/z calcd. for C32H36Cl2N5O4 [MH]+, 624.2144;
Found: 624.2140. IR (solid) vmax 2919, 2876, 2849, 1693, 1601, 1585, 1555, 1509,
1450, 1403, 1375, 1331, 1295, 1225, 1188, 1149, 1095, 1032, 1017, 943, 871, 814,
734. Purity: 95.4% (Method B).
4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4-triazol-3-
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one (76). 1H NMR (500 MHz, CDCl3) δ 7.61(m, 2H), 7.41 (m, 3H), 7.23 (m, 1H), 7.03
(m, 2H), 6.95 (m, 2H), 6.89 (m, 2H), 4.32 (m, 1H), 4.11 (m, 1H), 4.00 (m, 1H), 3.94 (m,
1H), 3.82 (m, 3H), 3.37 (m, 4H), 3.24 (m, 4H), 1.83 (m, 2H), 1.81 (s, 3H), 0.98 (t, J = 7.4
Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 153.0, 152.1, 150.5, 145.9, 138.0, 134.5, 133.8,

132.7, 131.1, 128.8, 126.7, 125.9, 123.5, 118.4, 116.6, 115.4, 109.0, 73.9, 69.2, 66.9,
50.6, 49.1, 47.2, 25.7, 22.0, 11.0. DART-HRMS: m/z calcd. for C32H36Cl2N5O4 [MH]+,
624.2144; Found: 624.2105. IR (solid) vmax 2918, 2876, 2849, 1693, 1585, 1555,
1509, 1464, 1449, 1374, 1330, 1294, 1224, 1187, 1149, 1095, 1035, 964, 942, 872,
817, 734. Purity: 97.8% (Method B).

4.2 Biological Assay Protocols
Gene expression assay protocol (C3H10T1/2): Cells were seeded (50,000 cells per
well; 500 µL total volume per well) in a 24-well tissue culture plate.

After 24h of

incubation (37°C, 5% CO2), growth media was removed and replaced with low FBS
media. DMSO (vehicle control) and analogues (1% DMSO concentration) were added
to the wells. Cells were incubated (37°C, 5% CO2) for 24h and RNA was isolated and
evaluated by qRT-PCR.
Gene expression assay protocol (ASZ-001): Cells were seeded (10,000 cells per well;
100 µL total volume per well) in a 96-well tissue culture plate. After 24h of incubation
(37°C, 5% CO2), growth media was removed and replaced with low FBS media. Cells
were incubated for an additional 24h.

After this time, DMSO (vehicle control) and

analogues (1% DMSO concentration) were added to the wells. Cells were incubated
(37°C, 5% CO2) for 48h and RNA was isolated and evaluated by qRT-PCR.
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RT-PCR protocol: Following treatment and incubation periods, both RNA extraction and
cDNA synthesis were performed using a TaqMan Cells-to-CT (fast) kit. cDNA synthesis
utilized a BioRad MyCycler and was programmed according to the manufacturer’s
instructions. Quantitative RT-PCR was performed on an ABI 7500 system and made
use of the following TaqMan Gene Expression Probes: mouse ActB (Mm00607939_s1)
and mouse Gli1 (Mm00494654_m1). Relative gene expression levels were computed
via ΔΔCT method using GraphPad Prism. Corresponding IC50 values were calculated
as mean ± SEM for at least three separate experiments performed in triplicate.
CYP3A4 inhibition protocol: ITZ and des-triazole ITZ were evaluated for their ability to
inhibit CYP3A4 by Cyprotex. This was accomplished by measuring their ability to inhibit
the metabolism of the known CYP3A4 substrate testosterone via LC/MS/MS. Briefly,
varying concentrations of either ITZ or des-triazole ITZ was mixed with microsomes (0.5
mg/mL) and testosterone (50 µM) in 50 mM potassium phosphate buffer containing
2mM NADPH and 3mM MgCl2 at pH 7.4. Following a10 min incubation at 37°C, the
assay was quenched with the addition of MeCN containing an internal standard. The
samples were centrifuged and the quantity of testosterone metabolite in the supernatant
was determined by LC/MS/MS.
Anti-proliferation protocol: HUVECs were seeded (3,000 cells per well; 100 µL) in a 96well tissue cultured plate and incubated (37°C, 5% CO2) overnight. After 24h, cells
were drugged with DMSO (control), and drugs at varying concentrations (1% DMSO
final concentration). Following 72h incubation, cells were treated with MTS: PMS and
incubated (37°C, 5% CO2) for 3h.

Plates were read at 490 nm utilizing a BioTek
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Synergy H1 Hybrid plate reader. Protocol follows Promega CellTiter 96 ® Aqueous NonRadioactive Cell Proliferation Assay.
Tube formation protocol: Matrigel (BD Biosciences) was diluted 1:1 with DMEM
(Matrigel protein concentration no less than 3 mg/mL) and used to coat the wells of a
24-well tissue culture dish (280 µL per well). Plates were incubated (37°C, 5% CO2) for
no more than 1h until the Matrigel solidified. HUVECs were suspended in M199 media
with 1% FBS and penicillin/streptomycin, and 50,000 cells were added to each well.
Plates were incubated at (37°C, 5% CO2) for 20-30 min to allow HUVECs to attach to
the Matrigel.

Cells were treated with control (DMSO), known angiogenic inhibitor

suramin (10 µM), or varying doses (10, 1, and 0.1 µM) of drug and incubated for 16h.
Phase contrast images were taken from multiple locations in each well (8/well) on an
inverted microscope and tube formation parameters were quantified using ImageJ
software (NIH).
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CHAPTER III: Structure-Activity Relationship Studies of Itraconazole Analogue
Generations III and IV
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1. Introduction
Based on our SAR results from analogue generations I and II, it was determined
that the triazole moiety of ITZ is not necessary for potent Hh pathway inhibition. These
SAR studies have resulted in a novel class of Hh pathway antagonists: des-triazole ITZ
analogues. It was also previously determined that the stereochemistry of the dioxolane
is important in terms of Hh pathway inhibition; the most potent stereochemical
orientation is the 2R,4R-trans-dioxolane region.

Thorough SAR studies have been

performed in terms of this dioxolane region and there is a solid understanding of what
structural functionalities of the dioxolane region of ITZ are necessary and unnecessary
for potent Hh pathway inhibition.

It has been established that while the chlorine-

substituents are less important, the phenyl moiety is necessary for anti-Hh activity. The
dioxolane region as a whole cannot be truncated to a smaller functionality without
abolishing activity.115 Further SAR could be performed on this region in terms of
exploring different N-containing substituents in replacement of the triazole group. In
addition, exploration could also be made in terms of different heteroatom ring systems
to compare to the dioxolane region. Eventually, this may be necessary to improve the
overall drug properties, such as solubility and stability, of this modified ITZ scaffold.
SAR data from generations I and II also yielded ample information in terms of the
triazolone and side-chain regions of the ITZ scaffold. While the stereochemistry is less
important, the methyl group of the sec-butyl region is crucial for Hh inhibitory activity.
Substitution of a propyl side chain region completely abolishes activity. Interestingly,
truncation of the side-chain region to the free triazolone maintains anti-Hh activity. In
addition, truncation of the entire triazolone region to smaller moieties such as an aniline
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or nitro substituent maintains this activity.115 With that being said, this triazolone/sidechain functionality of the ITZ scaffold remains an interesting region in terms of Hh
inhibitory activity. These regions of ITZ are amendable for further modification and the
resulting SAR studies could potentially improve both drug-like properties and biological
activity.
2. Design, Synthesis, and Evaluation of Generation III Analogues
2.1 Analogue Design
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Figure 1. Design of Generation III Analogues
The third generation of ITZ analogues focuses on probing the triazolone/sidechain region of the original ITZ scaffold.

In particular, this generation contains the

optimal dioxolane stereochemical orientation and substitutes the triazolone/side-chain
regions of the molecule with amide functionality (Figure 1). Utilizing amide functionality
would aid in exploring the electronics, hydrogen bonding, and sterics of the
triazolone/side-chain region of the ITZ scaffold. Amide functionality was chosen due to
its chemical stability, solubility, and ease of synthesis. An amide group consists of a
carbonyl bond (C=O) and a C—N bond, which both contain dipoles. The dipole of the
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carbonyl is stronger than the C—N due to increased π-bonding arrangement and the
electronegativity of the oxygen atom; this classifies an amide bond as being a
hydrogen-bond acceptor (HBA).117 The oxygen and nitrogen atoms can both bond with
water or protic solvents serving as hydrogen bond acceptors and the N—H bond can
serve as a hydrogen-bond donor (Figure 2). Amide bonds are generally stable due to
resonance and the synthetic approach towards this functionality is low-cost and time
efficient.
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Figure 2. Physiochemical Properties of Amides
Initially, this series of analogues was only going to include the most optimal
2R,4R-trans-dioxolane orientation; however, these initial compounds had very limited
activity during our preliminary in vitro evaluation. Because of this, amide analogues
were also synthesized containing the 2S,4R-cis-dioxolane region to determine if there
was a difference in activity between stereoisomers.
2.2 Synthetic Routes
2.2.1 Synthesis towards Key Aniline Intermediate
The synthetic approach towards the third generation of analogues begins with
the coupling of desired dioxolane with the unprotected nitro-linker region (44) as
described previously. The dioxolane containing nitro (77 or 87) can be reduced to the
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aniline (78 or 88) in the presence of 10% Pd/C and hydrazine monohydrate.103 This key
dioxolane-containing aniline intermediate (78 or 88) can then be utilized in amidation
reactions with standard amide coupling conditions and various carboxylic acids. This
synthetic route was deemed the most optimal due to the ability to produce key
intermediate (78 or 88) in bulk for rapid amidation with a variety of carboxylic acids
(Scheme 1). While there are a few different ways to approach the synthesis of ITZ, and
thus ITZ analogues, this synthetic route provides the most efficient production of a
diverse set of analogues.
Scheme 1. Synthesis of Aniline Intermediates
O
O
Cl

OTs

+

HO

N

Cl
59: trans
60: cis

N

NO 2

44

O
O
Cl

a

O
b
O

N

N

O

NO 2

Cl

Cl

O

N

N

NH 2

Cl

77: trans
87: cis

78: trans
88: cis

Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 90ºC, 12 h, 34-85%; (b) EDCI, DMAP,
DCM, RT, 12h, < 50%.

2.2.2 Synthesis of Final Amide Analogues
All amide analogues were synthesized utilizing standard amidation reaction
conditions: activating agent 1-ethyl-3-(3-dimethylamiopropyl)carboniimide (EDCI), 4dimethylaminopyridine (DMAP), and various carboxylic acids dissolved in anhydrous
DCM and stirred at room temperature for 12h (Scheme 2).118 This reaction must be
anhydrous, as any trace of water will not allow the amidation to proceed. These final
amide reactions did not provide an optimal yield < 50%; however, enough analogue was
obtained for characterization and preliminary biological evaluation.
94

Scheme 2. Synthesis towards Amide Analogues
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N
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88: cis
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R

79-86: trans
89-105: cis

Reagents and conditions: (a) EDCI, DMAP, DCM, RT, 12h, < 50%.

2.2.3 Synthesis towards Phenol-Substituted Amide Analogues
The above amidation method worked well for all amide substitutions except for
the phenol-substituted analogues. In the presence of EDCI, DMAP, and free acid, the
amidation reaction would not proceed.

It was anticipated that the free acid was

potentially reacting with itself rather than the aniline. Due to this hypothesis, the free
phenol was protected before coupling. Various esters were protected with a methoxymethyl ether (MOM-) and then saponified to yield MOM-protected carboxylic acids.119
These acids were then reacted with aniline under the previously described amide
conditions to obtain the MOM-protected amide analogue. Ideally, the MOM group could
then be cleaved to yield the final desired phenol amide product. However, this reaction
did not yield desired product regardless of the reaction conditions (Scheme 3).119,120
We believe that the MOM- group was removed but that the dioxolane ring was not
stable under the acidic and harsh conditions associated with MOM-deprotection
reactions.
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Scheme 3. MOM- Protected Amidation Route
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Reagents and conditions: (a) DIPEA, MOM-Cl, 0°C à RT, 12h, 33-84%; (b) 10% NaOH, MeOH,
RT, 4h, 48-85%;(c) EDCI, DMAP, DCM, RT, 12h, < 50%;(d) TFA, DCM 40min-1h, RT; (e) 3M
HCl (~10 drops), MeOH, RT, 12h; (f) TMSCl (10 eq), NaI (10 eq), ACN: DCM, RT, 20 min

There are a variety of synthetic approaches to form amide bonds.118,121 It is
known that acyl chlorides are generally more reactive than carboxylic acids.

We

attempted to form MOM- protected and free phenol acyl chlorides and then react them
with aniline intermediate (78 or 88).

Another attempt was made to couple MOM-

protected and free phenol esters to the aniline intermediate (78 or 88) in the presence of
trimethyl aluminum (Scheme 4).122 Neither of these synthetic routes proved successful
despite the use of the more reactive acyl chloride functionality.
Scheme 4. Alternate Amidation Approaches
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Reagents and conditions: (a) thionyl chloride, DCM, 1 drop of DMF, reflux 4.5 h; (b) Pyr, DMAP,
DCM, 4°C, 12h; (c) AlMe3, K2CO3, DCM 0°C à RT
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As the most successful amidation attempt involved protecting the starting
carboxylic acid and only did not yield product due to the deprotection reaction, it was
anticipated that a different protecting group could be utilized instead of MOM. Benzyl
(Bn) protecting groups were a feasible option as they are easily synthesized and stable.
In addition, benzyl groups can be removed under less harsh conditions including Pd/C
and H2. This approach was successful for the phenol-substituted analogues; however,
the analogues were obtained in low yields after the final hydrogenation reaction
(Scheme 5).123
Scheme 5. Benzyl- Protected Amides
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Reagents and conditions: (a) BnBr, K2CO3, acetone, RT, 12h, 64-quant.%; (b) LiOH (3 eq),
H2O:THF, 52-66%; (c) EDCI, DMAP, DCM, RT, 12h, < 50%; (d) 10% Pd/C, THF:EtOH, H2

In an attempt to obtain a higher yield for all of the amidation reactions, a new set
of

conditions

was

utilized:

N-methylmorpholine

(NMM)

and

1-

[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5,6]pyridinium3oxidhexafluorophosphate) HATU in DMF for 12h at room temperature (Scheme 6).124,125
These conditions were chosen as they are not as sensitive to water as are the
previously used reagents (EDCI and DMAP).

In addition to improving the yield of

amide product, these reaction conditions also allowed for direct coupling of free phenol
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carboxylic acids to the dioxolane containing aniline intermediate.

This is a more

efficient approach, as it would eliminate the benzyl-protected intermediate and
subsequent additional reactions.
Scheme 6. Synthesis towards Free-Phenol Analogues
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2.3 Biological Evaluation
Table 1. Generation III Analogues

R1
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Stereochemistry

R2
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N
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N
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The third generation of ITZ analogues was evaluated for Hh pathway inhibitory
activity by monitoring endogenous Gli1 mRNA levels in ASZ-001 cells (Table 1).
Analogues were tested in a dose-dependent manner in 96-well tissue culture plates; this
was done for efficiency and in an attempt to test these analogues in a higher-throughput
fashion. Des-triazole ITZ analogues were not evaluated in the initial mouse embryonic
fibroblast (C3H10T1/2) cells due to conflicting results from generation II analogue
biological evaluation.115 It was established from this generation II data that the ASZ cell
line represents a more appropriate model for Hh pathway activity in MB.126 Overall, the
evaluation of generation III analogues and their ability to inhibit Hh signaling in the ASZ
cell line provided interesting results (Tables 2, 3, and 4).
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Table 2. In Vitro Activity of Trans-Amide Analogues
Compound

IC50 (µM) a, b

Compound

IC50 (µM) a, b

77

0.31 ± 0.04

82

4.3 ± 0.2

78

0.92 ± 0.04

83

>10

79

>10

84

>>10

80

>10

85

0.19 ± 0.008

81

>10

86

>>10

a

b

IC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. All
analogues evaluated following 48 hr incubation.

Generation III analogue synthesis began with the 2R,4R-trans-dioxolane
stereochemistry because this was the most potent orientation determined in previous
SAR studies.

This initial amide series with 2R,4R-trans-dioxolane stereochemistry

yielded minimally active compounds with most IC50 values >10 µM (Table 2). However,
the truncated nitro (77) and aniline (78) intermediates exhibited moderate potency (IC50
= 0.31 ± 0.04 and 0.92 ± 0.04 µM, respectively) indicating that the truncation of both the
triazolone region and the triazole group is acceptable. Despite limited Hh inhibitory
activity within this first class of amides, the SAR data indicated that the meta-position
functionality off of the phenyl ring was favorable as 82 was moderately active (IC50 = 4.3
± 0.2 µM) and 85 was potent (IC50 = 0.19 ± 0.008 µM) when compared to the ortho- and
para- position analogues (Table 2). The nitrogen atom in the pyridine ring of 82 serves
as an H-bond acceptor while the oxygen in the phenol of 85 may serve as both an Hbond donor and an H-bond acceptor supporting the increased potency. These results
from this initial amide series indicate that functionality capable of hydrogen bonding at
the meta-position of the phenyl ring may be advantageous to binding with Smo, the
hypothesized target of these des-triazole ITZ analogues.
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Table 3. In Vitro Activity of Cis-Amide Analogues
Compound

IC50 (µM) a, b

Compound

IC50 (µM) a, b

87

0.26 ± 0.04

94

1.8 ± 0.4

88

0.39 ± 0.09

95

2.3 ± 0.05

89

>10

96

>10

90

>10

97

2.2 ± 0.3

91

3.9 ± 0.3

98

0.16 ± 0.03

92

0.19 ± 0.09

99

3.0 ± 0.1

93

>10

a

b

IC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. All
analogues evaluated following 48 hr incubation.

Despite the majority of analogues being inactive, this initial series of transamides provided interesting SAR information in terms of the triazolone/side-chain region
of the ITZ scaffold (Table 2).

Thus, a second series of amide analogues was

synthesized containing the 2S,4R-cis-dioxolane orientation.

These cis-amide

analogues contained the same functionality and substituents as the trans-amide
analogues in order to better compare the stereoisomers. Evaluation of the cis-amide
analogues provided confounding data (Table 3). First, all of the cis-amide analogues
were more potent than the trans-amide analogues, specifically amongst the phenol and
pyridine containing compounds. Second, following the same trend as the trans-amide
analogues, substituents at the meta-position better inhibited the Hh pathway in
comparison to the ortho- and para- positions.

The meta-pyridine analogues had a

modest difference in potency (82 = 4.3 ± 0.2 and 96 = 0.19 ± 0.09 µM) while the metaphenol analogues resulted in similar IC50 values (85 = 0.19 ± 0.008 and 98 = 0.16 ±
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0.03 µM). It is possible that the cis-amide analogues are more permeable than the
trans-amide analogues, accounting for their increased potency within these preliminary
cellular assays (Table 2 and Table 3). The SAR results from the stereochemicallydefined amide analogues reiterated the importance of the triazolone/side-chain region
and Hh pathway inhibitory activity. This highlights the need to further explore this region
of the ITZ scaffold.
Table 4. In Vitro Activity of Cis-Amide Analogues: Meta-Functionality
Compound

IC50 (µM) a, b

Compound

IC50 (µM) a, b

100

>10

103

>10

101

5.7 ± 1.9

104

>10

102

>10

105

0.089 ± 0.01

a

b

IC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. All
analogues evaluated following 48 hr incubation.

Taken together, a third series of amide analogues was designed and synthesized
to contain optimal cis-dioxolane stereochemistry and optimal amide meta-substitution.
This series of amides was necessary to further probe the sterics, electronics, and
hydrogen bonding of the triazolone/side-chain region of the original ITZ scaffold.
Analogues were designed according to the availability of carboxylic acids resulting in six
diverse derivatives, which included both 6-membered rings and 5-membered rings.
SAR studies concluded that the 5-membered ring analogues (102 and 103) are not
optimal for Hh pathway inhibition (Table 4). Not surprisingly due to the results from the
benzene and naphthalene analogues, the cyclohexane derivative (104) did not inhibit
the Hh pathway.

Results further indicated that the most potent analogue, 105,

contained an acetyl- functionality (Table 4).

The trend in Hh inhibitory activity can

partially be attributed to polarity at the meta-position of the phenyl ring.
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Although,

alcohol or amine functionality is typically more polar than a ketone, other characteristics
of this moiety may be contributing to its potent activity (Figure 3).

Ketone >> Alcohol >> Amine >> Methoxy >> Halogen
Figure 3. Relative Potency of Meta-Functionality in Amide Analogues
One difference between a ketone and an alcohol is that ketones are considered
to be electron-withdrawing groups (EWG) while alcohols are considered to be electrondonating groups (EDG). In addition, a ketone serves as a hydrogen bond acceptor
(HBA) while an alcohol can act as a hydrogen bond donor (HBD) or an HBA. The bond
length of the carbonyl and position of the oxygen atom may allow for tighter binding to a
particular residue in the Smo binding pocket. It is also interesting to note that the Hh
pathway inhibitor posaconazole (PSZ), an azole antifungal similar in structure to ITZ,
contains a hydroxylated side-chain region. These structural-similarities further support
adding polar moieties to the triazolone/side-chain region to improve drug-like properties
yet maintain Hh-pathway inhibitory activity (Figure 4).
O
N
H

O

O
N

N
N

OH

Figure 4. Triazolone/side-chain regions of PSZ vs. 105
Due to promising in vitro activity, a few select compounds were evaluated in
preliminary in vitro pharmacokinetic (PK) assays. These PK data helped determine if
any of the changes made to the ITZ scaffold improved their overall drug-like properties
(Table 5). Surprisingly, the amide substituents did not aid in increased solubility. The
half-life (T1/2) did not significantly change between ITZ and analogue 98. Interestingly,
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stereoisomers 82 and 92 had significantly different half-lives suggesting that the
stereochemistry plays a role in compound metabolism and clearance (T1/2 = 59.9 ± 2.0
and 8.9 ± 0.03 min, respectively). It was previously determined that removal of the
triazole group abolishes inhibition of CYP3A4.

This also translates over to the

generation III des-triazole amide analogues. Lastly, as these compounds are being
targeted to treat MB, they were screened in a parallel artificial membrane permeability
assay (PAMPA) for their ability to passively permeate cell membranes. Unfortunately,
while ITZ had moderate PAMPA permeability, none of the des-triazole ITZ analogues
were able to passively cross this artificial membrane barrier (Table 5).
Table 5. Pharmacokinetic Evaluation of Amide Analogues
Compound
ITZ
82
92
98

T1/2 (HLM, min)
27.0 ± 6.2
59.9 ± 2.0
8.9 ± 0.03
19.9 ± 0.6

Solubility (µM)
0.8
0.0042
0.0069
0.0016

105

PAMPA
Moderate
Poor
Poor
Poor

CYP3A4 IC50 (µM)
0.04
>20
>30
11.4

3. Design, Synthesis, and Evaluation of Generation IV Analogues
3.1 Analogue Design

O
2 4

O

Cl

O

N

H
N R

N

Cl

Probe triazolone region
Optimal dioxolane
stereochemistry

Figure 5. Design of Generation IV Analogues
The fourth generation of ITZ analogues focuses on further probing the
triazolone/side-chain region of the original ITZ scaffold. In particular, this generation
contains the optimal 4R-cis/trans-dioxolane stereochemistry determined through
previous SAR studies. In addition, this series of compounds will substitute the rightmost portion of the molecule with various functional moieties: carbamates, hydrazine
carboxamides, and triazolones (Figure 5). These functional groups were chosen, as
they are the intermediates leading up to the formation of the triazolone ring during the
linker region synthesis.

Utilizing this diverse set of functionality will further aid in

probing the electronics, hydrogen bonding, and sterics of the triazolone/side-chain
region of ITZ. This series of “triazolone mimic analogues” will provide a broader subset
of SAR data as it explores a variety of functionality that have differing physiochemical
properties. The overall goal of this series is to determine a potent ITZ analogue with
improved drug-like properties. These moieties may contribute to improved solubility
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while decreasing molecule size. This, along with truncation of the triazole region, will
greatly improve both drug-like properties and target selectivity of the ITZ scaffold in
terms of its Hh-inhibitory activity.
3.2 Synthetic Routes
Originally, the synthetic plan for the triazolone mimic analogues followed the
same

route

as

the

previously

mentioned

amide

analogues

(Figure

6).

Stereochemically-defined dioxolane would be coupled to the unprotected-nitro-linker
(44); this dioxolane containing nitro-linker (77 or 87) would then be reduced to the
aniline in the presence of Pd/C to yield key intermediate 78 or 88.103 However, as
previously noted, the dioxolane region is not stable under acidic conditions. A multitude
of these triazolone mimic analogue reactions require use of acid in order to form the
designated product. As a result, the synthetic approach was adjusted to avoid exposing
the dioxolane region to acid; this synthetic plan contains a few extra steps and
unfortunately is not as efficient as amide analogue production.
O
O
Cl

O
O

N

N

O

NH 2

Cl

Cl
78 or 88

O

N

N

H
N R

Cl
Gen. IV analogues

Figure 6. Original Synthetic Approach
As ITZ is FDA-approved, there are several synthetic approaches that have been
reported previously. One of which, involves the coupling of dioxolane to the linker
region at the beginning. After this initial coupling, the subsequent transformations can
be made towards the triazolone region.103 In order to effectively perform this synthesis,
the initial coupling must be done at a large enough scale to undergo all of these
transformations and result in ample product. While this is a possible synthetic route for
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des-triazole ITZ analogues, it is not necessarily feasible to produce a large amount of
stereochemically-defined dioxolane. For this reason, methoxy-protected linker regions
(carbamate, hydrazine carboxamide, and triazolone) were deprotected using HBr at
reflux (Scheme 7).
Scheme 7. Deprotection of Linker Intermediates
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Reagents and conditions: (a) HBr, AcOH, reflux 12h.
The resulting phenols were then utilized in the coupling reaction with
stereochemically-defined dioxolane and Cs2CO3 in DMSO.

This reaction was

performed at 90°C for the carbamate analogue and 40°C for the hydrazine carboxamide
and triazolone analogues. The temperature was adjusted in an attempt to discourage
dual dioxolane addition to both the phenol and hydrazine carboxamide/triazolone
moieties. Despite the temperature of the reaction, only the hydrazine carboxamide
substituent was successful. The carbamate coupling reaction did not proceed and the
triazolone coupling reaction underwent duel-addition of dioxolane to both the phenol
and the free triazolone. In an attempt to avoid going through all of the linker region
transformations starting from 44, previously synthesized analogues served as building
blocks for the carbamate and triazolone analogues (Scheme 8).

The carbamate

analogues (106 or 108) were synthesized from the aniline intermediate (78 or 88) with
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the previously utilized conditions of phenyl chloroformate and pyridine. The triazolone
analogue (110) was ultimately synthesized from the hydrazine carboxamide analogue
(109) with the previously utilized conditions of formamidine acetate.115 It is important to
note that this reaction also calls for the use of acetic acid (AcOH). AcOH is utilized to
aid in the crystallization of the triazolone product during linker synthesis.

As this

reaction was performed on a < 10 mg scale, precipitation of the desired product was not
expected to be the means of purification. As a result, this reagent could successfully be
removed without affecting the formation of the triazolone ring.
Scheme 8. Synthesis towards Triazolone Intermediates
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Reagents and conditions: (a) Cs2CO3 (10 eq), DMSO, 40ºC, 12 h, 56-94%; (b) Pyr (17 eq),
ClCOOPh (1.1 eq), 3 h, 24-40%; (c) formamidine acetate (4.5 eq), reflux, 3 h, 20%
It was also attempted to protect the triazolone region with a Boc-protecting
group.127 However, this proved unsuccessful, as the Boc group could not be added
before methoxy- deprotection; Boc-protection in the presence of both phenol and aniline
functionality resulted in dual-Boc addition.

Selective Boc-deprotection was also

attempted and did not yield desired product (Scheme 9).128
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Scheme 9. Protection of Free Triazolone Intermediate
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Reagents and conditions: (a) Boc anhydride, DMAP (10% mol), ACN, RT, 12 h; (b) 20%
KOH, MeOH, RT, 12h
3.3 Biological Evaluation
Table 6. Generation IV Analogues

Compound
106

R1

Final
Stereochemistry

R2
O
N
H

Trans-2R,4R

O
O

107

108

N
H

NHNH 2

O
N
H

Trans-2R,4R

Cis-2S,4R

O

O

109

N
H

NHNH 2

Cis-2S,4R

O

110

N

Cis-2S,4R

NH
N

The fourth generation of des-triazole ITZ analogues was evaluated for Hh
inhibitory activity by monitoring endogenous Gli1 mRNA levels in ASZ-001 cells (Table
6). It was previously established that this cell line represents an appropriate model for
110

Hh pathway activity in MB.115 This fourth generation of analogues was designed to
further probe the triazolone/side-chain region of the ITZ scaffold. These analogues offer
a wide range of functionality including carbamates, hydrazine carboxamides, and
triazolones. While these moieties were mainly chosen as they serve as intermediates
leading up to the formation of the triazolone ring, they also may aid in improving the
drug-like properties of this scaffold. For instance, carbamate functionality has been
widely studied within the field of medicinal chemistry and is a key structural moiety in
many FDA-approved compounds and prodrugs. Carbamates offer chemical stability
and hydrogen bonding; in addition, they are capable of penetrating cell membranes.129
Table 7. In Vitro Evaluation of Generation IV
Compound

IC50 (µM) a, b

Compound

IC50 (µM) a, b

106

3.2 ± 0.6

109

0.28 ± 0.01

107

0.29 ± 0.08

110

0.95 ± 0.08

108

1.0 ± 0.4

a

b

IC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. All
analogues evaluated following 48 hr incubation.

SAR results for generation IV analogues indicate that the most potent carbonyl
derivatives are the hydrazine carboxamides (107 and 109) (Table 7). This is likely due
to the increased polarity and ability to donate and accept hydrogen atoms. Interestingly,
the hydrazine carboxamide is an acyclic motif providing evidence that anti-Hh activity
can still be achieved without the cyclic functionality seen in the original triazolone region
and generation III analogues. The carbamate analogues (106 and 108) are the least
potent in this series and this may be attributed to the presence of the bulky
nonsubstituted hydrophobic ring. Surprisingly, the des-triazole ITZ analogue containing
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the free triazolone was not as potent as the structurally similar triazole-containing
analogue 53 (IC50 = 0.12 ± 0.03 µM).115 This may be due to decreased solubility or
ability to penetrate the cell membrane.

A similar trend is seen in terms of the

stereochemistry of the dioxolane ring: the cis-analogues are more potent than the transanalogues. Both dioxolane orientations were synthesized as the trans-isomer is formed
more readily in the ketalization reaction.

The trans-dioxolane was utilized during

reaction optimization and then the corresponding cis-analogue was subjected to these
reaction conditions. These SAR data support the design and synthesis of a further
subset of analogues containing truncated triazolone regions with acyclic polar moieties.
This will ultimately decrease overall size of the des-triazole ITZ scaffold as well as
increase Hh inhibitory activity.
4. Conclusion
Two subsequent des-triazole ITZ analogue generations were designed,
synthesized, and evaluated for their ability to inhibit the Hh pathway. The goal of these
analogues was to further probe the sterics, electronics, and hydrogen bonding in terms
of the triazolone/side-chain region of the ITZ scaffold.

Des-triazole ITZ analogues

contained the optimal 2S,4R-dioxolane region determined from previous SAR studies.
The triazolone/side-chain region was replaced with various functionalities: amide,
carbamate, hydrazine carboxamide, or triazolone.

SAR generation III analogues

determined the 2S,4R-cis-dioxolane amide analogues to be more potent than the
2R,4R-trans-dioxolane amide analogues.

In addition, different substituents and

positions around the phenyl ring were explored to determine if either of these
components contributed to potent Hh pathway inhibition. The most potent des-triazole
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ITZ analogues contained the 4R-cis-dioxolane region and meta-substitution around the
phenyl ring. Generally, anti-Hh activity becomes more potent with increasing metasubstituent polarity.
SAR results from generation IV analogues also determined that the 2S,4R-cisdioxolane containing analogues were the most potent.

Within this small subset of

compounds, the most potent analogues contained the hydrazine carboxamide moiety in
replacement of the triazolone/side-chain region. These results indicate that a small,
polar, acyclic motif may be favorable within this region of the ITZ scaffold; this would be
an ideal way to further scale down the overall size of these novel Hh pathway inhibitors.
Additional SAR studies should be performed to probe the triazolone/side-chain region
for potent Hh pathway inhibitory activity while also improving the overall properties of
the scaffold.

4.1 Experimental
Previously Characterized Intermediates: Benzyl-protected intermediates were prepared
as described previously and are described in the Appendix A.

1-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)4-(4-nitrophenyl)piperazine (77) To a solution of 44 (0.77 g, 2.61 mmol) in DMSO (30
mL) was added Cs2CO3 (8.5 g, 26.14 mmol) and 59 (1.2 g, 2.87 mmol). The solution
was warmed to 90° C and stirred for 12 h. The mixture was cooled to room temperature
and water was added slowly with vigorous stirring (~20 mL). A yellow precipitate
formed, which was filtered and recrystallized in EtOH to yield 77 (1.2g, 85%). 1H NMR
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(500 MHz, Chloroform-d) δ 8.28 – 8.14 (m, 2H), 7.66 (d, 1H), 7.46 (d, 1H), 7.28 (m, 1H),
7.03 – 6.87 (m, 6H), 4.37 (m, 1H), 4.16 (m, 1H), 4.11 – 3.95 (m, 2H), 3.89 (m, 1H), 3.69
– 3.53 (m, 4H), 3.35 – 3.18 (m, 4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 153.29,
134.59, 131.21, 128.89, 126.79, 125.98, 118.58, 115.56, 112.90, 109.99, 109.12, 77.28,
77.02, 76.77, 73.94, 69.27, 66.99, 50.39, 47.31, 25.73. DART-HRMS: m/z calcd. for
C27H27Cl2N3O5 [MH]+, 544.1406; Found: 544.1388. IR (solid) vmax: 3060, 2926, 2880,
2828, 1556, 1507, 1485, 1446, 1376, 1222, 1190, 1142, 1047, 995, 942, 821, 737.
4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)aniline (78) 10% palladium on carbon (24.4 mg, 5%
mole ratio) was added to a dry round bottom flask. Ethanol (100 mL) was added
followed by slow addition of 77 (250 mg, 0.459 mmol). Hydrazine monohydrate (0.14
mL, 4.59 mmol) was added dropwise and the mixture was stirred at reflux for 2 h. Upon
cooling to RT, the mixture was filtered through celite. The celite was washed with
ethanol (500 mL) to ensure complete elution of the aniline. The filtrate was concentrated
to afford a yellow solid, which was recrystallized in EtOH to afford 78 (100 mg, 42%).
1

H NMR (500 MHz, Chloroform-d) δ 8.20 (d, 1H), 7.66 (d, 1H), 7.46 (t, 1H), 7.06 – 6.85

(m, 6H), 6.72 (d, 1H), 4.37 (s, 1H), 4.16 (m, 1H), 4.13 – 3.94 (m, 2H), 3.94 – 3.82 (m,
1H), 3.63 (t, 2H), 3.50 (s, 1H), 3.35 – 3.16 (m, 6H), 1.86 (s, 3H).

13

C NMR (126 MHz,

CDCl3) δ 131.20, 128.91, 126.79, 125.99, 118.85, 118.59, 118.25, 116.23, 115.56,
115.46, 112.90, 77.28, 77.03, 76.78, 73.97, 69.29, 67.04, 51.25, 50.86, 50.39, 47.31,
25.74, 0.02. DART-HRMS: m/z calcd. for C27H29Cl2N3O3 [MH]+, 514.1664; Found:
514.1648. IR (solid) vmax: 2919, 2850, 1595, 1560, 1510, 1464, 1450, 1375, 1228,
1196, 1150, 1037, 877, 825, 754.
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N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (79) Aniline 78 (20 mg, 0.039
mmol), benzoic acid (14.3 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under
argon for 12h at room temperature. The crude reaction was immediately purified via
column chromatography (SiO2, 0-60% acetone in hexanes) to afford 79 (13.0 mg, 54%).
1

H NMR (500 MHz, Chloroform-d) δ 7.92 (d, 2H), 7.73 (s, 1H), 7.66 (d, 1H), 7.59 (m,

2H), 7.54 (t, 2H), 7.46 (d, 1H), 7.28 (m, 1H), 7.05 (d, 2H), 7.02 – 6.97 (m, 2H), 6.94 (d,
2H), 4.37 (m, 1H), 4.17 (m, 1H), 4.09 – 3.98 (m, 2H), 3.89 (t, 1H), 3.38 (m, 4H), 3.29 (m,
4H), 1.86 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 165.48, 152.92, 148.50, 146.09,

138.15, 135.17, 134.56, 132.83, 131.69, 131.19, 130.61, 128.91, 128.78, 126.95,
126.79, 121.64, 118.40, 116.95, 115.48, 110.66, 109.09, 77.27, 77.23, 77.02, 76.76,
73.96, 69.29, 67.03, 50.74, 49.88, 29.72, 25.74. DART-HRMS: m/z calcd. for
C34H33Cl2N3O4 [MH]+, 618.1926; Found: 618.1919. IR (solid) vmax: 3367, 3333, 2958,
2924, 2853, 1693, 1638, 1547, 1511, 1450, 1375, 1248, 1230, 1194, 1157, 1037, 941,
822, 703.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-naphthamide (80) Aniline 78 (20 mg,
0.039 mmol), naphtholic acid (20.1 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred
under argon for 12h at room temperature. The crude reaction was immediately purified
via column chromatography (SiO2, 0-60% acetone in hexanes) to afford 80 (6.0 mg,
23%).

1

H NMR (500 MHz, Chloroform-d) δ 8.39 (d, 1H), 7.97 (d, 1H), 7.93 – 7.85 (m,
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1H), 7.75 (d, 1H), 7.66 – 7.48 (m, 7H), 7.41 (d, 1H), 7.24 (m, 1H), 7.03 (d, 2H), 6.96 (d,
2H), 6.90 (d, 2H), 4.33 (m, 1H), 4.12 (m, 1H), 4.05 – 3.93 (m, 2H), 3.85 (m, 1H), 3.38 –
3.30 (m, 5H), 3.26 (m, 5H), 1.82 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 167.31, 152.94,

148.59, 146.09, 138.15, 134.75, 134.56, 133.81, 132.84, 131.20, 130.94, 130.75,
130.17, 128.91, 128.43, 127.33, 126.79, 126.59, 125.38, 125.02, 124.79, 121.41,
118.41, 117.01, 115.92, 115.49, 111.61, 109.09, 106.00, 101.89, 97.74, 77.28, 77.22,
77.02, 76.77, 73.96, 69.29, 67.03, 50.74, 49.92, 29.72, 25.74, 0.02. DART-HRMS: m/z
calcd. for C38H35Cl2N3O4 [MH]+, 668.2083; Found: 668.2075. IR (solid) vmax: 3294,
3247, 3042, 2985, 2873, 1639, 1586, 1509, 1450, 1373, 1226, 1192, 1146, 1035, 942,
821, 733.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)picolinamide (81) Aniline 78 (20 mg, 0.039
mmol), picolinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under
argon for 12h at room temperature. The crude reaction was immediately purified via
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 81 (9.0 mg, 37%).
1

H NMR (500 MHz, Chloroform-d) δ 9.96 (s, 1H), 8.69 – 8.62 (m, 1H), 8.35 (d, 1H), 7.95

(m, 1H), 7.76 (d, 2H), 7.66 (d, 1H), 7.55 – 7.48 (m, 1H), 7.46 (d, 1H), 7.28 (m, 1H), 7.06
(d, 2H), 7.00 (d, 2H), 6.94 (d, 2H), 4.37 (s, 1H), 4.17 (m, 1H), 4.09 – 3.97 (m, 2H), 3.89
(m, 1H), 3.38 (m, 4H), 3.33 – 3.25 (m, 4H), 1.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
161.67, 152.90, 150.10, 148.20, 147.94, 146.11, 138.16, 137.64, 134.56, 132.84,
131.20, 130.66, 128.91, 126.79, 126.26, 122.32, 120.91, 118.38, 116.97, 115.48,
111.61, 109.09, 106.05, 102.12, 77.28, 77.23, 77.03, 76.77, 73.97, 69.30, 67.04, 50.75,
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49.91, 25.74. DART-HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found:
619.1872. IR (solid) vmax: 3367, 2923, 2851, 1672, 1585, 1552, 1509, 1454, 1385,
1268, 1227, 1192, 1148, 1020, 940, 912, 814, 747, 620.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)nicotinamide (82) Aniline 78 (20 mg, 0.039
mmol), nicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under
argon for 12h at room temperature. The crude reaction was immediately purified via
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 82 (6.2 mg, 25%).
1

H NMR (500 MHz, Chloroform-d) δ 9.14 (s, 1H), 8.83 (s, 1H), 8.26 (d, 1H), 7.72 (s, 1H),

7.66 (d, 1H), 7.59 (d, 2H), 7.49 (d, 1H), 7.46 (d, 1H), 7.28 (m, 1H), 7.05 (d, 2H), 7.00 (d,
2H), 6.96 – 6.90 (m, 2H), 4.37 (m, 1H), 4.17 (m, 1H), 4.10 – 3.94 (m, 2H), 3.89 (m, 1H),
3.44 – 3.33 (m, 4H), 3.33 – 3.20 (m, 4H), 1.86 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ

131.20, 128.91, 126.80, 121.87, 118.43, 116.86, 115.49, 111.26, 109.10, 105.77,
101.72, 77.28, 77.23, 77.03, 76.77, 73.96, 69.29, 67.03, 50.73, 49.72, 25.74. DARTHRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1876. IR (solid)
vmax: 3639, 3570, 2920, 2824, 1644, 1509, 1447, 1374, 1227, 1194, 1150, 1037, 941,
828, 733, 534.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)isonicotinamide (83) Aniline 78 (20 mg,
0.039 mmol), isonicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred
under argon for 12h at room temperature. The crude reaction was immediately purified
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via column chromatography (SiO2, 0-80% acetone in hexanes) to afford 83 (12.0 mg,
49%).

1

H NMR (500 MHz, Chloroform-d) δ 8.85 (d, 2H), 7.75 (d, 3H), 7.66 (d, 1H),

7.60 (d, 2H), 7.05 (d, 2H), 7.00 (d, 2H), 6.94 (d, 2H), 4.17 (m, 1H), 4.09 – 3.95 (m, 2H),
3.44 – 3.33 (m, 4H), 3.33 – 3.24 (m, 4H).

13

C NMR (126 MHz, Chloroform-d) δ 150.79 ,

131.19 , 126.79 , 121.81 , 120.79 , 118.43 , 116.79 , 115.50 , 115.25 , 110.09 , 104.91 ,
77.22 , 73.96 , 69.30 , 67.02 , 50.72 , 49.66 , 25.73 . DART-HRMS: m/z calcd. for
C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1871. IR (solid) vmax: 3302, 3290, 2950,
2936, 1662, 1587, 1512, 1458, 1377, 1249, 1225, 1194, 1151, 1035 943, 823, 690.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-hydroxybenzamide (84) Salicylic acid
(13.4 mg, 0.097 mmol) and HATU (81.3 mg, 0.21 mmol) were added to a round bottom
flask. Anhydrous DMF was added (5 mL) followed by NMM (0.1 mL, 0.38 mmol) and
this reaction was stirred at room temperature for 30 mins. Aniline 88 (50 mg, 0.097)
was added to the reaction mixture and stirred for 12h at room temperature.

The

reaction was then added to ice cold water and extracted with EtOAc (3 x 20 mL).
Organic layers were combined and washed with H2O (2 x 20 mL) and brine (1 x 20 mL).
The organic layers were dried over Na2SO4 and evaporated to dryness. Crude material
was purified via column chromatography (SiO2, 0-50% acetone in hexanes) to afford 84
(10.0 mg, 16%). 1H NMR (500 MHz, Chloroform-d) δ 7.87 (s, 1H), 7.58 – 7.42 (m, 5H),
7.28 (m, 1H), 7.07 (m, 3H), 7.02 – 6.91 (m, 5H), 4.37 (m, 1H), 4.17 (m, 1H), 4.09 – 3.98
(m, 2H), 3.93 – 3.85 (m, 1H), 3.44 – 3.35 (m, 4H), 3.29 (t, 4H), 1.86 (s, 2H).

13

C NMR

(126 MHz, Chloroform-d) δ 134.52 , 131.20 , 128.91 , 126.79 , 125.25 , 122.85 , 118.97
, 118.43 , 116.79 , 115.49 , 73.96 , 69.29 , 67.03 , 50.72 , 49.65 . DART-HRMS IR
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(solid) vmax: 3310, 2956, 2916, 2848, 1646, 1596, 1511, 1453, 1373, 1250, 1228,
1196, 1152, 1036, 942, 821, 755.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-hydroxybenzamide

(85)

3-

Hydroxybenzoic acid (5.4 mg, 0.038 mmol) and HATU (31.7 mg, 0.083 mmol) were
added to a round bottom flask. Anhydrous DMF was added (5 mL) followed by NMM
(0.1 mL, 0.15 mmol) and this reaction was stirred at room temperature for 30 mins.
Aniline 88 (20 mg, 0.038 mmol) was added to the reaction mixture and stirred for 12h at
room temperature. The reaction was then added to ice cold water and extracted with
EtOAc (3 x 20 mL). Organic layers were combined and washed with H2O (2 x 20 mL)
and brine (1 x 20 mL). The organic layers were dried over Na2SO4 and evaporated to
dryness.

Crude material was purified via preparative thin layer chromatography

(Analtech Uniplate 20x20 cm 2000 micron, 3% acetone in hexanes) to afford 85 (6.0
mg, 24.8%). 1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, 4H), 7.63 – 7.48 (m, 6H), 7.48
– 7.37 (m, 6H), 7.17 – 6.84 (m, 8H), 5.21 (s, 1H), 4.37 (s, 1H), 4.16 (m, 1H), 4.12 – 3.95
(m, 2H), 3.37 (d, 4H), 3.29 (t, 4H), 1.88 (m, 2H).

13

C NMR (126 MHz, Chloroform-d) δ

131.20 , 130.08 , 126.79 , 125.30 , 121.68 , 118.41 , 116.94 , 115.49 , 114.42 , 69.29 ,
67.03 , 50.73 , 49.84 , 25.73 . DART-HRMS: m/z calcd. for C34H33Cl2N3O5 [MH]+,
634.1876; Found: 634.1847. IR (solid) vmax: 3311, 2967, 2926, 2877, 1736, 1644,
1586, 1513, 1449, 1375, 1230, 1198, 1038, 945, 825, 746.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide

(86)

(13.4

mg,

0.097 mmol) and HATU (81.3 mg, 0.21 mmol) were added to a round bottom flask.
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Anhydrous DMF was added (5 mL) followed by NMM (0.1 mL, 0.38 mmol) and this
reaction was stirred at room temperature for 30 mins. Aniline 88 (50 mg, 0.097) was
added to the reaction mixture and stirred for 12h at room temperature. The reaction
was then added to ice cold water and extracted with EtOAc (3 x 20 mL). Organic layers
were combined and washed with H2O (2 x 20 mL) and brine (1 x 20 mL). The organic
layers were dried over Na2SO4 and evaporated to dryness. Crude material was purified
via column chromatography (SiO2, 0-50% acetone in hexanes) to afford 84 (5.0 mg,
8%).
1-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)4-(4-nitrophenyl)piperazine (87) To a solution of 44 (260 mg, 0.87 mmol) in DMSO (20
mL) was added Cs2CO3 (3.1 g, 9.58 mmol) and 60 (400 mg, 0.0958 mmol). The solution
was warmed to 90° C and stirred for 12 h. The mixture was cooled to room temperature
and water was added slowly with vigorous stirring (~10 mL). A yellow precipitate
formed, which was filtered and recrystallized in EtOH to yield 87 (175 mg, 34%) 1H NMR
(500 MHz, Chloroform-d) δ 8.22 – 8.17 (m, 2H), 7.68 (d, 1H), 7.42 (d, 1H), 7.24 (m, 1H),
6.96 – 6.89 (m, 4H), 6.81 – 6.76 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 3.99 (m, 1H), 3.81
– 3.76 (m, 2H), 3.64 – 3.59 (m, 4H), 3.26 (m, 4H), 1.83 (s, 3H).

13

C NMR (126 MHz,

CDCl3) δ 154.78, 153.09, 145.50, 139.34, 138.76, 134.35, 132.82, 130.97, 128.55,
126.70, 125.98, 118.53, 115.31, 112.89, 109.18, 77.29, 77.03, 76.78, 75.05, 68.41,
67.33, 50.38, 47.30, 25.90. DART-HRMS: m/z calcd. for C27H27Cl2N3O5 [MH]+,
544.1406; Found: 544.1409. IR (solid) vmax: 2922, 2850, 1596, 1555, 1509, 1450,
1375, 1321, 1228, 1195, 1151, 1036, 944, 827, 753.
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4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)aniline (88) 10% palladium on carbon (10 mg, 5%
mole ratio) was added to a dry round bottom flask. Ethanol (50 mL) was added followed
by slow addition of 87 (100 mg, 0.184 mmol). Hydrazine monohydrate (0.06 mL, 1.84
mmol) was added dropwise and the mixture was stirred at reflux for 2 h. Upon cooling
to RT, the mixture was filtered through celite. The celite was washed with ethanol (300
mL) to ensure complete elution of the aniline. The filtrate was concentrated to afford a
yellow solid, which was recrystallized in EtOH to afford 88 (89 mg, 94%).

1

H NMR (500

MHz, Chloroform-d) δ 8.20 (d, 1H), 7.68 (d, 1H), 7.43 (s, 1H), 7.24 (d, 1H), 6.92 (m,
3H), 6.81 – 6.68 (m, 3H), 4.70 – 4.59 (m, 1H), 4.35 (m, 1H), 4.00 (d, 1H), 3.78 (m, 2H),
3.61 (m, 1H), 3.49 (s, 1H), 3.25 (m, 5H).

13

C NMR (126 MHz, CDCl3) δ 130.97, 128.59,

126.70, 125.99, 118.85, 118.54, 118.21, 116.24, 115.21, 112.90, 77.28, 77.03, 76.78,
75.07, 68.43, 67.40, 51.24, 50.85, 50.38, 47.30, 25.90. DART-HRMS: m/z calcd. for
C27H29Cl2N3O3 [MH]+, 514.1664; Found: 514.1666. IR (solid) vmax: 2921, 2823, 1590,
1510, 1450, 1375, 1321, 1227, 1193, 1149, 1037, 944, 824, 753.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (89) Aniline 88 (20 mg, 0.039
mmol), benzoic acid (14.3 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under
argon for 12h at room temperature. The crude reaction was immediately purified via
column chromatography (SiO2, 0-60% acetone in hexanes) to afford 89 (5.0 mg,
20.6%).

1

H NMR (500 MHz, Chloroform-d) δ 7.91 (d, 2H), 7.73 (s, 1H), 7.69 (d, 1H),

7.59 (m, 2H), 7.54 (t, 2H), 7.04 (d, 2H), 6.95 (d, 2H), 6.78 (d, 2H), 4.65 (m, 1H), 4.35 (m,
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1H), 4.00 (m, 1H), 3.82 – 3.74 (m, 2H), 3.36 (d, 3H), 3.28 (d, 4H), 1.83 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 131.68, 130.97, 128.78, 128.58, 126.95, 126.70, 121.64, 118.35,
116.95, 115.24, 112.04, 109.16, 106.31, 77.27, 77.22, 77.02, 76.77, 75.07, 68.44,
67.39, 50.73, 49.88, 25.90. DART-HRMS: m/z calcd. for C34H33Cl2N3O4 [MH]+,
618.1926; Found: 618.1916. IR (solid) vmax: 3305, 2964, 2824, 1637, 1592, 1511,
1448, 1374, 1226, 1192, 1152, 1034, 943, 818, 728, 703.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-naphthamide (90) Aniline 88 (20 mg,
0.039 mmol), naphtholic acid (20.1 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred
under argon for 12h at room temperature. The crude reaction was immediately purified
via column chromatography (SiO2, 0-60% acetone in hexanes) to afford 90 (3.0 mg,
11.5%).

1

H NMR (500 MHz, Chloroform-d) δ 8.43 (s, 1H), 8.08 – 7.92 (m, 4H), 7.89 (s,

1H), 7.73 – 7.58 (m, 5H), 7.06 (d, 2H), 6.96 (d, 2H), 6.78 (d, 2H), 4.65 (m, 1H), 4.35 (m,
1H), 4.00 (m, 2H), 3.86 – 3.71 (m, 2H), 3.45 – 3.33 (m, 4H), 3.33 – 3.21 (m, 4H), 1.83
(s, 3H).

13

C NMR (126 MHz, CDCl3) δ 165.53, 152.75, 148.50, 146.03, 139.34, 134.83,

134.36, 132.80, 132.69, 132.36, 130.97, 130.68, 128.96, 128.73, 128.59, 127.83,
127.41, 126.94, 126.71, 123.57, 121.69, 118.36, 116.96, 115.63, 115.24, 111.68,
109.16, 105.89, 77.27, 77.22, 77.02, 76.77, 75.07, 68.44, 67.40, 50.74, 49.87, 25.91,
1.04. DART-HRMS: m/z calcd. for C38H35Cl2N3O4 [MH]+, 668.2083; Found: 668.2116. IR
(solid) vmax: 3326, 2920, 2851, 1663, 1596, 1558, 1513, 1450, 1373, 1229, 1195,
1151, 1037, 948, 822, 760.
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N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)picolinamide (91) Aniline 88 (20 mg, 0.039
mmol), picolinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under
argon for 12h at room temperature. The crude reaction was immediately purified via
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 91 (5.0 mg,
20.6%).

Aniline 78 (20 mg, 0.039 mmol), picolinic acid (14.4 mg, 0.117 mmol), EDCI

(22.4 mg, 0.117 mmol), and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous
DCM (10mL) and stirred under argon for 12h at room temperature. The crude reaction
was immediately purified via column chromatography (SiO2, 0-80% acetone in hexanes)
to afford 81 (9.0 mg, 37%).

1

H NMR (500 MHz, Chloroform-d) δ 9.96 (s, 1H), 8.71 –

8.60 (m, 1H), 8.34 (m, 1H), 7.95 (m, 1H), 7.76 (m, 2H), 7.69 (d, 1H), 7.57 – 7.48 (m,
1H), 7.25 (m, 1H), 7.06 (d, 2H), 6.96 (d, 2H), 6.78 (d, 2H), 4.65 (m, 1H), 4.35 (m, 1H),
4.00 (m, 1H), 3.83 – 3.74 (m, 2H), 3.37 (s, 5H), 3.28 (s, 4H), 1.83 (s, 3H). 13C NMR (126
MHz, CDCl3) δ 147.93, 137.64, 130.97, 128.58, 126.71, 122.31, 120.91, 118.33,
116.96, 115.25, 111.75, 77.28, 77.02, 76.77, 75.06, 68.44, 67.39, 50.74, 49.90, 25.91.
DART-HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1862. IR
(solid) vmax: 3365, 2955, 2849, 1675, 1586, 1568, 1510, 1453, 1373, 1268, 1229,
1193, 1151, 1097, 1037, 942, 823, 747.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)nicotinamide (92) Aniline 88 (20 mg, 0.039
mmol), nicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and DMAP
(14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred under
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argon for 12h at room temperature. The crude reaction was immediately purified via
column chromatography (SiO2, 0-80% acetone in hexanes) to afford 92 (6.0 mg,
24.7%).

1

H NMR (500 MHz, Chloroform-d) δ 9.15 (s, 1H), 8.83 (s, 1H), 8.26 (d, 1H),

7.86 (s, 1H), 7.68 (d, 1H), 7.60 (d, 2H), 7.49 (s, 1H), 7.43 (d, 1H), 7.28 – 7.20 (m, 1H),
7.01 (m, 4H), 6.83 – 6.73 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.83 – 3.74
(m, 2H), 3.44 – 3.34 (m, 4H), 3.29 (t, 4H), 1.83 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ

139.33, 134.36, 132.80, 130.97, 128.58, 126.71, 121.92, 118.54, 116.92, 115.27,
109.17, 77.29, 77.24, 77.03, 76.78, 75.05, 68.43, 67.36, 50.88, 49.67, 25.90. DARTHRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879; Found: 619.1866. IR (solid)
vmax: 3364, 3315, 2960, 2924, 2853, 1673, 1511, 1456, 1372, 1259, 1227, 1193, 1097,
1035, 826, 807.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)isonicotinamide (93) Aniline 88 (20 mg,
0.039 mmol), isonicotinic acid (14.4 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred
under argon for 12h at room temperature. The crude reaction was immediately purified
via column chromatography (SiO2, 0-80% acetone in hexanes) to afford 93 (8.0 mg,
33%). 1H NMR (500 MHz, Chloroform-d) δ 8.85 (s, 2H), 7.82 – 7.70 (m, 3H), 7.68 (d,
1H), 7.59 (d, 2H), 7.43 (d, 1H), 7.24 (m, 1H), 7.04 (d, 2H), 7.01 – 6.88 (m, 2H), 6.82 –
6.72 (m, 2H), 4.66 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.85 – 3.71 (m, 2H), 3.38 (m,
4H), 3.27 (m, 4H), 1.86 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.80, 150.80, 145.98,

139.36, 134.36, 132.81, 130.97, 128.58, 126.70, 121.81, 120.80, 118.38, 116.79,
115.27, 111.58, 109.16, 77.27, 77.22, 77.02, 76.77, 75.07, 68.46, 67.39, 50.71, 49.65,
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29.72, 25.90, 1.03. DART-HRMS: m/z calcd. for C33H32Cl2N4O4 [MH]+, 619.1879;
Found: 619.1866. IR (solid) vmax: 3256, 2963, 2854, 1660, 1587, 1510, 1449, 1376,
1261, 1226, 1193, 1150, 1034, 940, 826, 740.
2-(benzyloxy)-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (94) Aniline 88 (100 mg, 0.194
mmol), 2-(benzyloxy)benzoic acid (133 mg, 0.583 mmol), EDCI (111.8 mg, 0.583
mmol), and DMAP (14.3 mg, 0.583 mmol) was dissolved in anhydrous DCM (10mL) and
stirred under argon for 12h at room temperature. The crude reaction was immediately
purified via column chromatography (SiO2, 0-30% acetone in hexanes) to afford 94 (20
mg, 14.2%).

1

H NMR (500 MHz, Chloroform-d) δ 9.91 (s, 1H), 8.39 (m, 1H), 7.69 (d,

1H), 7.62 – 7.49 (m, 6H), 7.43 (d, 1H), 7.29 – 7.15 (m, 5H), 6.97 – 6.91 (m, 2H), 6.91 –
6.85 (m, 2H), 6.82 – 6.73 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.82 – 3.74
(m, 2H), 3.31 (m, 4H), 3.25 (m, 4H), 1.83 (s, 3H).13C NMR (126 MHz, CDCl3) δ 156.61,
135.35, 132.99, 132.63, 131.57, 130.97, 129.15, 129.08, 128.59, 126.71, 122.13,
121.96, 120.88, 118.31, 116.81, 115.23, 112.58, 109.15, 77.28, 77.03, 76.77, 75.07,
71.81, 68.44, 67.40, 50.73, 49.99, 25.90.
3-(benzyloxy)-N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (95) Aniline 88 (100 mg, 0.194
mmol), 3-(benzyloxy)benzoic acid (133 mg, 0.583 mmol), EDCI (111.8 mg, 0.583
mmol), and DMAP (14.3 mg, 0.583 mmol) was dissolved in anhydrous DCM (10mL) and
stirred under argon for 12h at room temperature. The crude reaction was immediately
purified via column chromatography (SiO2, 0-30% acetone in hexanes) to afford 95 (60
mg, 43%). 1H NMR (500 MHz, Chloroform-d) δ 7.80 (s, 1H), 7.69 (d, 1H), 7.62 – 7.54
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(m, 3H), 7.52 – 7.35 (m, 10H), 7.27 – 7.22 (m, 1H), 7.18 (m, 1H), 7.03 (d, 2H), 6.96 (d,
2H), 6.78 (d, 2H), 5.16 (d, 3H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.78 (m, 2H),
3.42 – 3.32 (m, 4H), 3.28 (m, 4H), 1.83 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 159.13,

139.34, 136.64, 136.53, 134.36, 132.80, 130.98, 129.82, 128.69, 128.59, 128.17,
127.59, 126.72, 121.62, 119.02, 118.61, 118.41, 116.97, 115.24, 113.50, 109.16, 77.31,
77.05, 76.80, 75.07, 70.25, 68.42, 67.38, 50.74, 49.85, 25.91. DART-HRMS: m/z calcd.
for C41H39Cl2N3O5 [MH]+, 724.2345; Found: 724.2377. IR (solid) vmax: 3289, 2928,
2878, 2824, 1693, 1639, 1583, 1556, 1509, 1484, 1451, 1225, 1188, 1027, 941, 820,
732, 622, 600
4-(benzyloxy)-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (96) Aniline 88 (100 mg, 0.194
mmol), 3-(benzyloxy)benzoic acid (133 mg, 0.583 mmol), EDCI (111.8 mg, 0.583
mmol), and DMAP (14.3 mg, 0.583 mmol) was dissolved in anhydrous DCM (10mL) and
stirred under argon for 12h at room temperature. The crude reaction was immediately
purified via column chromatography (SiO2, 0-30% acetone in hexanes) to afford 95 (50
mg, 35%).

1

H NMR δ 9.04 (s, 2H), 7.91 – 7.84 (m, 7H), 7.71 – 7.63 (m, 2H), 7.57 (d, J

= 8.5 Hz, 2H), 7.52 – 7.36 (m, 22H), 7.09 (d, J = 8.6 Hz, 6H), 7.05 – 6.96 (m, 5H), 6.95
(d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 5.13 (s, 2H), 4.65 (m, 1H), 4.35 (m, 1H),
3.85 – 3.73 (m, 2H), 3.35 (d, J = 5.5 Hz, 5H), 3.28 (d, J = 5.3 Hz, 5H), 1.83 (s, 3H).
DART-HRMS: m/z calcd. for C41H39Cl2N3O5 [MH]+, 724.2345; Found: 724.2329.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-hydroxybenzamide (97) DART-HRMS:
m/z calcd. for C34H33Cl2N3O5 [MH]+, 634.1876; Found: 634.1843.
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N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-hydroxybenzamide (98) Protected ester
95 (20 mg, 0.0276 mmol) was dissolved in EtOH: THF (2:1). 10% palladium on carbon
(10 mg) was then added. The reaction vessel was sealed with a rubber septum and
charged with an atmosphere of hydrogen gas. The reaction was stirred overnight at
room temperature. The reaction mixture was filtered over a pad of celite and rinsed with
EtOAc and concentrated under reduced pressure. The crude residue was purified via
column chromatography (SiO2, 0-80% acetone in hexanes) to yield 98 (8 mg, 45.5%).
1

H NMR (500 MHz, Chloroform-d) δ 7.70 (s, 1H), 7.64 (d, 1H), 7.52 (d, 2H), 7.46 (s,

1H), 7.38 (s, 1H), 7.34 (s, 2H), 7.24 – 7.17 (m, 1H), 7.04 – 6.96 (m, 3H), 6.90 (d, 2H),
6.73 (d, 2H), 5.72 (s, 1H), 4.65 – 4.56 (m, 1H), 4.31 (t, 1H), 3.95 (m, 1H), 3.74 (t, 2H),
3.31 (d, 4H), 3.23 (d, 4H), 1.80 (d, 3H).

13

C NMR (126 MHz, Chloroform-d) δ 130.05 ,

128.58 , 126.71 , 121.75 , 118.47 , 118.36 , 116.92 , 115.25 , 114.62 , 111.69 , 106.06 ,
102.05 , 77.22 , 75.07 , 67.39 , 50.71 , 49.81 , 25.90 . DART-HRMS: m/z calcd. for
C34H33Cl2N3O5 [MH]+, 634.1876; Found: 634.1884. IR (solid) vmax: 3279, 2925, 2852,
2824, 1639, 1590, 1446, 1409, 1373, 1228, 1190, 115, 1036, 944, 826, 747.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide (99) DART-HRMS:
m/z calcd. for C34H33Cl2N3O5 [MH]+, 634.1876; Found: 634.1843.
3-chloro-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (100) Aniline 88 (20 mg, 0.039
mmol), 3-chlorobenzoic acid (18.3 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol), and
DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred
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under argon for 12h at room temperature. The crude reaction was immediately purified
via column chromatography (SiO2, 0-80% acetone in hexanes) to afford 100 (6.0 mg,
23.5%).

1

H NMR (500 MHz, Chloroform-d) δ 7.90 (t, 1H), 7.78 (d, 1H), 7.68 (d, 2H),

7.60 – 7.54 (m, 3H), 7.47 (t, 1H), 7.43 (d, 1H), 7.24 (m, 1H), 7.04 (d, 2H), 6.98 – 6.92
(m, 2H), 6.81 – 6.75 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.82 – 3.73 (m,
2H), 3.41 – 3.32 (m, 4H), 3.27 (m, 4H), 1.83 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ

130.97, 130.10, 128.58, 127.34, 126.71, 121.74, 118.36, 116.88, 115.24, 111.47,
109.16, 105.92, 101.77, 77.27, 77.02, 76.76, 75.06, 68.44, 67.39, 50.72, 49.77, 25.90.
DART-HRMS: m/z calcd. for C34H32Cl3N3O4 [MH]+, 648.2032; Found: 648.1998. IR
(solid) vmax: 3311, 3283, 3254, 2961, 2854, 1640, 1588, 1512, 1451, 1375, 1228,
1192, 1152, 1037, 943, 820, 755.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-3-methoxybenzamide (101) Aniline 88
(20 mg, 0.039 mmol), m-anisic acid (17.8 mg, 0.117 mmol), EDCI (22.4 mg, 0.117
mmol), and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and
stirred under argon for 12h at room temperature. The crude reaction was immediately
purified via column chromatography (SiO2, 0-60% acetone in hexanes) to afford 101
(4.0 mg, 15.7%).

1

H NMR (500 MHz, Chloroform-d) δ 7.74 (s, 1H), 7.68 (d, 1H), 7.59

(d, 2H), 7.51 – 7.46 (m, 1H), 7.45 – 7.41 (m, 3H), 7.24 (m, 1H), 7.14 – 7.08 (m, 1H),
7.04 (d, 2H), 6.95 (d, 2H), 6.81 – 6.75 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H),
3.92 (s, 3H), 3.81 – 3.74 (m, 2H), 3.42 – 3.31 (m, 5H), 3.27 (t, 4H), 1.83 (s, 3H). 13C NMR
(126 MHz, Chloroform-d) δ 129.75 , 121.58 , 118.35 , 118.35 , 116.93 , 116.93 , 115.24
, 110.72 , 109.81 , 104.93 , 100.60 , 96.72 , 77.21 , 55.52 , 50.72 , 49.86 .
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DART-HRMS: m/z calcd. for C35H35Cl2N3O5 [MH]+, 652.1537; Found: 652.1532. IR
(solid) vmax: 3289, 2922, 2823, 138, 1580, 1510, 1450, 1374, 1288, 1190, 1150, 1033,
943, 817, 746, 686, 524
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)furan-3-carboxamide (102) Aniline 88 (20
mg, 0.039 mmol), 3-thiophene carboxylic acid (14.9 mg, 0.117 mmol), EDCI (22.4 mg,
0.117 mmol), and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM
(10mL) and stirred under argon for 12h at room temperature. The crude reaction was
immediately purified via column chromatography (SiO2, 0-50% acetone in hexanes) to
afford 102 (2.0 mg, 8.1%).

1

H NMR (500 MHz, Chloroform-d) δ 7.53 (s, 3H), 7.02 (d,

2H), 6.98 – 6.90 (m, 2H), 6.83 – 6.71 (m, 3H), 4.35 (m, 1H), 3.78 (m, 2H), 3.43 – 3.30
(m, 4H), 3.30 – 3.17 (m, 4H), 1.83 (s, 3H). DART-HRMS m/z calcd. for C32H31Cl2N3O5
[MH]+, 608.1719; Found: 608.1701
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)thiophene-3-carboxamide (103) Aniline 88
(20 mg, 0.039 mmol), 3-furic acid (13.1 mg, 0.117 mmol), EDCI (22.4 mg, 0.117 mmol),
and DMAP (14.3 mg, 0.117 mmol) was dissolved in anhydrous DCM (10mL) and stirred
under argon for 12h at room temperature. The crude reaction was immediately purified
via column chromatography (SiO2, 0-50% acetone in hexanes) to afford 90 (3.0 mg,
12.6%).

1

H NMR (500 MHz, Chloroform-d) δ 7.99 (d, 1H), 7.68 (d, 1H), 7.59 – 7.49

(m, 4H), 7.44 (m, 2H), 7.24 (m, 1H), 7.03 (d, 2H), 6.95 (d, 2H), 6.78 (d, 2H), 4.65 (m,
1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.78 (m, 2H), 3.41 – 3.32 (m, 4H), 3.27 (m, 4H).

13

C

NMR (126 MHz, CDCl3) δ 152.75, 146.02, 139.34, 134.36, 130.97, 128.58, 128.36,
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126.83, 126.70, 126.03, 121.67, 119.77, 118.35, 116.93, 115.88, 115.24, 111.51,
109.16, 105.96, 101.84, 97.85, 93.77, 77.27, 77.22, 77.01, 76.76, 75.07, 68.44, 67.39,
50.72, 49.84, 31.95, 30.18, 29.72, 29.38, 25.90, 22.71, 14.13, 1.04. DART-HRMS: m/z
calcd. for C32H31Cl2N3O4S [MH]+, 624.1491; Found: 624.1473.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)cyclohexanecarboxamide (104) 1H NMR
(500 MHz, Chloroform-d) δ 8.19 (s, 1H), 7.56 (d, J = 7.5 Hz, 2H), 7.46 – 7.33 (m, 3H),
6.92 (dd, J = 18.1, 8.7 Hz, 4H), 6.79 (dd, J = 12.5, 8.7 Hz, 2H), 6.72 (d, J = 8.5 Hz, 2H),
4.42 – 4.28 (m, 1H), 4.00 (dd, J = 9.6, 5.8 Hz, 1H), 3.83 – 3.66 (m, 2H), 3.40 (s, 4H),
3.24 (d, J = 6.3 Hz, 8H), 2.28 – 2.18 (m, 2H), 1.93 (d, J = 12.9 Hz, 3H), 1.89 – 1.79 (m,
5H), 1.72 (s, 4H), 1.68 (s, 1H), 1.52 (t, J = 12.7 Hz, 5H).
3-acetyl-N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)benzamide (105)

1

H NMR (500 MHz,

Chloroform-d) δ 8.47 (s, 1H), 8.15 (t, J = 8.6 Hz, 2H), 7.92 (s, 1H), 7.71 – 7.52 (m, 5H),
7.45 – 7.32 (m, 2H), 7.29 – 7.22 (m, 1H), 7.04 (d, J = 8.7 Hz, 2H), 6.95 (t, J = 6.5 Hz,
2H), 6.84 – 6.74 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.82 – 3.66 (m, 2H),
3.36 (m, 4H), 3.27 (m, 4H), 2.71 (d, J = 6.6 Hz, 3H).
phenyl

(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-

yl)methoxy)phenyl)piperazin-1-yl)phenyl)carbamate (106)

1

H NMR (500 MHz,

Chloroform-d) δ 7.66 (m, 1H), 7.52 – 7.36 (m, 6H), 7.30 – 7.21 (m, 4H), 7.21 – 7.17 (m,
1H), 7.04 – 6.96 (m, 4H), 6.96 – 6.90 (m, 2H), 6.86 (s, 1H), 4.38 (m, 1H), 4.16 (m, 1H),
4.09 – 4.04 (m, 1H), 4.04 – 3.97 (m, 1H), 3.90 (m, 1H), 3.44 (m, 1H), 3.35 (m, 3H), 3.28
(m, 4H), 1.87 (s, 3H).

13

C NMR (126 MHz, Chloroform-d) δ 152.92 , 138.15 , 134.56 ,
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132.83 , 131.20 , 129.39 , 128.91 , 126.80 , 125.59 , 121.66 , 121.30 , 120.32 , 118.38 ,
117.16 , 116.17 , 115.49 , 109.09 , 77.24 , 73.96 , 69.30 , 67.03 , 50.74 , 49.98 , 48.91 ,
25.75. IR (solid) vmax: 3332, 3292, 2926, 2825, 1733, 1706, 1510, 1490, 1450, 1414,
1227, 1179, 1161, 1034, 943, 823, 747, 687.
N-(4-(4-(4-(((2R,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)hydrazinecarboxamide

(107)

1

H

NMR

(500 MHz, Chloroform-d) δ 7.66 (d, 1H), 7.45 (d, 1H), 7.28 (m, 1H), 7.02 – 6.95 (m,
2H), 6.92 (m, 4H), 6.76 – 6.68 (m, 2H), 4.37 (m, 1H), 4.16 (m, 1H), 4.06 (m, 1H), 4.01
(m, 1H), 3.89 (m, 1H), 3.41 (d, 1H), 3.32 – 3.26 (m, 4H), 3.26 – 3.17 (m, 3H), 1.86 (s,
3H).

13

C NMR (126 MHz, Chloroform-d) δ 131.19 , 128.91 , 126.79 , 118.85 , 118.25 ,

116.23 , 115.46 , 110.18 , 77.23 , 73.97 , 69.30 , 67.04 , 51.25 , 50.86 , 25.74. IR (solid)
vmax: 2916, 2848, 1546, 1510, 1462, 1450, 1375, 1225, 1197, 1037, 945, 824.
phenyl

(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4-

yl)methoxy)phenyl)piperazin-1-yl)phenyl)carbamate (108)

1

H NMR (500 MHz,

Chloroform-d) δ 7.59 – 7.53 (m, 2H), 7.47 – 7.37 (m, 11H), 7.27 – 7.22 (m, 6H), 7.01 (d,
J = 8.9 Hz, 3H), 6.95 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 7.9 Hz, 2H), 6.84 – 6.73 (m, 3H),
4.65 (p, J = 6.1 Hz, 1H), 4.39 – 4.30 (m, 1H), 4.00 (s, 2H), 3.82 – 3.69 (m, 3H), 3.40 (s,
3H), 3.33 (d, J = 5.4 Hz, 4H), 3.27 (dd, J = 6.3, 3.7 Hz, 4H). IR (solid) vmax: 3332,
2958, 2926, 2853, 1757, 1736, 1553, 1510, 1491, 1417, 1229, 1195, 1181, 1162, 1024,
911, 828, 751, 688.
N-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)hydrazinecarboxamide

(109)

1

H NMR

(500 MHz, Chloroform-d) δ 7.68 (d, 1H), 7.43 (d, 1H), 7.24 (m, 1H), 6.99 – 6.87 (m, 5H),
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6.81 – 6.68 (m, 4H), 4.65 (m, 1H), 4.35 (m, 1H), 4.00 (m, 1H), 3.85 – 3.74 (m, 3H), 3.40
(s, 2H), 3.30 – 3.20 (m, 8H), 1.82 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 128.59 ,
126.71 , 119.01 , 118.35 , 116.21 , 115.22 , 110.03 , 105.12 , 76.87 , 75.06 , 68.43 ,
67.39, 50.80 , 29.72 , 25.89. IR (solid) vmax: 2920, 2876, 2851, 1554, 1511, 1464,
1450, 1377, 1225, 1184, 1151, 1035, 944, 826.
4-(4-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-methyl-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (110). 1H NMR
(500 MHz, Chloroform-d) δ 8.55 (d, J = 11.6 Hz, 0H), 8.38 (s, 0H), 7.68 (d, J = 8.4 Hz,
1H), 7.50 (d, J = 16.7 Hz, 1H), 7.43 (s, 1H), 7.23 (d, J = 2.1 Hz, 1H), 7.08 (d, J = 18.3
Hz, 1H), 7.00 (d, J = 15.3 Hz, 2H), 6.93 (s, 2H), 6.78 (s, 2H), 4.65 (s, 1H), 4.36 (s, 1H),
3.98 (s, 1H), 3.81 – 3.75 (m, 2H), 3.40 (s, 1H), 3.26 (q, J = 4.6, 3.6 Hz, 5H), 1.83 (s,
3H).

4.2 Biological Assay Protocols
Gene expression assay protocol (ASZ-001): Cells were seeded (10,000 cells per well;
100 µL total volume per well) in a 96-well tissue culture plate. After 24h of incubation
(37°C, 5% CO2), growth media was removed and replaced with low FBS media. Cells
were incubated for an additional 24h.

After this time, DMSO (vehicle control) and

analogues (1% DMSO concentration) were added to the wells. Cells were incubated
(37°C, 5% CO2) for 48h and RNA was isolated and evaluated by qRT-PCR.
RT-PCR protocol: Following treatment and incubation periods, both RNA extraction and
cDNA synthesis were performed using a TaqMan Cells-to-CT (fast) kit. cDNA synthesis
utilized a BioRad MyCycler and was programmed according to the manufacturer’s
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instructions. Quantitative RT-PCR was performed on an ABI 7500 system and made
use of the following TaqMan Gene Expression Probes: mouse ActB (Mm00607939_s1)
and mouse Gli1 (Mm00494654_m1). Relative gene expression levels were computed
via ΔΔCT method using GraphPad Prism. Corresponding IC50 values were calculated
as mean ± SEM for at least three separate experiments performed in triplicate.
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CHAPTER IV: Using Nanotechnology for Targeted ITZ Delivery
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1. Introduction
Nanoscience refers to research at a scale of 100 nm or less and it represents a
broad range of scientific disciplines. Nanomedicine consists of utilizing nanoscience for
medical diagnosis, prevention, and treatment of a disease. Applying nanoscience to
drug delivery is seen to be extremely promising and represents the bulk usage of
nanoscience.130,131 Often times, clinically approved drugs are not necessarily the most
potent but rather have the most optimal physicochemical properties.

Nanoparticles

mask a drug’s limiting properties as the drug of interest is dissolved, entrapped,
absorbed, attached and/or encapsulated into or onto the nano-matrix.132 As a result,
utilizing nanotechnology will aid in the approval of compounds with the most potent
activity rather than the most optimal drug properties. Nanotechnology offers a wide
range of advantages including improved delivery of water insoluble drugs, targeted
delivery of drugs in a cell or tissue specific manner, crossing of drugs across tight
epithelial/endothelial barriers, delivery of large macromolecule drugs to intracellular
sites of action, co-delivery of two or more drugs, visualization of drug delivery with
imagining, and real-time read out of in vivo efficacy experiments.133 To date, there are
over two-dozen nanotechnology therapeutic products that are clinically approved and
this number is expected to increase as research in the nanomedicine field is rapidly
growing.133
The most studied nanoparticles, liposomes, were first discovered in the 1960s.134
Liposomes can be described as molecules that self-assemble into hollow spherical
structures into which a wide variety of cargo molecules can be packaged.135,134
Liposomes bring tremendous promise towards achieving targeted drug-delivery.
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Various lipids can be utilized to form liposomes and these lipids affect the overall size
and charge of the liposome.134,136 In addition, there are a variety of different ways to
manufacture liposomes, and this process ultimately affects these same properties of the
liposomes. The flexibility in making liposomes presents an ideal way to selectively
target certain types of diseases such as cancer.134,136
2. Liposomes
Liposomes are composed of naturally occurring or synthetically produced
phospholipids such as phosphatidyl choline (PC), phosphatidyl ethanolamine (PE),
phosphatidyl serine (PS), phosphatidyl inositol (PI), and phosphatidyl glycerol (PG).135
Phospholipids themselves have rotational freedom, which can lead to leaky liposomes,
and the addition of cholesterol helps stabilize this bilayer.

The hydroxyl group of

cholesterol is positioned towards the aqueous surface and the aliphatic chain is aligned
in parallel to the hydrocarbon chains of the bilayer.134,135 The high solubility of
cholesterol within the phospholipid bilayer is attributed to its aliphatic chemical structure.
Cholesterol is usually added to the liposome formulation in high concentrations;
however, large amounts of cholesterol have been attributed to larger liposome
vesicles.134,135 This is important to consider if a certain size liposome is necessary for
targeted drug delivery.

Polyethylene glycol (PEG) is the standard polymer that is

attached to the drug molecule or added to the liposome formulation to aid with safety
and efficacy.134,135 By covalently linking PEG to liposomes, the active drug is protected
from the immune system and therefore increases its blood circulatory time. PEG has
also been shown to aid in binding efficiency and general targeted transport in vitro and
in vivo.137
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2.1 Liposome Formation
There are four conventional ways to prepare liposomes: thin-film hydration method,
reverse-phase evaporation technique, ethanol-injection method, and detergent
dialysis.132,134 The thin-film hydration method involves dissolving lipids in organic solvent
and then evaporating off the solvent resulting in a thin-film. To ensure that solvents are
removed completely, the film is put on high vacuum overnight.132,134 Rehydration with
aqueous solvent forms the liposomes: vigorous shaking yields multilamellar vesicles
(MLVs) and gentle shaking yields giant unilamellar vesicles. Small unilamellar vesicles
can be formed with various size reduction techniques. The reverse-phase evaporation
technique involves dissolving lipid in organic solvent and then evaporating off the
solvent to create a thin film.132,134 The film is redissolved in solvent and aqueous buffer
is added to create a two-phase system. Slow evaporation of the organic solvent leads
to liposome formation. The ethanol-injection method involves dissolving phospholipids
in organic solvent (ethanol) and adding to aqueous solvent.

Upon addition of the

ethanol solution, liposomes are formed.132,134 The detergent dialysis method uses
phospholipids dissolved in detergents to create micelles, which are added to an
aqueous phase.

Removal of the detergent via dialysis or size-exclusion gel

chromatography results in large unilamellar vesicles.132,134
All four of these liposome formation methods typically result in larger-sized
liposomes.134 However, small unilamellar vesicles can be formed with various size
reduction techniques. As liposome size and size distribution are the most important
liposome characteristics, it is often necessary to utilize additional size reduction
techniques after the initial liposome formation.134,132 Size reduction can be achieved via
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sonication or extrusion.

Probe sonication uses a titanium probe inserted into the

liposome preparation. This generates smaller liposomes efficiently and can be used to
prepare a desired liposome size.134 Water sonication can also be used if there is
concern of metal contamination or high temperature affecting liposomes/lipid
components. Alternatively, the size extrusion method uses a pressurized instrument to
force liposomes through a polycarbonate membrane. The number of extrusion cycles
depends on the size of the polycarbonate membrane pores.134

Figure 1. Structure of Liposome
Liposomes are useful drug delivery vehicles as they can carry hydrophilic, lipophilic,
and amphiphilic drugs.134 Hydrophilic drugs reside in the core of the nanoparticle while
hydrophobic drugs are incorporated into the lipid bilayer (Figure 1). It is important to
understand the physicochemical properties of both the drug and the lipids being used in
the formulation. For instance during the thin film hydration method, lipophilic drugs are
often highly embedded in the lipid bilayer during the step when liposomes selfassemble.134 However, hydrophilic drugs often do not get encapsulated as well due to
water content being higher outside of the liposome than inside of the liposome. Drug
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loading is dependent not only on the physicochemical properties of drug/lipids but it is
also dependent on the method of liposome formulation. There are two types of drug
loading: passive and active.134 Passive loading consists of drug loading during the
method of preparation without any additional steps. Active loading involves forming the
liposome without the drug and adding it into the liposome after. This is done with a
series of buffers to actively load a drug into the liposome and keep it within the
liposome.134
2.2 Liposome Characterization
As previously described, the characteristics of the liposomes depend heavily on the
lipid composition and liposome formation method. Liposome characteristics such as
size, membrane lamellarity, and charge are crucial for ultimately determining a route of
administration (Table 1).134 Liposome size varies from very small (0.025 µM) to large
vesicles (2.5 µM). The liposome size is important for in vivo distribution, biological fate,
toxicity, and target specificity.132 In addition, particle size affects drug release and
storage. Smaller particles have a larger surface area-to-volume ratio and result in faster
drug release while larger particles encapsulate more drug particles and allow for slower
release. In terms of storage, smaller particles have a greater risk of aggregation.132 It is
also important to consider the liposome size dispersion throughout a sample. This is
referred to as the polydispersity index (PDI) and samples with uniform size distribution
are optimal (PDI = 0.1).132 Liposomes can be classified by different bilayers, also known
as membrane lamellarity, (Table 1) and this affects a wide-range of properties such as
drug entrapment capacity, the addition of surface bound ligands, drug release from the
system, storage characteristics, and liposome cell interaction and internalization.134
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Unilamellar liposomes consist of one lipid bilayer while multilamellar liposomes consist
of multiple concentric lipid bilayers, similar to an onion.138 Liposomes can be either
negatively or positively charged depending on their composition. The addition of oleic
acid generates negatively charged liposomes while the addition of N-[1(2,3dioleoyloxy)propyl]-N,N,N-trimethylammonium

chloride

(DOTAP)

results

in

the

generation of positively charged liposomes.134 When liposomes are charged, they
exhibit electrostatic repulsion, which is favorable for storage conditions as the liposomes
are unable to aggregate. In addition, cell membranes are negatively charged and there
is an electrostatic interaction with positively charged (cationic) liposomes.

This

ultimately increases cell permeability and internalization.134
Table 1. Classification of Liposomes134
Vesicle
Small unilamellar (SUV)
Large unilamellar (LUV)
Giant unilamellar (GUV)
Oligolamellar (OLV)
Multilamellar (MLV)

Size (nm)
20-100
> 100
> 1000
100-1000
> 500

Composition
Conventional liposomes
Long-circulating liposomes
Cationic liposomes
Stimuli-sensitive liposomes
Immunoliposomes

Liposome size can be determined by a variety of different methods, which
include dynamic light scattering (DLS), size exclusion chromatography (SEC), nuclear
magnetic resonance (NMR), and microscope technologies including transmission
electron microscopy (TEM), cryogenic-TEM, and atomic force microscopy.134 Dynamic
light scattering is the easiest and most popular technique. DLS analyzes Brownian
motion of colliding particles resulting from scattering of the incident light; light scattering
depends on the refractive index between suspended particles and solvent.134 Size
exclusion chromatography with the use of HPLC provides high-resolution results while
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only using a small amount of sample.134 This can be used alone or in combination with
DLS. While this method is efficient in determining and separating size, it also may lead
to issues as a result of the liposome chemistry and columns. Microscopy is used to
visualize and measure the size of liposomes. The downside to this method is that
liposomes must be removed from their native environment and the lipid chemistry may
be disturbed.134
In addition to affecting cell permeability, liposome charge is also important for
stability. The charge of a liposome sample can be calculated via the zeta-potential.134
The zeta-potential is measured by adding liposomes to a sample cell, which is then
illuminated with light. The scattered light measures the zeta potential as the liposomes
move due to their electric fields.134 The number of bilayers in a liposome will influence in
vivo fate and applications.

There are various chemical based techniques that use

labeled reagents or radiolabeled ions that aid in estimating the number of layers or the
amounts of lipids on the surface. Other techniques used include cryo-TEM analysis,
NMR and small-angle x-ray scattering (SAXS).134
2.3 Liposome-Cell Interactions
There are four different in vitro mechanisms of liposome-cell interaction: exchange of
lipids or proteins with cell membranes, adsorption or binding of liposomes to cells,
internalization of liposomes by endocytosis or phagocytosis, and fusion of bound bilayer
with the cell membrane (Figure 2).139 All four of these interactions are dependent on
lipid composition, type of cell, and presence of specific receptors/targeting vectors.
Stable absorption consists of the association of intact liposomes with the cell surface,
without internalization.139 This adsorption may be mediated by nonspecific forces
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(hydrophobic, electrostatic) or by specific components (surface receptors, antibodies).
Endocytosis is the uptake of intact liposomes into endocytotic vesicles.139 Endocytosis
leads to delivery to the lysosome; however, in some cases content may be released into
the cytoplasm. Fusion is the merging of the lipid bilayer with the plasma membrane and
simultaneous release of liposome contents into the cytoplasm.139 It is possible that
liposome contents release into the medium during this process. Lipid transfer includes
the transfer of lipid molecules between liposomes and cells without cell association of
aqueous liposome contents.139

Figure 2. Schematic Liposome-Cell Interactions139
3. Coaxial Continuous Liposome Formation
As previously described, there are a variety of methods to form liposomes. After
this initial formation, liposomes must often undergo size reduction to attain the optimal
size liposome and to improve the uniformity of the particle size distribution.

This

complete process may take hours or days to obtain the desired size liposome.132,134
142

These methods of formation are not optimal or convenient for large-scale liposome
processing.

It is necessary to have direct control over the size and distribution of

liposomes as the size ultimately affects cellular uptake and biodistribution.140 As a
result, recent advances in technology have been utilized to create novel methods to
mass-produce liposomes of a particular size in an efficient and sterile manner.
The most well-known liposomal formulation is the ethanol-injection method. This
method offers a plethora of advantages including using less toxic solvents, control over
particle size/distribution, avoiding size reduction measures, and most importantly, that it
is a naturally continuous process.140 Continuous processing offers benefits in
comparison to batch processing and is thus important to consider in the pharmaceutical
industry. Continuous processing is faster, more efficient, and may also be safer than
batch processing. In addition, continuous processing has the potential to be automated
and this reduces human involvement and error.140 Both of these factors are important to
consider when scaling up a pharmaceutical process.
With this in mind, Dr. Diane Burgess and her lab at the University of Connecticut
set out to determine a continuous processing method for the production of
monodispersed liposomes.140 This production method depends heavily on fluid
mechanics and physics. There have been a few reports of utilizing the ethanol-injection
method for the production of unilamellar liposomes and these processes involve the use
of two different fluid mixing techniques: laminar and turbulent.140 In terms of the ethanolinjection method, laminar flow consists of smooth, steady fluid motion and relies heavily
on fluid viscosity and turbulent flow consists of chaotic fluid motion and relies less on
the viscosity of the fluid.141 Reynolds number (Re) is an important factor in fluid flow and
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is described as the ratio of inertial to viscous forces.

Reynolds number takes into

account the fluid’s resistance to change of motion and the amount of friction due to
viscosity of fluid.142

Laminar conditions consist of water slowly mixing with the alcohol

phase (low Reynolds number).

Turbulent conditions consist of rapid mixing of the

alcohol stream with the aqueous stream (high Reynolds number).142 Taking this into
consideration, the liposome formation process was explored by relating these fluid
dynamic properties with liposomal physical properties.
The Burgess lab successfully identified a novel continuous processing method
for the formation of liposomes that utilizes a coaxial turbulent jet in co-flow.

The

turbulent jet co-flow apparatus begins with preparation containers that house lipid and
aqueous solutions separately (Figure 3).140 A solution containing lipids and a watermiscible organic solvent is prepared by heating the solution to 50-60°C and sonication.
Once the components are dissolved, the lipid solution can be taken up by stainless steel
tanks, which are pressurized and can be heated to help maintain lipid solubility.140
These three tanks converge at a single point and static mixers are used to make sure
the lipid solutions from three different tanks are mixed appropriately before introducing
the aqueous phase.

The aqueous phase enters the apparatus straight from its

preparation container. The lipid solution is injected into the aqueous phase at different
flow rates (5-40 mL/min or 60-400 mL/min, respectively).140 It is important to note that a
hydrophilic drug would be incorporated into the aqueous solution and a hydrophobic
drug would be incorporated into the lipid solution. This apparatus is controlled by a
computer program, which was custom designed by the Burgess lab. The entire system
is automated and exceptionally user friendly.140 The user only needs to define the final
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lipid concentration and the molar ratios of the lipid formulation. This apparatus is also
attached to a Zetasizer® which records the size and polydispersity index (PDI) of a
liposome population. This allows the lipid and aqueous phase flow rates to be adjusted
in real-time to obtain the optimal size liposomes.140

Figure 3. Coaxial Turbulent Jet in Co-Flow Schematic140
4. FDA-Approved and Clinical Stage Liposome Formulations
To date, liposomal drug formulations are becoming increasingly popular within
the clinic. Liposomes are the first nanoparticles that have been successfully translated
into clinically utilized applications. Liposomes have been FDA-approved for a wide
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variety of indications including cancer, fungal infections, viral infections, and pain
management (Table 2).143
Table 2. Clinically Approved Liposomes143
Clinical Products
(Approval Year)
Doxil® (1995)
DaunoXome®
(1996)
Depocyt® (1999)
Myocet® (2000)
Mepact® (2004)
Marqibo® (2012)
Onivyde® (2015
Abelcet® (1995)
Ambisome®
(1997)
Amphotec®
(1996)
Visudyne® (2000)
DepoDur® (2004)
Exparel® (2011)

Administration

Active Agent

Indication

i.v.

Doxorubicin

Cancer

i.v.

Daunorubicin

Cancer

Spinal
i.v.
i.v.
i.v.
i.v.
i.v.

Cytarabine/Ara-C
Doxorubicin
Mifamurtide
Vincristine
Irinotecan
Amphotericin B

Cancer
Cancer
Cancer
Cancer
Fungal
Fungal

i.v.

Amphotericin B

Fungal

i.v.

Amphotericin B

Fungal

i.v.
Epidural
i.v.

Verteporphin
Morphine sulfate
Bupivacaine
Inactivated hepatitis A virus
(strain RGSB)
Inactivated hemaglutinine of
Influenza virus strains A/B

Fungal
Pain
Pain

Epaxal® (1993)

i.m.

Inflexal®V (1997)

i.m.

Hepatitis A
Influenza

i.v. (Intravenous); i.m. (Intramuscular)
The first liposome formulation approved in the U.S. in 1995 was Doxil®, which
delivered doxorubicin and was approved for the treatment of patients with ovarian
cancer and AIDS-related Kaposi’s sarcoma.143

A year later DaunoXome® was

approved for the delivery of daunorubicin for the management of advanced HIVassociated Kaposi’s sarcoma.

Depocyt® was approved in 1999 for the delivery of

Cytarabine/Ara-C for the treatment of neoplastic meningitis. In 2000, Myocet® was
another approved doxorubicin formulation for combinatory chemotherapeutic treatment
alongside cyclophosphamide in metastatic breast cancer.143
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Liposome formulation

containing mifamurtide, Mepact®, was approved in 2004 for the treatment of high-grade
resectable non-metastatic osteosarcoma. In 2012, Marqibo® (vincristine) was approved
for acute lymphoblastic leukemia.143 In 2015, OnivydeTM, which contains Irinotecan,
was approved for the treatment of metastatic pancreas adenocarcinoma in combination
with fluorouracil and leocovorin. While the majority of research in terms of liposomes
and drug discovery is aimed at cancer, a few liposome formulations are approved for
other indications (Figure 4).143
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Figure 4. Structures of Liposome-Encapsulated Chemotherapeutic Drugs
During 1995-1997, the FDA approved three different formulations (Abelcet®,
Ambisome®, and Amphotec®) containing amphotericin B for various fungal
infections.143 These three liposome formulations treat invasive and life-threating fungal
infections, especially if patients have renal impairment or experience unexpected
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toxicity to typical amphotericin B treatment. Visudyne® was the first light-activated drug
available for eradicating abnormal blood vessels that result from age-related macular
degeneration.143

This liposome contains verteporfin, which absorbs light at 692nm.

DepoDur®, a liposome formulation of morphine, is intended for administration before
surgery or following clamping of the umbilical cord during caesarean section. Exparel®
is an approved formulation containing bupivacaine, designed for extended release of
drug up to 72h.143 In 1993, the first approved liposome vaccine (virosome) was FDAapproved for hepatitis A and this formulation causes fewer adverse local side effects.
Inflexal® V is a virosomal influenza vaccine that shows superior immunogenicity above
other influenza vaccines and this was FDA-approved in 1997 (Figure 5).143
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Figure 5. Structures of Liposome-Encapsulated Therapeutic Agents
Due to their success in the clinic to date, there has been extensive research in
regards to liposomes and drug discovery. This has led to a multitude of formulations
that are currently being studied in clinical trials for the treatment of various diseases
(Figure 6).143 Current liposomes in Phase III clinical trials include Stimuvax®, a vaccine
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that has shown positive results in cancer patients.

Thermodox is a temperature

sensitive liposome formulation that does not release drug until 42°C.

Most of the

liposome formulations in Phase III clinical trials are tumor or site specific for more
targeted therapy. Current treatments in Phase II clinical trials include liposomes that
contain both novel and established chemotherapeutic agents.143

This includes two

Paclitaxel liposome formulations that decrease side effects; Endotag-1 contains
Paclitaxel and also consists of a cationic lipid formulation that can interact with the
negatively charged endothelial cells required for tumor angiogenesis.

OSO-211

contains a novel topoisomerase I inhibitor, lurtotecan, which will be a competitor to
topotecan.

Phase I clinical trials include both liposomal formulations composed of

siRNA and sphingosomal encapsulations (INX-0125 and INX-0076).143 Phospholipids
are compounds of fatty acids, a nitrogenous base, phosphoric acid, and either glycerol,
inositol, or sphingosine. Sphingosomal liposome formulations consist of sphingosine,
which is an amino alcohol that contains a long unsaturated hydrocarbon chain.144 While
sphingosomal encapsulation is a novel form of targeted drug delivery, utilizing
sphingoloids has demonstrated increased cell permeability and increased tumor
targeting specificity.143
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Figure 6. Liposomes in Clinical-Development143
5. Liposome-Based Strategies for Effective Drug Delivery
5.1 Brain Cancer
Currently, there are an estimated 700,000 Americans living with a brain tumor.
There are more than 140 types of malignant brain tumors and most of these tumors also
have their own subtypes.145 Despite the amount of brain tumors and their devastating
prognosis, there are only 4 FDA-approved drugs and one device being used to treat
brain tumors. In children, brain tumors are the leading cause of cancer-related death
(Figure 7).146 It is important to highlight that there has never been a drug developed and
approved specifically for malignant pediatric brain tumors despite the relatively high
diagnosis rate. Brain tumors are still a difficult health challenge due to their fast
150

development and poor prognosis despite the application of aggressive surgery,
radiation, and chemotherapy treatments.145
Acute Lymphoblastic Leukemia (ALL)
Brain and Central Nervous System
Hodgkin Disease
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)
Neuroblastoma
Bone Tumors
Thyroid Carcinoma
Wilms/Kidney
Germ Cell Tumors
Rhabdomyosarcoma
Retinoblastoma
Melanoma
Other

Figure 7. Pediatric Cancer Diagnosis146
Malignant brain tumors are difficult to treat with chemical and pharmaceutical
compounds due to the presence of the blood brain barrier.

The blood-brain barrier

(BBB) is an intricate network of vascular endothelial cells, cerebral endothelial cells,
glial cells, pericytes, and neurons.147 The BBB endothelium is uniquely characterized by
the presence of tight junctions, which consist of transmembrane proteins including
claudin (3,5, and 12), occludin (1,2, and 3), and junctional-adhesion molecules (JAM-A,
-B, and –C).148 The BBB has dual functions as it restricts the transport of potentially
toxic and harmful substances from the blood to the brain and it also allows for the
selective transport of nutrients to the brain and removal of metabolites from the cerebral
spinal fluid that surrounds CNS tissue.147 The BBB contains efflux transporters that
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significantly limit delivery of numerous therapeutics that could otherwise diffuse across
the plasma membrane. Two such efflux transporters are P-glycoprotein (P-gp) and
breast cancer resistance protein (BCRP) which are classified as ATP-binding cassette
(ABC) transporters.149,150

ABC transporters are ATP-dependent pumps that are

ubiquitous membrane bound proteins that can move substances into (influx) and out
(efflux) of the cell.

These transporters are predominantly found in the liver, BBB,

kidney, and placenta.151 Thus, the BBB remains a constant challenge in the world of
drug discovery and development.
Liposomes offer an alternative mode of delivery of drugs to the brain. Often
times, drugs that could be advantageous chemotherapeutic agents are not considered
due to their physicochemical properties. A nanoparticle vehicle such as a liposome
holds promise as a large percentage of small molecules and antibodies are not able to
penetrate the BBB. In addition to modifying liposome properties via different lipids and
different formation methods, liposomes can also be tagged with proteins that can aid in
BBB penetration.152 For instance, liposomes can be formulated to contain a target
ligand that can aid in penetrating the BBB and reaching the brain; these proteins include
but are not limited to transferrin receptor (TfR), lipoprotein receptor-related protein
(LRP), and nicotinic acetylcholine receptor (nAChRs). Transferrin receptors are widely
expressed in endothelial cells of the BBB. While nanotechnology has proved successful
with transferrin ligand, it is not optimal to have this drug delivery system competing with
natural ligand.152 A mouse monoclonal antibody (MAb) against rat TfR, OX26, has
successfully

been

used

to

target

liposomes

across

the

BBB

and

coined

“immunoliposome-based drug delivery.” LRP has been reported to mediate transport of
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various lipid-conjugated nanoparticles across the BBB. The LRP ligand Aprotinin and
more specifically, Angioprep, have effectively increased liposome treatment to the brain
and have increased survival time of brain tumor-bearing mice.152 Nicotinic acetylcholine
receptors (nAChRs) are ligand-ion channels that are expressed in the brain and brain
capillary endothelial cells. Various peptides derived from viruses and toxins have been
tagged to nanoparticles and enabled successful brain-targeted drug delivery.152 In
addition to being advantageous for brain cancers, liposomes serve as a promising route
of drug delivery for pediatric cancers.
5.2 Pediatric Cancer
In the mid-1970s, the 5-year survival rate for pediatric cancer was 58%. While
this number has improved to 80%, this survival rate has remained steady for the past
few decades.153,154 In addition, chemotherapy has become more aggressive and longterm toxicities are becoming more frequent in children that survive through adulthood.
Current chemotherapy involves administration of drug with the hope that enough of the
active agent permeates tumor cells and does not prove cytotoxic to the rest of the body.
Nanotechnology presents an alternative drug delivery system for the treatment of
pediatric malignancies.154 Specifically, liposomes serve as flexible drug delivery vehicles
that have the potential to improve targeted delivery while minimizing effective drug
dose.154 In addition to improving drug specificity and minimizing short and long-term
side effects, more efficacious drugs could be utilized despite their undesired
physicochemical properties. Macromolecules, such as siRNA, hold promise as specific
chemotherapeutic agents in pediatric bone and soft tissue sarcomas such as Ewing
sarcoma,

rhabdomyosarcoma,

and

synovial
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sarcoma.154

These

promising

macromolecules could be formulated into liposomes and provide a more promising form
of treatment for these children. There are a few liposomal drug formulations in clinical
trials to date reiterating the promise of this drug delivery system for the treatment of
pediatric malignancies (Table 3).11
Table 3. Liposomal Drug Formulations in Clinical Trials for Pediatric Indications
Formulation

Active Agent

ThermoDox

Doxorubicin

LipoDox

Doxorubicin

VSLI

Vincristine

MM-398

Irinotecan

Pediatric Indication
Solid tumors, Ewing sarcoma, soft tissue
sarcoma, osteosarcoma, neuroblastoma,
Wilms’ tumors, hepatic tumors, and germ cell
tumors
Liver cancer and soft tissue sarcoma
Soft tissue sarcoma, lymphoma, leukemia,
Wilms’ tumors, and osteosarcoma
Recurrent or refractory solid tumors, Ewing
sarcoma, rhabdomyosarcoma, neuroblastoma,
and osteosarcoma

Phase
I
I
II
I

6. Itraconazole Liposome Formulations: Fungal Infections
There have been numerous efforts to aid in improving the physicochemical
properties of itraconazole (ITZ). These efforts include utilizing nanotechnology such as
nano-amorphous powders and nanocrystalline suspensions.155,156 Both of these drug
formulations have improved the bioavailability of this poorly soluble drug. Due to the
success of amphotericin B liposomes for the treatment of fungal infections, there have
been attempts at formulating azole antifungals into liposomes. ITZ, specifically, offers
treatment to a wide range of fungal infections. However, orally available compounds
are not necessarily ideal for immunocomprised patients.157 There have been significant
efforts to formulate ITZ into liposomes to improve solubility and aid in producing an
intravenous ITZ formulation (Table 4).157,158,159 These liposome formulations improved
bioavailability, maintained fungal activity, and in one instance resulted in BBB
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penetration. Formulating ITZ into liposomes proves promising for the ultimate treatment
of MB. However, there are currently no FDA-approved or clinical stage ITZ liposome
formulations.11
Table 4. Experimental ITZ Liposome Formulations
Lipids
1 Soy phosphatidyl choline,
cholesterol, stearylamine
2 Lecithin, cholesterol,
3 Lecithin, cholesterol, cyclodextrin

Solvent
CHCl3

Aqueous Phase
Phosphate buffer (pH = 7.4)

CHCl3
CHCl3:
MeOH
CHCl3

Phosphate buffer (pH = 5.8)
N/A

Ref

160
157
161

4 Soy lecithin, cholesterol,
Phosphate buffer (pH = 7.4) 158
carboxymethyl chitosan
5 DPPC, cortisone acetate,
CHCl3
Phosphate buffer (pH = 7.4) 159
polyethylene glycol (PEG200)
162
6 DPPC
CHCl3
10 mM PBS (pH = 7.4)
163
7 Egg PC, MPEG-2000 DSPE,
CHCl3
6.67 mM KH2PO4 (pH = 6)
cholesterol
Dipalmitoylphosphotidylcholine (DPPC), potassium dihydrogen phosphate (KH2PO4),
1,2-distearoyl-phosphitdylehtanolamine-methyl-polyethylene glycol-2000 (DSPE)
7. Itraconazole Liposome Formulation: Medulloblastoma
There is tremendous promise in utilizing liposomes to attain more targeted
treatment regimens for both pediatric and brain cancers. If ITZ or des-triazole ITZ
analogues are going to be used for the treatment of MB, they must be able to penetrate
the BBB and reach the brain. Due to their large size, it is anticipated that ITZ and our
des-triazole ITZ analogues will have trouble crossing the BBB and liposomes serve as a
viable option for achieving this targeted drug delivery. Modifying the characteristics of
liposomes, such as size and composition, can aid in the nanoparticles’ ability to cross
the BBB.

Liposomes containing ITZ or des-triazole ITZ analogues would be

advantageous for the targeted treatment of pediatric SHH subtype MB.

155

7.1 ITZ Liposome Formulation
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Figure 8. Structures of Lipid Components
Our liposome formulation was based on previous ITZ formulations with a few
modifications. The lipids used were hydrogenated soy phosphatidyl choline (HSPC),
1,2-distearoyl-phosphitdylethanolamine-methyl-polyethylene glycol-2000 (mPEG-2000
DSPE), and cholesterol (Figure 5).163 This liposome formulation consists of PEG,
cholesterol, and synthetic lipid (HSPC) while other ITZ liposome formulations contain
natural ligand and either PEG or cholesterol. Synthetic lipid is present in all FDAapproved parenteral liposome formulations while natural lipid is utilized in FDAapproved liposome formulations with a variety of administration routes.164,165 In addition,
these liposomes are being formed with the novel coaxial jet in co-flow apparatus
established by the Burgess Lab. As the liposomes were being manufactured with the
turbulent coaxial jet in co-flow, lipids and ITZ could not be dissolved in a waterimmiscible solvent such as chloroform (CHCl3). Because of this, the solubility of ITZ
was determined in a variety of water-miscible solvents such as ethanol (EtOH),
methanol (MeOH), and isopropanol (IPA). ITZ was most soluble in EtOH (0.6 mg/mL)
after heating and sonication. The aqueous solvent utilized was 6.67 mM potassium
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dihydrogen phosphate (KH2PO4) at pH = 6. The flow rates of both the organic phase
and the aqueous phase were adjusted until the optimal size liposomes (ITZ liposomes =
67.72 nm – 75.23 nm; empty liposomes = 65.42 – 72.39 nm) and reasonable polydispersion index (PDI) values were attained. It was determined that faster flow rates for
both the lipid solution (30 mL/min) and aqueous solution (300 mL/min) resulted in
smaller particle size and optimal PDI values (Table 5). Sample #6 had a particle size of
66.82 nm and a PDI of 0.086. It is important to note that the optimal size liposome to
achieve BBB penetration is less than 100 nm and an optimal PDI for a sample of
liposomes is around 0.1.166,167 To date, ITZ liposomes have not been formed with the
coaxial jet in co-flow apparatus, and as a result, this preliminary batch of liposomes was
utilized solely for optimization of the formulation within this instrument (Table 5). After
this initial optimization, a second batch of liposomes was formulated and analyzed for
encapsulation efficiency and in vitro Hh pathway inhibitory activity.
Table 5. ITZ Liposome Batch 1: Flow Rate Optimization

#1
#2
#3
#4
#5
#6

Lipid Solution
(mL/min)

Aqueous Solution
(mL/min)

Particle Size (nm)

PDI

10
10
10
30
30
30

90
100
300
300
300
300

174.8
204.3
170.1
112.4
100.6
66.82

0.446
0.676
0.362
0.235
0.173
0.086

7.2 Separation of Free Drug
Inevitably, free drug will remain in the aqueous environment after liposome
formulation because not all of the drug will be encapsulated into the liposomes. Free
drug must be removed before determining the encapsulation efficiency.
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With

hydrophilic drugs, this is often done with filtration. Liposomes can be rinsed on a filter
with water; however, this will not work for hydrophobic drugs. Liposomes containing
hydrophobic drug could be rinsed with organic solvent, but ITZ is soluble only in harsh
solvents (dichloromethane and chloroform) that may disrupt the liposome. Therefore, a
centrifugation method was utilized to separate free hydrophobic drug from liposomes.168
This method relies on the size and density of free drug. As ITZ is large, hydrophobic,
dense (d = 1.41 g/cm3), and poorly water-soluble it was anticipated that free ITZ would
form a pellet upon centrifugation.

Liposomes remain suspended in the aqueous

solution and upon decanting, are separated from free drug. Removal of free drug is
necessary for further liposome evaluation including calculating the encapsulation
efficiency.
7.3 Encapsulation Efficiency
It is necessary to determine the amount of drug encapsulated into the liposomes.
Encapsulation efficiency is described as the concentration of the incorporated material,
in this instance ITZ, detected in the formulation over the initial concentration used to
make the formulation.169 Lysing the liposomes and measuring drug content via UV or
fluorescence detection can determine the drug concentration. When comparing to a
standard curve of drug, the concentration can be determined. The absorbance of
various concentrations of ITZ was measured using a UV-vis-spectrophotometer at 254
nm.

Plotting absorbance versus concentration created a standard curve of ITZ

(Appendix A). After removal of free drug via centrifugation, the liposomes were lysed to
release ITZ. ITZ liposomes were lysed with 5% Triton solution and heated for 2 h at
60°C. Upon heating for shorter time periods (20 min), less ITZ was released from the
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liposomes. This may be due to the way ITZ is being encapsulated into the lipid bilayer
of the liposome or the way it is interacting with the other lipids. Absorbance of these
liposome samples was measured and concentrations of drug released were determined
by using the slope equation of the standard curve. Drug concentrations ranged from
115.3 µg/mL – 162.2 µg/mL throughout the liposome samples collected (Table 6). If
100% of ITZ (60 mg) were encapsulated into the collected volume (~350 mL) of
liposomes, the concentration would be 171 µg/mL. The encapsulation efficiency of ITZ
into this liposome formulation was averaged to be 80.2% across the different
samples.170

𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =

𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 − 𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔
× 100%
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔

Table 6. ITZ Liposome Batch #2: Encapsulation Efficiency

#1
#2
#3
#4

ITZ
Concentration
(µg/mL)
162.2
146.9
115.3
138.6

Encapsulation
Efficiency (%)
94.8
85.9
67.4
81.1

#5
#6
#7

ITZ
Concentration
(µg/mL)
124.7
147.9
124.6

Encapsulation
Efficiency (%)
72.9
86.5
72.8

7.4 In Vitro Biological Evaluation
After determining the encapsulation efficiency and concentration of ITZ in
liposomes, they were used in our cellular assays to determine if ITZ liposomes exhibit
biological activity comparable to free drug. Empty liposomes were also utilized during in
vitro evaluation as a secondary control. Ideally, ITZ liposomes will exhibit potent Hh
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pathway inhibitory activity similar to free ITZ. Both ITZ and empty liposomes utilized
within in vitro assays were formulated in a second liposome batch with a previously
optimized flow rate of 30 mL/min (lipid solution) and 300 mL/min (aqueous solution);
these ITZ liposome encapsulation efficiencies are described in Table 6.
ITZ liposomes, empty liposomes, and free ITZ were evaluated in our gene
expression assay utilizing ASZ cells.

Before testing liposomes in vitro, a drug

concentration of encapsulated ITZ needed to be determined and this was calculated
from the same ITZ concentration used to determine the encapsulation efficiency
(Appendix A). It is important to note that the same ITZ liposome sample was used
throughout all in vitro assays. Liposomes were also frequently checked via UV (254
nm) to confirm that they were not leaking drug contents over time.

Initial gene

expression assays were run in a time dependent manner. Instead of immediately lysing
cells after 48h incubation with treatment, cells were lysed at various time points (24h,
48h, 72h, and 96h) to determine if liposomes exhibited anti-Hh activity in a similar
manner to free drug. Evaluation of Hh pathway inhibition at various time points was
performed as it is unknown how long it would take ITZ liposomes to enter the cell and
release drug.

Two subsequent time course experiments were performed, each

exploring different concentrations of liposomes and free drug. An initial experiment was
performed utilizing 0.195 mM, 0.01 mM, and 0.001 mM concentrations of treatment
(Figure 9A). This experiment resulted in ~50% Gli1 mRNA expression when cells were
treated with 0.195 mM of liposomes at all time points explored.

However, lower

concentrations of ITZ liposomes (0.01 and 0.001 mM) as well as empty liposomes
exhibited 100% Gli1 mRNA expression indicating that the Hh pathway remained active.

160

While there was a dose-dependent trend with free ITZ, there was no clear dosedependent trend in terms of the ITZ liposomes. In fact, this early data suggested that
low concentrations of ITZ liposomes and empty liposomes might be upregulating the Hh
pathway as some Gli1 mRNA expression values exceeded 100%. Because of this, a
second gene expression assay was performed utilizing 0.195 mM, 0.075 mM, and 0.01
mM concentrations of treatment (Figure 9B). This assay resulted in more of a dosedependent trend within the ITZ liposomes at all the observed time points. Interestingly,
empty liposomes at 48h and 72h time points resulted in high Gli1 mRNA values further
suggesting that empty liposomes may actually upregulating the Hh pathway.

It is

important to note that in both assays, treatment with empty liposomes resulted in cell
death at 96h.
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Figure 9. Time Dependent Gli1 mRNA Expression in ASZ Cells
Cells were treated with ITZ liposomes/empty liposomes and incubated for various time periods
(24h, 48h, 72h, and 96h). At each time period, cells were lysed and the Gli1 mRNA expression
was determined via q-PCR. (a) Treatment with 0.195 mM, 0.01 mM, and 0.001 mM of
drug/liposome; (b) Treatment with 0.195 mM, 0.075 mM, and 0.01 mM of drug/liposome.

Due to these preliminary ASZ results, it was hypothesized that the cholesterol
component of the liposome formulation may be upregulating the Hh pathway.
Oxysterols, oxidated forms of cholesterol, are known to upregulate the Hh pathway and
are a well-characterized method to activate Hh signaling in MEFs. Due to cholesterol
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having a similar steroidal structure to oxysterols, we needed to determine if the
liposomes themselves were having an effect on the Hh pathway.

Empty liposomes,

centrifuged and not centrifuged, were treated in our gene expression assay with MEF
cells. This cell line does not have aberrant Hh signaling and therefore these cells need
to typically be treated with Hh pathway activators (Hh ligand or oxysterols). Cells were
only treated with empty liposomes at various volumes and it was determined that they
did not activate Hh signaling. Water was set to “100% Gli1 activation” despite the
pathway not being activated with Hh ligand or oxysterols. Empty liposomes that were
centrifuged and not centrifuged exhibited similar Gli1 expression levels to water,
indicating that the liposomes themselves were not activating or deactivating Gli1 mRNA
expression in C3H10T1/2 cells (Figure 7).
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Figure 10. Relative Gli1 mRNA Expression in C3H10T1/2 Cells
Cells were treated with empty liposomes for 24h at different volumes, as a “drug” concentration
could not be experimentally determined. Water (no liposomes) was set to 100% and mRNA
expressions for empty liposomes were calculated accordingly.

After determining that the liposomes themselves were not upregulating the Hh
pathway, ITZ liposomes were tested in a dose dependent manner alongside free ITZ
(Figure 8). Two liposome samples were utilized: one that was centrifuged and one that
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was not centrifuged. Both liposome samples were tested to confirm removal of free ITZ;
however, there should be a difference in activity between liposomes alone and
liposomes with free drug. At two different time points (48h and 96h) results indicated
that the most potent compound was free ITZ, followed by non-centrifuged liposomes,
and then centrifuged liposomes. ITZ potently inhibited the Hh pathway (IC50 = 0.11 ±
0.025 µM at 48h) followed by liposome + free drug treatment (IC50 = 0.49 ± 0.04 µM at
48h) and liposome treatment alone (IC50 = 2.5 ± 0.37 µM at 48h). There is a trend in
this data indicating that the liposomes containing free ITZ were more potent than the
ITZ liposomes that were subjected to centrifugation (Table 6). This further confirms that
free drug was removed with the centrifugation method. It is important to note that at
96h, liposome potency slightly increased (IC50 = 1.04 ± 0.17 µM) in comparison to 48h
(IC50 = 2.5 ± 0.37 µM) indicating that more drug may have been released during this
longer incubation period resulting in increased Hh inhibitory activity (Table 6).
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Figure 11. Relative Gli1 mRNA Expression in ASZ Cells
Cells were treated with ITZ liposomes/empty liposomes for 48h and 96h in a dose dependent
manner. At each time point, cells were lysed and Gli1 mRNA expression was determined via qPCR. (a) Dose dependent treatment for 48h (b) Dose dependent treatment for 96h
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Table 7. In Vitro Analysis of Liposomes
Treatment
ITZ
Liposomes
Liposomes + ITZ
a

IC50 (µM) 48h a, b
0.11 ± 0.025
2.5 ± 0.37
0.49 ± 0.04

IC50 (µM) 96h a, c
0.14 ± 0.012
1.04 ± 0.17
0.45 ± 0.26

b

IC50 values represent the Mean ± SEM of at least two separate experiments performed in triplicate. All
c
analogues evaluated following 48 hr incubation. All analogues evaluated following 96 hr incubation.

8. Conclusion
Liposome formulations would be advantageous to brain cancer patients.
Specifically, incorporation of ITZ into liposomes may prove beneficial for the treatment
of pediatric SHH subtype MB. Itraconazole was successfully formulated into a novel
liposome formulation utilizing a coaxial turbulent jet in co-flow.

This ITZ liposome

formulation was prepared specifically for BBB penetration and optimal liposomal size
was obtained (< 100 nm). ITZ liposomes demonstrated moderate Hh pathway inhibitory
activity in comparison to free ITZ. While ITZ liposomes would ideally exhibit similar antiHh activity as free drug, this proves to be a good starting point for achieving targeted
drug delivery of ITZ utilizing nanotechnology. To date, it is unknown how ITZ liposomes
are releasing their drug in vitro. Both drug release and cell permeability issues may
explain the difference in anti-Hh activity between ITZ liposomes and free ITZ. Further
exploration towards ITZ liposome behavior in vitro will determine how this formulation
can be optimized to improve overall biological activity.

Thank you to Dr. Diane Burgess and Rajan Jog for their help and guidance with the
formulation and preparation of ITZ liposomes.
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8.1 Experimental Protocols
Preparation of liposomes: Liposomes were formulated utilizing the coaxial turbulent jet
in co-flow instrument developed by Dr. Diane Burgess and her lab. HSPC (900 mg),
DSPC mPEG-2000 (300 mg), cholesterol (300 mg), and ITZ (60 mg) were dissolved in
EtOH (100 mL) with the help of slight heating (50°C) and sonication. In parallel, four
liters of a 6.6 mM KH2PO4 solution were prepared and adjusted to pH 6. Lipid solution
was added to stainless steel tank within the coaxial turbulent jet apparatus and this
solution were incubated at 50°C to ensure lipids and drug remains in solution. The
aqueous solution was attached to the apparatus within its preparation container. The
lipid concentration and lipid formulation were added into the computer program and the
flow rates were set. Liposome size and PDI were measured with Malvern Zetasizer
Nano S and liposomes were collected in 50 mL Eppendorf centrifuge tubes. Liposome
samples were stored at 4°C.
Free drug separation: Free ITZ was separated from liposomes by centrifugation.
Liposomes were centrifuged in a Beckman J2-HC centrifuge at 13,000 rpm for 90
minutes in a 4°C environment.

Liposomes were decanted leaving behind a pellet

containing free drug.
Determination of encapsulation efficiency: After removal of free drug, the percentage of
drug encapsulated into liposomes was determined by monitoring UV absorbance with a
plate reader (BioTek Synergy H1 Hybrid Reader). Liposomes were lysed with 5% triton
and heat (60°C) for 2 hours. The concentration of ITZ was determined by measuring
UV at 254 nm in triplicate and comparing to a standard curve of ITZ.
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Gene expression assay protocol (ASZ-001): Cells are seeded (10,000 cells per well;
100 µL total volume per well) in a 96-well tissue culture plate. After 24h of incubation
(37°C, 5% CO2), growth media was removed and replaced with low FBS media. Cells
were incubated for an additional 24 h. After this time, DMSO (vehicle control) and
liposomes (Aqueous Solution) were added to the wells. Cells were incubated (37°C,
5% CO2) for 48h and RNA was isolated and evaluated by qRT-PCR.
RT-PCR protocol: Following treatment and incubation periods, both RNA extraction and
cDNA synthesis were performed using a TaqMan Cells-to-CT (fast) kit. cDNA synthesis
utilized a BioRad MyCycler and was programmed according to the manufacturer’s
instructions. Quantitative RT-PCR was performed on an ABI 7500 system and made
use of the following TaqMan Gene Expression Probes: mouse ActB (Mm00607939_s1)
and mouse Gli1 (Mm00494654_m1). Relative gene expression levels were computed
via ΔΔCT method using GraphPad Prism. Corresponding IC50 values were calculated
as mean ± SEM for at least three separate experiments performed in triplicate.
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CHAPTER V: Future Directions in the Development of ITZ and des-ITZ Analogues
for the Treatment of SHH Subtype Medulloblastoma
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1. Contributions of ITZ Project
High-throughput screening efforts have recently been utilized to repurpose FDAapproved and clinical stage compounds for novel biological indications. This idea of
“repurposing” or “repositioning” drugs has become a way to bypass the long and
expensive process of drug development.1 Itraconazole (ITZ), a clinically efficacious
antifungal agent, has recently been determined to inhibit both the hedgehog (Hh)
pathway and angiogenesis.9,10 Dysregulation of both the Hh pathway and angiogenesis
contribute to various types of tumors and cancers.

In particular, Hh pathway

antagonists that are clinically approved often lose activity due to conferred resistance as
a result of a point mutation in Smo.49–51 ITZ is able to potently inhibit the Hh pathway in
the presence of wild type Smo and mutant Smo, making it a very desirable candidate
especially for those patients who have acquired resistance from other Hh pathway
antagonists.9,78 As a result, ITZ is currently in clinical trials for various cancers resulting
from these aberrant activities.11 While ITZ is FDA-approved, it still contains a few
properties that are not considered to be “drug-like.”

For instance, ITZ has a large

molecular weight and is poorly soluble. In addition, ITZ contains a triazole moiety, while
important for its antifungal activity, is able to coordinate with CYP3A4 leading to drugdrug interactions and adverse side effects.171 As cancer patients are often on a multidrug treatment regimen to treat the cancer and resulting symptoms, it is necessary to try
to minimize these drug-drug interactions and adverse side effects.
The structure of ITZ has been minimally explored in terms of its novel anticancer
activities. Thus, a series of thorough structure-activity relationship (SAR) studies were
undertaken to determine the ITZ functional groups required for potent Hh pathway and
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angiogenesis inhibition.115 Four generations of analogues were designed, synthesized,
and evaluated in preliminary cellular assays. Analogue generations I and II focused on
exploring all three regions of the ITZ scaffold and its stereochemistry.

SAR data

concluded that the triazole moiety of ITZ can be removed and potent Hh pathway
inhibition is maintained.

Removal of the triazole group also abolishes unwanted

inhibition of CYP3A4 and its subsequent adverse side effects.115 It was also determined
that the most potent stereoisomer of des-triazole ITZ contains the 2R,4R-dioxolane
orientation and the 2’(R)-sec-butyl side-chain region (Figure 1).

In terms of

angiogenesis, there was not a clear SAR pattern; however, none of the generation I and
II analogues were more potent than ITZ in two separate in vitro assays indicating that all
of the functionality of ITZ, including the triazole region, must be crucial for potent
angiogenesis inhibition.115
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Figure 1. Summary of Generations I and II
SAR results from generations I and II were crucial in the design of subsequent
analogues.

Generations III and IV contained the optimal des-triazole-dioxolane
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stereochemistry and focused on probing the triazolone/side-chain region of the original
ITZ scaffold. Modulation to this region included a range of functionality such as amides,
carbamates, hydrazine carboxamides, and triazolones. SAR data indicated that polar
substitution at the meta-position of amide functionality was favorable for Hh pathway
inhibitory activity (Figure 2). This potency increased in the presence of the 2S,4Rdioxolane orientation.

In terms of other functionalities in this region, the hydrazine

carboxamide analogues were moderately potent suggesting that an acyclic moiety can
be utilized in replacement of the bulky triazolone ring. SAR results from generations III
and IV proved interesting in exploring the triazolone/side-chain region of ITZ and further
modifications should be explored in this area to improve the potency and
physicochemical properties of these des-triazole ITZ analogues.
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Figure 2. Summary of Generations III and IV
These SAR results from generations I-IV offer interesting information surrounding
the ITZ scaffold and its novel anticancer properties. However, preliminary PK studies
indicate that the modifications being made to the scaffold are not improving the overall
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drug like properties. There are still a few regions and structural features of ITZ that
could be further explored in terms of Hh pathway inhibition (Figure 3). For instance, the
triazolone/side chain region could be modified to contain different acyclic and cyclic
ureas such as modified 5- and 6-membered rings (113).

The sec-butyl side-chain

region could also be replaced with modified alkyl chains that contain polar functionality
(alcohols, thiols, and amines), similarly to the hydroxylated side-chain region of PSZ
(114).

It is also important to note that previous SAR studies determined that the

triazolone region could be truncated to the nitro, aniline, and hydrazine carboxamide
functionalities indicating that a cyclic moiety may not be necessary at this position.
Acyclic moieties should be synthesized and explored as this is a position to incorporate
hydrogen-bonding functionality and this would also reduce the overall size of the
molecule (115).

These additional modifications to the triazolone/side-chain region will

offer more information in terms of the electronics, sterics, and hydrogen bonding of this
region of the scaffold.
The linker region has generally remained untouched throughout these analogue
generations and this may be a way to incorporate polar groups to help aid in the
solubility of the scaffold.

Such modifications include adding nitrogen atoms to the

aromatic rings of the linker region (116). In terms of the dioxolane region, it would be
worth exploring different polar moieties in replacement of the triazole group. Removal
of this triazole substituent abolishes CYP3A4 coordination but also decreases the
solubility of the des-triazole ITZ analogues. Various polar moieties could be utilized at
this position such as amines, alcohols, thiols, amides, and other 5-membered rings such
as thiophenes, imidazoles, or pyrroles (111). While CF3 functionality typically adds
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lipophilicity, it may be interesting to utilize this moiety to further explore the triazole
region in terms of electronegativity. The phenyl ring of the dioxolane region was also
determined to be necessary for Hh pathway inhibition.

However, the chlorine

substitution was not necessary. This functionality of the dioxolane region offers another
location for adding polar groups in an attempt to increase solubility.

Various

heterocycles could substitute the phenyl ring, including pyridine (112). As the ITZ
scaffold contains a lot of functionality that is amendable for modification, it is important
to further explore this structure to both improve the physicochemical properties as well
as improve Hh pathway inhibitory activity.
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Figure 3. Proposed Future ITZ Analogues
In addition to further SAR studies, it will be necessary to determine the binding
mode of ITZ/des-triazole ITZ analogues within the Hh pathway. While ITZ has been
hypothesized to bind to Smo in a different manner than other Hh pathway antagonists, it
has not been experimentally determined.

A photo-affinity probe of ITZ has been

previously developed and could be utilized to isolate and identify the binding mode of
ITZ within the ASZ cell line.172 Cells could be treated with probe and co-treated with ITZ
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to confirm the binding proteins are the same. Treated cells could then be subjected to
UV to activate the photolabile diazirine and covalently link the probe to the binding
protein. Cells could then be lysed, proteins could be denatured, and denatured lysates
could then be subjected to fluorophores via click chemistry and proteins can be resolved
on SDS-PAGE. To isolate and identify a protein of interest, biotin can be used, as the
fluorophore and biotinylated proteins can be isolated on streptavidin-agarose beads
before SDS-PAGE. From this pull down experiment, the band can be cut out and
analyzed via mass spectrometry.172 It is important to note that a des-triazole ITZ probe
could also be synthesized and subjected to pull down assays. This would confirm if
these analogues inhibit the Hh pathway in a similar manner.
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Figure 4. Structure of ITZ Probe
One of the main reasons why ITZ is being explored as an anticancer
chemotherapeutic is because of its ability to inhibit the Hh pathway in the presence of
both wild type Smo and mutant Smo. It is crucial to determine if des-triazole ITZ and
our analogues are also able to inhibit the Hh pathway in the presence of these Smo
mutants.

Two in vitro assays could be utilized to determine the ability of these

analogues to remain active in the presence of Smo mutants. Both cell assays would
utilize an Hh-dependent mouse embryonic fibroblast (C3H10T1/2). These cells could
be transfected with various Smo constructs (Smo mutant constructs were generously
gifted to the Hadden lab). For screening a few select ITZ analogues, transfected cells
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can be incubated for 24 hours with recombinant sonic hedgehog ligand (rShh) and drug.
A gene expression assay measuring endogenous Gli1 mRNA could determine whether
the Hh pathway is active or inactive. For a higher-throughput screen of compounds, a
Gli-luciferase assay could be utilized. C3H10T1/2 cells could be plated in a 96-well
plate (20,000 cells/well). After 24 hours, cells could be transfected with Smo construct,
Renilla luciferase control reporter, and Gli-Luc reporter using Gene Juice transfection
agent.

After 12 hours of incubation, recombinant hedgehog ligand (rShh) or sonic

hedgehog (Shh) supplemented media would be added to each well along with drug.
Luciferase activities would be determined 48 hours after transfection using DualGlo
luciferase reporter assay system.51,60
In collaboration with Dr. Robert Wechsler-Reya and the Sanford Burnham Prebys
Medical Discovery Institute, the most potent des-triazole ITZ analogues can be
evaluated for their anti-proliferative and anti-Hh activity in primary Hh dependent murine
cells. These cells are isolated from Patched (Ptch) knockout (Math1-Cre-ER; Ptc11/11,
MERP) mice. Mice with Ptch mutations have been used to mimic human Hh-associated
MB.112–114 These primary cells will more closely represent the disease state of cells in
vivo and have been used for the preclinical testing of other Hh pathway inhibitors.
Evaluation of these compounds in this primary MB cell line will provide more relevant
data in comparison to the preliminary evaluation within our established cell lines (murine
embryonic fibroblast C310T1/2 and ASZ).

The Sanford Burnham Prebys Medical

Discovery Institute will also aid in testing the most potent ITZ analogues in vivo with
these same Ptch knockout (MERP) mice.
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2. Contributions of ITZ Liposome Project
Thorough SAR studies were undertaken to improve the drug-like properties of ITZ.
However, despite our efforts, it is anticipated that ITZ and des-triazole ITZ analogues
will have issues crossing the BBB and reaching the brain. In addition to medicinal
chemistry efforts, nanotechnology can be utilized to encapsulate drugs and improve
targeted tissue delivery.134 Liposomes are the most studied form of nanoparticles and
have the potential of improving treatment for patients suffering from pediatric and/or
brain cancer.152,154 ITZ-liposomes have been studied for the treatment of various fungal
infections, however, there are currently no ITZ-liposome formulations that are FDAapproved or in clinical trials.11,157,158–163 In collaboration with Dr. Diane Burgess, a
preliminary ITZ liposome formulation for the treatment of MB was developed and
studied in vitro. These liposomes were an optimal size for penetrating the BBB (<100
nm) and had good encapsulation efficiency (~80%). While ITZ liposomes were not as
potent as free ITZ within our in vitro assays, this formulation still offers promise for the
targeted treatment of MB.
More research is still necessary to understand how ITZ liposomes behave in vitro.
Further exploration is needed in terms of how ITZ liposomes interact with cells and how
they release their drug contents. This information is critical for determining what
modifications could be made to the liposome formulation to aid in their cell penetration
or to manipulate the speed at which they release their contents. Drug release could be
explored with a dialysis assay or by evaluating the media environment of our gene
expression assay with the use of mass spectrometry.173 In addition, liposomes could
undergo a BBB model PAMPA assay to determine if this liposome formulation is
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actually capable of penetrating the BBB.174 The Burgess Lab utilizes a PAMPA assay
with primary rat brain endothelial cells that would represent a good model of the BBB.175
Based on these results, it may be necessary to further modify this current ITZ-liposome
formulation to improve BBB and/or cellular permeability. Such modifications include
adding BBB-targeting proteins to the liposomes or utilizing cationic liposomes as they
have been determined to increase BBB permeability and cell permeability,
respectively.134,137
3. Future Outlook on the Development of ITZ and Des-triazole-ITZ Analogues
as Anticancer Chemotherapeutic Agents
The treatment of pediatric MB still remains a challenge in modern medicine. Despite
the knowledge of MB and its subtypes, a targeted chemotherapeutic treatment has not
been clinically developed.

Treating MB presents many challenges including the

average age of patients (7 years old) and the presence of the BBB. Current treatment
involves surgery followed by high-dose chemotherapy and radiation. If the cancer does
not spread, survival rates are generally between 70 and 80%. However, this harsh
treatment regimen results in long-term side effects in these young patents.33 It is
necessary to develop a more targeted therapeutic for the treatment of pediatric MB.
Due to MB subtypes, it is difficult to develop just one therapeutic and ultimately,
each subtype will need to be treated in a different manner. As SHH subtype MB is
driven by aberrant Hh pathway activity, a viable strategy to treat this subtype is with Hh
pathway inhibitors.33 FDA-approved Hh pathway inhibitors such as vismodegib often
result in decreased activity due to conferred resistance; this was specifically seen in a
clinical trial involving vismodegib and an MB patient.49,50,51 It would be advantageous to
identify Hh pathway antagonists that do not lead to resistant forms of Smo.9,78 One way
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to bypass this would be to identify Hh pathway inhibitors that target downstream of
Smo. ITZ serves as a promising scaffold due to its ability to inhibit the Hh pathway in
the presence of both wild type Smo and mutant forms of Smo. ITZ is already FDAapproved and there is a good understanding of its overall safety and adverse side
effects. In addition, this antifungal agent is currently administered to and tolerated by
children for the treatment of various fungal infections.176 Due to these reasons, ITZ
serves as a promising starting point for targeted MB therapeutic development with an
Hh pathway antagonist. Treatment with an Hh pathway inhibitor such as ITZ may allow
for cancer treatment without harsh life-changing side effects seen with current therapy.
The blood brain barrier remains a large roadblock in the development of therapeutics
to treat MB. A very small percentage of compounds, regardless of physiochemical
properties, are capable of penetrating the BBB.147 One efficient way to ensure BBB
penetration is by using nanoparticles, such as liposomes, to ensure targeted drug
delivery.

Liposomes can be formulated to contain certain characteristics that are

optimal for BBB penetration. In addition, liposomes serve as viable treatment options
for patients suffering from brain or pediatric cancer as they have been proven to limit off
target toxicities.137,154 Due to its large size, it is anticipated that ITZ will not be able to
cross the BBB and reach the brain.

As a result, ITZ has been formulated into a

preliminary liposome model that proves promising for Hh pathway inhibitory activity.
This liposome formulation should be further explored to increase cell permeability and
BBB penetration. An ITZ-liposome formulation may prove advantageous for targeted
drug delivery and may aid in the development of ITZ as an anticancer agent. More
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specifically, liposome formulations of Hh pathway inhibitors may prove to be a promising
chemotherapeutic option for children suffering from SHH subtype MB.
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SYNTHETIC PROCEDURES
Linker Region Intermediates
1-(4-methoxyphenyl)-4-(4-nitrophenyl)piperazine

(13).

1-(4-

methoxyphenyl)piperazine (11) (8.0 g, 41.6 mmol) and 1-chloro-4-nitrobenzene (12)
(6.3 g, 40.0 mmol) were dissolved in anhydrous DMSO (80 mL). K2CO3 (6.0 g, 43.5
mmol) was added and the mixture refluxed at 160°C for 12 h. The reaction was cooled
to RT and a red solid precipitated. The red solid was filtered and washed with CHCl3.
The filtrate was concentrated to afford 13, which was immediately utilized as the crude
solid.
4-(4-(4-methoxyphenyl)piperazin-1-yl)aniline (14). 10% palladium on carbon (0.88 g,
5% mole ratio) was added to a dry 3-neck round bottom flask. Ethanol (200 mL) was
added followed by slow addition of 13 (5.2 g, 16.59 mmol). Hydrazine monohydrate (5.2
mL, 165.9 mmol) was added dropwise and the mixture was stirred at reflux for 3.5 h.
Upon cooling to RT, the mixture was filtered through celite. The celite was washed with
ethanol (250 mL) and chloroform (1000 mL) to ensure complete elution of the aniline.
The filtrate was concentrated to afford 14, which was immediately utilized as the crude
solid.
Phenyl (4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)carbamate (15). A solution of
aniline (14) (2.7 g, 9.51 mmol) and pyridine (12.8 mL, 158.8 mmol) in CHCl3 (100 mL)
was cooled to 0°C. Phenyl chloroformate (1.25 mL, 9.9 mmol) was added dropwise and
the mixture stirred at RT for 3 h. Water and petroleum ether (50 mL: 50 mL) were added
at which point an off-white precipitate formed. The solid was washed with H2O and
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isopropyl alcohol to provide the crude carbamate 15, which was immediately utilized
without further purification.
N-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)hydrazinecarboxamide

(16).

A

solution of hydrazine hydrate (1.33 mL, 42.8 mmol) and 15 (3.2 g, 7.9 mmol) in 1.4dioxane (70 mL) was stirred at reflux for 3 h. The mixture was poured into H2O (250
mL), and the resulting off-white solid was filtered and washed with H2O and isopropyl
alcohol to give carboxamide 16, which was immediately utilized without further
purification.
4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
(17). A solution of formamidine acetate (2.86 g, 27.5 mmol), 16 (2.1 g, 6.15 mmol), and
acetic acid (4 mL) in anhydrous DMF (30 mL) was stirred at 130°C for 3 h. The mixture
was cooled to room temperature and diluted with H2O (100 mL) at which point a light
brown precipitate formed. The solid was filtered and washed with CHCl3 to provide
triazolone 17, which was immediately utilized without further purification.
4-(4-(4-nitrophenyl)piperazin-1-yl)phenol (44). N-(4-hydroxyphenyl)-piperazine (5.3 g,
29.7 mmol), 1-chloro-4-nitrobenzene (6.57 g, 41.7 mmol), and DIPEA (7.74 mL, 44.4
mmol) were dissolved in 50 mL anhydrous NMP and heated to 125°C for 12 h. The
reaction was cooled to 80°C and isopropanol (250 mL) was added portion wise over 30
mins. The reaction mixture was cooled to room temperature and precipitate started to
form. The reaction was further cooled to -20°C and stirred for 30 mins. The precipitate
was vacuum filtered and washed with cold isopropanol to give the product, a brown
powder, in quantitative yield. Characterization matched that previously reported.1
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Side Chain Intermediates
(R)-sec-butyl 4-bromobenzenesulfonate (20). (R)-2-butanol (18) (3.0 g, 40.5 mmol),
Et3N (12.0 mL, 13.5 mmol), and DMAP (5.0 g, 40.5 mmol) in DCM. Cool the reaction to
0°C and slowly add a solution of 4-bromobenzene-1-sulfonylchloride (22.7 g, 89.1
mmol) in DCM. The mixture was stirred at 0°C for 4h. Dilute the reaction with H2O and
extract with DCM. Combine the organic layers, dry over sodium sulfate, filter, and
concentrate. The crude residue was purified by column chromatography (SiO2, 0-2%
EtOAc in hexanes) to afford the product (37.9%, 4.5 g). 1H NMR (500 MHz, CDCl3) δ
7.68 (m, 2H), 7.57 (m, 2H), 4.47 (m, 1H), 1.45 (m, 2H), 1.15 – 1.09 (m, 3H), 0.65 (m,
3H). 13C NMR (126 MHz, CDCl3) δ 137.12, 132.83, 129.53, 128.95, 83.03, 31.99, 29.88,
23.05, 20.76, 14.51, 9.71. DART-HRMS: m/z calcd. for C10H13BrO3S [MH]+, 294.9827;
Found: 294.9822. IR (solid) vmax: 2954, 2930, 2869, 1588, 1463, 1376, 1364, 1313,
1224, 1188, 1093, 1070, 1034, 942, 903, 821, 752. [α]D20 = -16.0 (c = 1.984, MeOH).
(S)-sec-butyl 4-bromobenzenesulfonate (21). (S)-(+)-2-butanol (19) (3.0 g, 40.5
mmol), Et3N (12.0 mL, 13.5 mmol), and DMAP (5.0 g, 40.5 mmol) in DCM. Cool the
reaction to 0°C and slowly add a solution of 4-bromobenzene-1-sulfonylchloride (22.7 g,
89.1 mmol) in DCM. The mixture was stirred at 0°C for 4h. Dilute the reaction with H2O
and extract with DCM. Combine the organic layers, dry over sodium sulfate, filter, and
concentrate. The crude residue was purified by column chromatography (SiO2, 0-2%
EtOAc in hexanes) to afford the product (53.9%, 6.4 g). 1H NMR (500 MHz, CDCl3) δ
7.84 – 7.72 (m, 2H), 7.65 (m, 2H), 4.57 (m, 1H), 1.56 (m, 2H), 1.32 – 1.19 (m, 3H), 0.77
(m, 3H).

13

C NMR (126 MHz, CDCl3) δ 136.56, 132.31, 129.00, 128.40, 82.50, 60.22,

31.43, 29.33, 20.21, 14.07, 9.16. DART-HRMS: m/z calcd. for C10H13BrO3S [MH]+,
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294.9827; Found: 294.9856. IR (solid) vmax: 3090, 2975, 2937, 2880, 1576, 1501,
1471, 1389, 1361, 1226, 1185, 1112, 1090, 1068, 994, 895, 819, 751, 608. [α]D20 =
+11.5 (c = 4.466, MeOH).
Linker/Triazolone/Side Chain Intermediates.
General Protocol for alkylation of triazolone (propyl- or sec-butyl-substitutions)
(24-27). To a suspension of triazolone 17 (1.0 g, 2.8 mmol) in anhydrous NMP (30 mL)
was added Cs2CO3 (2.74 g, 8.4 mmol), and an alkylating agent (20-23) (8.4 - 14 mmol).
The mixture was stirred at RT for 2 h, then warmed to 60º C for 12 h and finally to 110º
C for 4h. The mixture was then cooled to RT, diluted with water (125 mL), and extracted
with EtOAc (3 X 150 mL).

The organic layers were combined, dried (MgSO4), filtered,

and concentrated. The crude residue was purified by column chromatography (SiO2, 0
to 20% EtOAc in Hex) to afford 24-27 as off-white solids (45-88%). Compounds were
further purified as needed via recrystallization (EtOH) to remove a “grease-like” impurity
(observed in 1H NMRs at 0.88, 1.31 ppm).
(S)-2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H1,2,4-triazol-3-one (24). 1H NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.46 – 7.40 (m, 2H),
7.03 (d, J = 9.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 6.90 – 6.84 (m, 2H), 4.35 – 4.24 (m,
1H), 3.78 (s, 3H), 3.37 (m, 4H), 3.23 (m, 4H), 1.86 (m, 1H), 1.78 – 1.66 (m, 1H), 1.39 (d,
J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 154.24, 152.07,
150.60, 145.53, 133.91, 125.96, 123.55, 118.63, 116.66, 114.57, 55.61, 52.72, 50.83,
49.31, 28.47, 19.25, 10.80. DART-HRMS: m/z calcd. for C23H29N5O2 [MH]+, 408.2400;
Found: 408.2368. IR (solid) vmax: 3120, 3053, 2967, 2935, 2877, 2821, 2765, 1686,
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1549, 1507, 1446, 1388, 1240, 1222, 1154, 1117, 1030, 943, 823, 805, 720. [α]D20 = +
12.6 (c = 0.996, DMSO).
(R)-2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H1,2,4-triazol-3-one (25). 1H NMR (500 MHz, CHCl3) δ 7.61 (s, 1H), 7.47 – 7.40 (m, 2H),
7.06 – 6.99 (m, 2H), 6.96 (m, 3H), 6.90 – 6.84 (m, 2H), 4.30 (m, 1H), 3.78 (d, J = 1.3
Hz, 2H), 3.40 – 3.28 (m, 4H), 3.24 (m, 4H), 1.94 – 1.76 (m, 1H), 1.78 – 1.67 (m, 1H),
1.39 (d, J = 6.7 Hz, 2H), 0.91 (t, J = 7.4 Hz, 2H).

13

C NMR (126 MHz, CDCl3) δ 154.21,

152.06, 150.58, 145.50, 133.94, 125.94, 123.54, 118.62, 116.65, 114.55, 55.60, 52.70,
50.81, 49.29, 28.47, 19.29, 10.83. DART-HRMS: m/z calcd. for C23H29N5O2 [MH]+,
408.2400; Found: 408.2430. IR (solid) vmax: 3120, 3052, 2967, 2821, 1686, 1549,
1507, 1444, 1386, 1240, 1221, 1030, 943, 824, 805, 719, 530. [α]D20 = -12.2 (c = 0.873,
DMSO).
2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H1,2,4-triazol-3-one (26). 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 0.6 Hz, 1H), 7.51 –
7.43 (m, 2H), 7.11 – 7.04 (m, 2H), 7.04 – 6.97 (m, 2H), 6.96 – 6.88 (m, 2H), 4.34 (m,
1H), 3.83 (s, 3H), 3.44 – 3.38 (m, 4H), 3.31 – 3.25 (m, 4H), 1.91 (m, 1H), 1.83 – 1.70
(m, 1H), 1.44 (d, J = 6.8 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
154.22, 152.07, 150.60, 133.98, 125.92, 123.59, 118.66, 116.69, 114.54, 55.61, 52.69,
50.85, 49.29, 32.36, 28.49, 19.33, 10.85. DART-HRMS: m/z calcd. for C23H29N5O2
[MH]+, 408.2400; Found: 408.2388. IR (solid) vmax: 3120, 3053, 2970, 2877, 2818,
2763, 1686, 1548, 1508, 1444, 1399, 1241, 1223, 1030, 943, 823, 805.
4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4triazol-3-one (27): 1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H), 7.50 – 7.43 (m, 2H), 7.04
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– 6.97 (m, 2H), 6.96 – 6.88 (m, 2H), 3.86 (m, 2H), 3.83 (s, 3H), 3.44 – 3.38 (m, 4H),
3.31 – 3.25 (m, 4H), 1.89 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
154.22, 152.22, 150.66, 145.51, 133.93, 125.87, 123.60, 118.64, 116.67, 114.55, 55.61,
50.83, 49.28, 47.23, 22.06, 11.13. DART-HRMS: m/z calcd. for C22H27N5O2 [MH]+,
394.2243; Found: 394.2265. IR (solid) vmax: 3122, 3053, 2956, 2873, 2830, 1686,
1555, 1511, 1451, 1409, 1390, 1250, 1225, 1032, 942, 813, 733.
General Protocol for phenol synthesis (demethylation protocol) (28-31). Hydrogen
bromide (48% aqueous solution, 10 mL) was added to a solution of methoxy-alkyl
substituted triazolone 24-27 (500 mg, 1.2 mmol) in toluene (6 mL) was refluxed for 6-12
h. The reaction was cooled to RT and water (10 mL) was added. The precipitate that
formed was collected by filtration and washed with copious amounts of water.

1

H NMR

analysis indicated pure phenol in good yields (55-80%). The filtrate was neutralized
with saturated NaHCO3 and washed with EtOAc (2 X 150 mL). The organic layers were
dried (MgSO4), filtered, and concentrated to afford remaining phenol (28-31) in
moderate purity that required chromatography.
(S)-2-(sec-butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H1,2,4-triazol-3-one (28).

1

H NMR (500 MHz, DMSO) δ 8.38 (s, 1H), 7.58 (m, 2H), 7.53

(s, 1H), 7.19 (m, 2H), 6.91 (d, J = 8.4 Hz, 2H), 4.13 (m, 1H), 3.67 (s, 8H), 1.71 (m, 2H),
1.31 (d, J = 6.7 Hz, 3H), 0.81 (t, J = 6.6 Hz, 3H).

13

C NMR (126 MHz, DMSO) δ 161.5,

151.2, 148.5, 134.9, 126.4, 122.9, 122.0, 116.2, 116.1, 53.8, 51.7, 46.4, 27.8, 19.2,
10.5. DART-HRMS: m/z calcd. for C22H28N5O2 [MH]+, 394.2243; Found: 394.2216. IR
(solid) vmax 3331, 2958, 2875, 2832, 2807, 1688, 1509, 1448, 1385, 1222, 1181, 1152,
965, 824, 741, 729. [α]D20 = +13.0 (c = 0.994, DMSO).
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(R)-2-(sec-butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H1,2,4-triazol-3-one (29).

1

H NMR (500 MHz, DMSO) δ 8.38 (s, 1H), 7.58 (d, J = 8.9 Hz,

2H), 7.48 (s, 1H), 7.19 (d, J = 8.9 Hz, 2H), 6.89 (m, 2H), 4.14 (m, 1H), 3.62 (s, 8H), 1.70
(m, 2H), 1.31 (d, J = 6.7 Hz, 3H), 0.82 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, DMSO)

δ 157.2, 151.4, 148.6, 135.1, 126.4, 123.1, 122.1, 122.0, 116.4, 116.3, 53.9, 51.9, 46.6,
28.0, 19.3, 10.7. DART-HRMS: m/z calcd. for C22H28N5O2 [MH]+, 394.2243; Found:
394.2212. IR (solid) vmax: 3241, 3055, 2965, 2928, 2855, 1670, 1509, 1451, 1378,
1234, 1185, 1110, 967, 921, 832, 807, 746. [α]D20 = -13.7 (c = 1.254, DMSO).
2-(sec-butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4triazol-3-one (30). 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 0.6 Hz, 1H), 7.41 – 7.35
(m, 2H), 7.00 – 6.94 (m, 2H), 6.86 – 6.80 (m, 2H), 6.72 – 6.67 (m, 2H), 4.31 (m, 1H),
3.37 – 3.31 (m, 4H), 3.23 – 3.17 (m, 4H), 1.87 (m, 1H), 1.73 (m, 1H), 1.40 (d, J = 6.7
Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 152.72, 151.21, 151.13,

134.68, 125.80, 124.64, 119.18, 116.91, 116.38, 53.32, 51.44, 49.53, 28.85, 19.64,
11.18. DART-HRMS: m/z calcd. for C22H27N5O2 [MH]+, 394.2243; Found: 394.2221. IR
(solid) vmax: 3333, 3058, 2959, 2876, 2833, 2809, 1690, 1509, 1449, 1385, 1224,
1182, 1153, 965, 825, 739.
4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2-propyl-2,4-dihydro-3H-1,2,4triazol-3-one (31): 1H NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.44 – 7.36 (m, 2H), 7.05
– 6.98 (m, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.80 – 6.73 (m, 2H), 3.82 (m, 2H), 3.37 (t, J =
5.0 Hz, 4H), 3.22 (m, 4H), 1.82 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H).

13

C NMR (126 MHz,

CDCl3) δ 152.40, 150.78, 150.50, 134.14, 125.58, 124.03, 118.86, 116.60, 115.99,
51.03, 49.16, 47.33, 22.05, 11.12. DART-HRMS: m/z calcd. for C21H25N5O2 [MH]+,
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380.2087; Found: 380.2099. IR (solid) vmax: 3344, 2969, 2934, 2893, 1466, 1378,
1365, 1185, 1160, 1127, 1104, 950, 815.
Dioxolane Region Intermediates.
1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-one (38). A solution of 2chloro-2’,4’-dichlorophenylacetone (34) (10.0 g, 45.0 mmol), 1H-1,2,4-triazole (35) (6.2
g, 89.0 mmol), NaHCO3 (6.1 g, 72.0 mmol), and toluene (100 mL) were heated to reflux
(110-120°C) overnight. The reaction vessel was then placed in the -20°C freezer for ~6
h. The solid was filtered, dissolved in H2O, and extracted with ethyl acetate (~50 mL x
3). The organic layer was collected, washed with brine, and dried over sodium sulfate.
The solvent was evaporated and the remaining solid was washed with EtOAc/hexanes
(1:1, 100 mL) resulting in a yellow solid (7.4 g, 64.2%). Characterization matched that
previously reported.2
(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate

(39a). DL-1,2-

isopropylideneglycerol (39) (25 g, 89 mmol) was added to 300 mL of DCM with
molecular sieves. Pyridine (30.5 g, 378 mmol) was then added to the mixture. The
solution was cooled to 0°C and TsCl (54 g, 283.5 mmol) was added portion wise over
30 mins. The reaction stirred overnight at room temperature. The solution was washed
with pH 2.0 H2O (6M HCl) and brine.

The organic layer was collected and

concentrated. The crude product was purified via column chromatography (SiO2, 0 25% EtOAc in hexanes) yielding a white solid in quantitative yield. Characterization
matched that previously reported.3
2,3-dihydroxypropyl 4-methylbenzenesulfonate (40). Tosylated dioxolane 39a (9.3
g) was dissolved in 300 mL of MeOH and 30 mL of 0.5N HCl was added to the solution.
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The reaction was stirred and heated to reflux for 5h. The reaction was cooled to room
temperature and neutralized to pH 7 with dropwise addition of saturated NaHCO3. The
solution was extracted (~150 mL x 1) with ethyl acetate and then washed with brine.
The organic layers were collected, dried over sodium sulfate, filtered, and concentrated
(7.7 g, 89.0%). Characterization matched that previously reported.4
(2-((1H-1, 2,4-triazol-1-yl) methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl) methyl
4-methylbenzenesulfonate (43). Ketone 38 (2.0 g, 7.8 mmol) and 40 (1.98 g, 8.03
mmol) were added to a dry round bottom flask. Anhydrous toluene (15 mL) was added
to the reaction. The reaction was cooled to 0°C and TfOH (2.8 mL, 31.9 mmol) was
added dropwise with a glass syringe. The reaction was stirred at room temperature for
60 h. The mixture was diluted with 50 mL of ethyl acetate and slowly dropped into a
solution of K2CO3 (5 g) in water (40 mL). The organic layer was separated with ethyl
acetate (50 mL x 3). The organic layers were combined, dried over sodium sulfate,
filtered, and concentrated to ~70 mL EtOAc. A solution of TsOH monohydrate (2.0 g) in
EtOAc (13 mL) was slowly added at room temperature. The product precipitated as the
salt (3.6 g, 70.3%). Characterization matched that previously reported.5
(S)-2,3-dihydroxypropyl

4-methylbenzenesulfonate.

(S)-(+)-1,2-

isopropylideneglycerol was tosylated following the above procedure for 39a and was
then subjected to the acid-mediated hydrolysis procedure for 40. Characterization
matched that previously reported.
(R)-2,3-dihydroxypropyl

4-methylbenzenesulfonate.

(R)-(-)-1,2-

isopropylideneglycerol was tosylated following the above procedure for 39a and was
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then subjected to the acid-mediated hydrolysis procedure for 40. Characterization
matched that previously reported.
Amide Region Intermediates
General Preparation of Benzyl Protected Esters. To a solution of ester phenol (500
mg, 3.2 mmol) in acetone (5 mL) was added potassium carbonate (anhydrous, 6 eq,
19.2 mmol) followed by benzyl bromide (2.5 eq, 8.2 mmol). The reaction was stirred for
12h at room temperature. The mixture was filtered over a celite pad, washed with
EtOAc (30 mL), and concentrated under reduced pressure. The crude residue was
purified via column chromatography (SiO2, 5% EtOAc in hexanes) to afford benzyl
protected esters.
General Preparation of Benzyl Protected Acids. To a solution of ester (500 mg, 2.1
mmol) in H2O: THF (3 mL: 9 mL) lithium hydroxide (monohydrate, 3 eq, 6.3 mmol) was
added to the reaction. The reaction mixture was refluxed for 12h at which time it was
neutralized and then acidified with 1M HCl. The aqueous mixture was extracted with
EtOAc (3 x 50 mL). The combined organic layers were dried, filtered, and concentrated
under reduced pressure. The crude residue was purified by column chromatography
(SiO2, 30 – 50 % EtOAc in hexanes) to afford benzyl protected esters.
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HSQC:
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HSQC zoomed (3.2 to 4.8ppm): (1) HC4 (methine at C4 of dioxolane) direct correlation
via HSQC experiment: 4.23à72.82ppm. (2) Remaining 1H nuclei in the expanded
region below are methylene, correlating to the diastereomeric pairs at C5 of dioxolane
and α-carbon to tosyl group (not specified: 3.76à66.20ppm; 3.91à66.20ppm;
4.08à69.37ppm; 4.13à69.37ppm).
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NOESY:

217

NOESY zoomed (3.2 to 4.8ppm): (1) HC4 (methine at C4 of dioxolane) very weak to no
NoE signal with methyl at C2 of dioxolane (2,4-correlation) in experiment:
4.23à1.73ppm.

218

X-RAY:
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HSQC:
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HSQC zoomed (3.2 to 4.8ppm). (1) HC4 (methine at C4 of dioxolane) direct correlation
via HSQC experiment: 4.50à73.73ppm. (2) Remaining 1H nuclei in the expanded
region below are methylene, correlating to the diastereomeric pairs at C5 of dioxolane
and α-carbon to tosyl group (not specified: 3.61à66.56ppm; 3.85à68.62ppm;
3.96à68.59ppm; 4.25à66.57ppm).
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NOESY:

223

NOESY zoomed (3.2 to 4.8ppm): (1) HC4 (methine at C4 of dioxolane) moderate NoE
signal with methyl at C2 of dioxolane (2,4-correlation) in experiment: 4.50à1.74ppm.
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APPENDIX B: Selected ITZ Liposome Data
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Encapsulation Efficiency
ITZ Standard Curve + Raw Data (254 nm)

µg/mL

250

200

150

100

50

25

20

10

5

1

0.944

0.922

0.71

0.51

0.318

0.203

0.174

0.157

0.118

2

0.986

1.067

0.79

0.515

0.327

0.199

0.186

0.14

0.116

3

0.989

1.047

0.83

0.567

0.324

0.215

0.193

0.143

0.12

1.2

Absorbance

1
0.8
0.6
y = 0.0046x + 0.0935
R² = 0.9994

0.4
0.2
0
0

50

100

150

Concentration (µg/mL)
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200

250

ITZ Liposomes Raw Data
-

Each liposome sample was centrifuged @ 13,000 rpm for 90 min to remove free
drug
Each liposome sample (1 mL) was treated with 5% triton X-100 (1 mL), vortexed
for 30 seconds, and heated at 60°C for 2-2.5 h
After heating, liposome samples were vortexed again for 30 seconds
Aliquot into UV-appropriate 384 well plate in triplicate
Read absorbance at 254 nm

Sample

1

2

3

Average

Normalized

y = mx + b

Final

A

1.912

1.778

1.693

1.79433333

0.46666667

81.12318841

162.2463768

B

1.776

1.772

1.729

1.759

0.43133333

73.44202899

146.884058

C

1.922

1.412

1.725

1.68633333

0.35866667

57.64492754

115.2898551

D

1.762

1.739

1.719

1.74

0.41233333

69.3115942

138.6231884

E

1.656

1.73

1.738

1.708

0.38033333

62.35507246

124.7101449

F

1.781

1.715

1.788

1.76133333

0.43366667

73.94927536

147.8985507

G

1.648

1.743

1.732

1.70766667

0.38

62.2826087

124.5652174

Controls Raw Data
Control

1

2

3

Average

EtOH

0.103

0.121

0.114

0.11266667

5% Triton

2.614

2.646

2.629

2.62966667

1:1

1.257

1.291

1.435

1.32766667

Intact Liposomes
Sample

1

2

3

Intact empty-liposomes

0.136

0.142

0.139

Intact ITZ-liposomes

0.311

0.403

0.364

Trial 2: Concentration Confirmation for Drug Solution
Sample
A
B

1
1.748
1.872

2
2.006
1.912

3
1.867
1.807

Average
1.873
1.863

1:1 EtOH: 5% Triton Control à 1.46
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Normalized
0.41
0.4

y = mx+b
68.8
66.6

Final
137.6
133.3

Concentration Calculation
Trial 1 + Trial 2 + Trial 3
= Average Absorbance
Total # of Trials
1.912 + 1.778 + 1.693
= 1.794
3
Average Absorbance − Control = Noramlized Absorbance
1.794 − 1.327 = 0.466
y = 0.0046x + 0.0935
0.466 = 0.0046x + 0.0935
0.466 − 0.0935 = 0.0046x
0.372 = 0.0046x
0.372
= 80.07 = x
0.0046
x=

1 mL liposomes
2 mL total volume

2x = Concentration of Drug
2 80.07 = 161.95 µg/mL
Encapsulation Efficiency
Original concentration
60 mg
= 0.6 mg/mL
100
Collected 7 tubes of ~50 mL of liposomes (350 mL total)
New concentration
60 mg
= 0.171 mg/mL
350 mL
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Free Drug
Total Concentration
171

µg
− Experimental Concentration = Free Drug
mL

µg 161µg
µg
−
= 8.8
mL
mL
mL

Encapsulation Efficiency
Total Drug − Free Drug
x 100% = Encapsulation Efficiency (EE)
Total Drug
µg
µg
µg
171 mL − 8.8 mL
161 mL
=
µg
µg = 0.941 x 100% = 94.2 % EE
171
171
mL
mL

Drug Solution Concentrations
137.6 µg
1g
0.0001376 g
x
=
mL
1,000,000 µg
mL
0.0001376 g 1,000 mL 0.1376 g
x
=
mL
1L
L
0.1376 g
1 mol
0.000195 mol
x
=
= 0.195 mM
1L
705.6 g
L

300

